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SUMMARY 
 
Cutaneous wounds in patients with diabetes typically show abnormal healing.  Such ulcers 
are characterised by chronicity, persistent inflammation, copious exudate, hypergranulation, 
increased bacterial load and reduced ability to heal.  Diabetic foot ulceration is a cause of 
significant morbidity and financial burden.  This thesis examines the effect of two topical 
therapies on healing in wounds in individuals with diabetes.   
 
The protein connective tissue growth factor (CTGF) is induced during normal wound healing, 
whereas it is deficient in diabetic wounding models.  Topical application of CTGF to rodent 
diabetic and control wounds in an established model was examined in this thesis.  CTGF 
treated diabetic wounds showed an accelerated closure rate compared with vehicle treated 
diabetic wounds.  Healed incision site skin was able to withstand more strain before breaking 
in CTGF treated rat wounds compared with untreated wounds.  Granulation tissue examined 
after CTGF treatment in wounds in rats with diabetes showed collagen-IV accumulation 
compared with vehicle treated diabetic animals.  The α-smooth muscle actin in fibroblasts 
and endothelial cells was increased in CTGF treated diabetic wounds compared with 
untreated diabetic wounds, as was macrophage infiltration. Wound breaking strength data 
showed that untreated diabetic wounds were able to tolerate significantly less final strain 
before breaking than either treated or untreated control wounds; the CTGF treated diabetic 
wounds had a slightly higher mean final strain (2.32 MPa) than the untreated diabetic wounds 
(2.20 MPa), however this did not reach statistical significance. 
 
Propolis is a naturally occurring potent anti-inflammatory bee-derived protectant resin that is 
reported to aid wound healing in general but it has not been studied systematically in wounds 
xviii 
 
in a cohort of humans with diabetes.  To determine if propolis shows efficacy in a pilot study 
of foot ulcer healing in diabetic human subjects and if it is well tolerated, serial consenting 
subjects (n=24) with diabetic foot ulcers were studied.  Propolis was applied topically at each 
clinic review for 6 weeks.  The controls were a prespecified historic control group who were 
previously treated at the same clinic.  Ulcer healing data compared with the control group of 
n=84 showed that wound closure rate was increased in propolis treated vs control ulcers. 
Post-debridement wound fluid analysed for viable bacterial count and the pro-inflammatory 
matrix metallo-proteinase, MMP-9 activity (a pro-inflammatory protease), showed that active 
MMP-9 and bacterial counts were significantly reduced from baseline in propolis treated 
ulcers vs. controls.  Wound fluid CTGF was not clearly induced by propolis, although only 
early time points in wound healing were examined.  No adverse effects of propolis treatment 
were reported. 
 
In summary, this novel data shows that topical CTGF improves wound healing in diabetic 
rats.  When combined with evidence that endogenous CTGF is induced as human diabetic 
foot ulcers heal, it provides rationale for considering studies of CTGF as therapy in human 
diabetic foot ulcers.  The propolis pilot study indicates for the first time in a human diabetic 
foot ulcer series that topical propolis may enhance wound closure and it is well tolerated. A 
multi-site randomised controlled of topical propolis in diabetic foot ulcers now appears to be 
warranted. 
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 Chapter 1 
 
OVERVIEW OF DIABETES AND ITS COMPLICATIONS  
 
Introduction 
The purpose of this chapter is to provide a brief overview to the themes that will be examined 
more broadly in subsequent chapters this thesis.  
 
Prevalence of diabetes 
Diabetes mellitus is a serious metabolic condition and one of the world’s leading chronic 
diseases, affecting more than 381 million adults worldwide ~8% of the world’s adult 
population (Guariguata, Whiting et al. 2014).  Moreover, 45.8%, or 174.8 million of all 
diabetes cases in adults are estimated to be undiagnosed (Beagley, Guariguata et al. 2014). 
The burden of diabetes is becoming increasingly prevalent. Boyle, Honeycutt et al. (2001) 
estimated that in 2001 11 million US citizens suffered from diabetes, representing 4% of the 
total population.  By 2050 this number is predicted to increase to 29 million or 7.2% of the 
population (Boyle, Honeycutt et al. 2001).  Similarly, the International Diabetes Federation, 
(2014) estimates for current and prospective diabetes each continue to rise (Guariguata, 
Whiting et al. 2014).  The Australian experience indicates that from 1989–90 to 2011–12, the 
prevalence of diabetes in the general population more than doubled, from 1.5% to 4.2%.  The 
prevalence of diabetes rose in all population groups measured and rates of diabetes were 
similar across geographic regions, with some exceptions according to the Australian Institute 
of Health and Welfare (AIHW 2013).  Between 2001 and 2004–05, the prevalence of 
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 diabetes among Aboriginal and Torres Strait Islander Australians was more than three times 
that of non-Indigenous Australians (AIHW 2013). 
 
There are two main types of diabetes, which vary considerably in their pathogenesis, clinical 
features and therapeutic approaches.  The most common is type 2 diabetes which accounts for  
85-90% of diabetes patients and  type 1 diabetes accounting for 10%-15%.  There are other, 
less common types of diabetes, including those occurring due to corticosteroid therapy, end 
stage liver disease, or from monogenic gene defects such as maturity onset diabetes of the 
young (MODY),(Fajans 1987; Wang, Tekeuchi et al. 1999). 
 
Type 2 diabetes results from relative insulin deficiency typically with insulin resistance and 
some degree of impaired insulin secretion. In contrast, type 1 diabetes results from an 
absolute inability of the pancreas to produce insulin, attributable to a destructive autoimmune 
process.  Most subjects with type 2 diabetes have reached middle age when they are 
diagnosed although it can also occur in youth (Diabetes UK, 2012).  Type 2 diabetes is 
usually managed successfully through a controlled diet and exercise combined with oral 
hypoglycaemic medication and/or incretin mimetic treatment.  In subjects for whom this is 
ineffective, parenteral insulin therapy is used.  People with type 1 diabetes tend to become 
symptomatic earlier in life and typically are diagnosed before 30 years of age.  Type 1 
diabetes is managed through intensive diabetes management, including multiple times daily 
insulin therapy and control of oral carbohydrate intake.  In each type of diabetes mellitus, 
assessment for diabetes complications is required on a regular basis, in order to detect and 
treat certain complications early and to prevent their progression.  
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 Complications Associated with Diabetes 
Despite improvement in effective management regimens, people with diabetes are prone to 
develop a variety of secondary complications that may result in permanent and irreversible 
damage to organs and tissues.  Such complications include atherosclerotic cardiovascular 
disease, diabetic nephropathy, retinopathy and diabetic foot disease.  The latter may give rise 
to wounds that fail to heal satisfactorily, which can then lead to lower limb amputation. 
 
The aetiology of these complications is generally multifactorial and not attributable to a 
single root cause.  The rate of onset and the severity of diabetic complications may be 
influenced directly by the severity of hyperglycaemia in diabetes, as well as by the 
dyslipidaemia and hypertension usually present in type 2 diabetes. In addition indirect factors 
such as genetic susceptibility to diabetes and its complications and environmental issues such 
as cigarette smoking and sedentary lifestyle can also effect the development of diabetic 
complications.  DCCT (Diabetes Control and Complications Trial (DCCT 1996)) and 
UKPDS (1999) (U.K. Prospective Diabetes Study) (King, Peacock et al. 1999).  
 
Diabetic Foot Ulcers 
Foot ulceration is common in people with diabetes mellitus (Moulik, Mtonga et al. 2003) 
occurring in up to one quarter of people who have diabetes and commonly recurs in those 
who develop the complication (Singh, Armstrong et al. 2005).  Foot ulceration as a 
consequence of diabetes is the most common reason for lower limb amputation, accounting 
for some 50-70% of non-traumatic lower limb amputations (Boulton and Vileikyte 2000; 
Boulton, Vileikyte et al. 2005).   One-third of the US$116 billion directly apportioned to 
diabetes care in the US in 2007 was used to treat foot ulceration (Driver, Fabbi et al. 2010). 
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 The pathogenesis of foot ulceration is complex. While most foot ulcers will heal in people 
with diabetes, some do not, and ulcer recurrence rates are high, around 50% (Dubsky, 
Jirokowska et al. 2013).  
 
Major causes of diabetic foot ulceration include: 
• neuropathy (sensory, motor, and autonomic deficits), especially reduced sensation in 
the feet due to a distal sensori-motor bilateral peripheral neuropathy; 
• peripheral arterial disease causing ischaemia with delayed ulcer healing;  
often a combination of both ischaemia and neuropathy co-exist, further impairing ulcer 
healing compared with either condition alone; 
• other important factors as referenced below include: mechanical foot deformity such 
as occurs secondary to peripheral neuropathy with calluses or after amputation; and ulcers  
complicated by secondary bacterial infection, a common and serious complication of diabetes 
mellitus.  Increase of infections in patients with diabetes is known to depend upon an 
immunosuppressive state.  The relationship between hyperglycemia and immune function is 
controversial and relevance of hyperglycemia and/or hyperinsulinemia to immunosuppressive 
mechanisms is currently unclear. (Tanaka, 2008) 
An important deleterious effect associated with diabetes is the formation of sugar-derived 
substances called advanced glycation end products (AGEs). AGEs form at a constant but 
slow rate in the normal body, however, their formation is markedly accelerated in diabetes 
because of the increased availability of glucose.  
The effects of glycosylation, that is accumulation of AGEs  are observed in the lower 
extremities of people with diabetes.  Skin thickness and bone density decreases; tendons 
thicken; muscles and fat pads atrophy; joints mobility is reduced; and fat pads  migrate 
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 distally.  These local soft tissue changes also alter a patient’s gait, putting them at risk of foot 
ulceration’. (wrobel 2010).  In terms of ulcer precipitants, as opposed to the predisposing 
factors described above, a foot ulcer may result from an initiating injury such as acute trauma 
or from repetitively/continuously applied mechanical stress, usually attributable to 
neuropathy (Reiber, Vileikyte et al. 1999).  
For example, new foot-wear combined with excessive walking is a common foot ulcer 
precipitant.  In addition, tinea pedis can cause loss of skin integrity and risk of subsequent 
bacterial infection, which with continued trauma and suboptimal foot ulcer management, can 
further compromise healing (Xu, McLennan et al. 2007, Lipsky, Berendt et al. 2004 and 
Armstrong, Lipsky et al. 2004).   
 
Diabetic foot ulcers are notably slow to heal and according to Jeffcoate et al. (2008) even 
with organised delivery of standardised care only 33% of the ulcers that are deep to tendon or 
bone will heal (Jeffcoate, Lipsky et al. 2008).  In 2007-08 4.1 people per 100,000 were 
hospitalised for lower limb amputations in Australia as a result of diabetes (AIHW, 2013) .  A 
cost-analysis and cost of a single patient episode of an amputation in Australia attributable to 
a diabetic foot ulcer was estimated during that decade to be $26,700  (Ray, Valentine et al. 
2005)  
 
Historically diabetic foot ulcers have been neglected in healthcare research and planning, 
with clinical practice based more on opinion than as a result of methodologically robust 
evidence-based enquiry (Jeffcoate and Harding 2003).  Furthermore, associated pathological 
processes are often not well understood by health care professionals and administrators and 
tend to be communicated inadequately (Jeffcoate and Harding, 2003). 
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 Pathogenesis of Wound Healing in Diabetes 
As described previously, the delayed wound healing in diabetic foot disease is attributable to 
a variety of factors including peripheral arterial disease, peripheral neuropathy, foot 
deformity and secondary bacterial infection (American Diabetes Association (ADA) 1999; 
Margolis, Kantor et al. 2000).  Furthermore, the wound microenvironment in diabetes is 
reported to be abnormal and pathogenic factors lead to delayed ulcer closure and suboptimal 
granulation tissue formation with abnormal composition of extra-cellular matrix (ECM) 
(Lobmann, Ambrosch et al. 2002).  These pathogenic factors appear to emanate from diabetes 
impairing key processes in wound healing including, as described below, the normal cellular 
functions involved in cutaneous wound healing.  It has also been proposed that persistent 
inflammatory infiltrates associated with bacterial colonisation in the wound contribute to 
delayed healing in diabetes (Zhao, Hochwalt et al. 2010; Loots, Lamme et al. 1998). 
 
In diabetic patients ulceration is characterised by chronicity, copious exudate, 
hypergranulation, increased bacterial load and reduced healing capacity (Berlanga-Acosta, 
Schultz et al. 2012).  At a cellular level, in diabetic wounds, inflammatory cytokines, local 
proteases, reactive oxygen and nitrogen species produce a cytotoxic and pro-degradative 
wound environment and delayed healing arises from the resulting adverse local metabolic 
environment (Berlanga-Acosta, Schultz et al. 2012).  In particular, pathological persistence of 
a pro-inflammatory high protease activity wound microenvironment and inflammatory cell 
infiltrate in foot ulcers in diabetes has been well recognised (Liu, Min et al. 2007). 
 
 A cytokine/chemokine mediated imbalance between synthetic and degradative matrix 
pathways is thought to be responsible for reduced formation of productive granulation tissue 
that is able to aggregate cells and proteins.  Therefore the quantity and quality of extra-
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 cellular matrix (ECM) is reduced (Lobmann, Ambrosch et al. 2002).  Human wounds in 
diabetes also exhibit an excess of pro-inflammatory cytokines such as tumour necrosis factor 
alpha (TNF-α), which leads to increased protease activity and consequently, persistent 
inflammation and delayed healing (Lobmann, Ambrosch et al. 2002). 
 
ECM accumulation is controlled by matrix metalloproteinases (MMPs), which degrade ECM, 
and MMP tissue inhibitors or TIMPs (Visse and Nagase, 2003, Gill and Park, 2008).  Growth 
factors are also involved in the regulation of ECM.  Connective tissue growth factor (CTGF), 
is a profibrotic growth factor capable of inducing fibroblast proliferation, migration and 
adhesion - suggesting it may play a role in ECM accumulation (Moussad and Brigstock 
2000). CTGF is also known as CCN2, and the term CCN is derived from the first three 
members of the family discovered, namely CYR61, CTGF, and NOVH (Shi-Wen, Leask et 
al. 2008).  Throughout this thesis, the term CTGF will be used for this protein.  
 
Altered levels of CTGF gene expression and protein levels have been reported in tissues and 
biological fluids of diabetic subjects, especially when associated with excess fibrosis.  This 
includes diabetic nephropathy (Wang, Denichilo et al. 2001), diabetic cardiomyopathy, and 
retinopathy (Hinton, Spee et al. 2004), in which CTGF levels are elevated.  This contrasts to 
findings in skin, with baboon skin studies showing a deficiency of CTGF in diabetic wound 
tissue compared with wound tissue in non-diabetic control animals (Thompson, McLennan et 
al. 2010).  These results suggest that CTGF may have therapeutic benefit in wound healing 
although CTGF as therapy has not been examined in cutaneous wounds in diabetes.    
 
In addition to CTGF, naturally occurring substances, or ‘neutraceuticals’ isolated or purified 
from foods have a potential physiological benefit in wound healing.  Propolis is one such 
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 neutraceutical: it is a bee-derived product with reported antibacterial and anti-inflammatory 
properties and noted effects on wound cytokines including suppression of inflammatory 
cytokines which are overexpressed in diabetic wounds (Reinhold, Ansorge et al. 2003).  
Propolis has yet to be trialled in human subjects with foot ulcers in diabetes. 
 
The following literature review will discuss in more detail: 
a) the pathogenesis of complications in diabetes, focusing on wound healing; 
b) current and emerging wound healing therapies in diabetes; and 
c) the therapeutic potential of growth factors, specifically CTGF, and the beehive 
protectant propolis, to aid the wound microenvironment and promote wound healing in 
diabetes. 
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 Chapter 2 
 
LITERATURE REVIEW 
 
2.1 Tissue damage in diabetes 
 
The complications of diabetes can generally be categorised into macrovascular (coronary 
artery disease, peripheral arterial disease and stroke) and microvascular complications 
(diabetic nephropathy, neuropathy and retinopathy).  The Diabetes Control and 
Complications Trial, (DCCT 1996) and U.K. Prospective Diabetes Study, 1999 (King, 
Peacock et al. 1999) established that hyperglycaemia is the initiating cause of diabetic tissue 
damage and that targeting this parameter across many years can help to reduce both 
microvascular and macrovascular complications of diabetes. Indeed, while abnormal blood 
lipids and systemic hypertension also increase the risk of organ complications from diabetes, 
it is hyperglycaemia presence that defines diabetes mellitus and also causes complications in 
both type 1 and type 2 diabetes. 
 
Despite the enormity of the burden of diabetic complications, no single theory can explain 
hyperglycaemia-induced biochemical changes that contribute to pathology in diabetes 
(Rafehi, El-Osta et al. 2011); however, several mechanisms have been implicated in the 
pathological process, and these are shown in the schematic Fig. 2.1 overleaf:  
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 Figure 2.1: General features of hyperglycaemia-induced tissue damage.   
Adapted from Brownlee 2005 (Brownlee 2005).  
 
 
Biochemical pathways implicated in mediating adverse effects of hyperglycaemia include: 
protein kinase C, advanced glycation, aldose reductase and hexosamine pathways, and 
excessive reactive oxygen species (Brownlee 2005).  Currently poorly defined genetic 
susceptibility factors are thought to place some people more at risk of diabetes complications 
than others, and the adverse effects of these pathways (Rafehi, El-Osta et al. 2011).  While 
these metabolic pathways are thought to mediate end-organ damage, notably targeting of 
each alone has not to date been shown to prevent complications in human diabetes (Brownlee 
2005).  
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 The delayed healing in diabetic ulcers is, according to the cited studies, attributable initially 
to hyperglycaemia, however control of hyperglycaemia has not been shown to aid wound 
healing in an experimental mouse model (Berdal and Jenssen, 2013) nor in any human 
intervention studies to date.  Furthermore, factors common to other chronic wounds (e.g. 
decubitus and venous ulcers) also contribute to the failure of diabetic wounds to heal (for 
example, increased macrophage and B-cell infiltration) indicating that a number of factors are 
responsible for the recalcitrance of these wounds (Loots, Lamme et al. 1998).  Whilst 
peripheral neuropathy and peripheral arterial disease can be prevented in people with diabetes 
by long term blood glucose control, across many years (DCCT, 1996; King, Peacock et al. 
1999), relatively acute improvement of blood glucose has not been shown to aid foot ulcer 
healing in people with diabetes.  Indeed, it may be that blood glucose control is most 
important to prevent and stabilise pre-existing diabetes complications as reported in the 
DCCT (DCCT 1996), but that such a strategy is much less able to reverse these 
complications, at least acutely.  
   
2.1.1 Diabetic foot ulceration - epidemiology  
In the developed world, 2-3% of patients with diabetes are likely to have a foot ulcer at any 
given time point (Abbott Carrinagton et al. 2002; Muller, de Grauw et al. 2002).  The lifetime 
risk of a patient with diabetes developing a foot ulcer may be as high as 25% (Singh, 
Armstrong et al. 2005) and diabetes increases the risk of lower extremity amputation 10- to 
20-fold (Wrobel, Mayfield et al. 2001).  The incidence of lower-extremity amputation in 
people with diabetes ranges from 2.1 to 13.7 per 1000 patients (Bartus and Margolis 2004). 
 
The cost to healthcare systems of providing care for diabetes-related foot ulcers is high. 
According to the Fremantle Diabetes Study (Davis, Norman et al. 2006) the average length of 
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 hospital stay for a diabetes foot ulcer admission was 31 days and the cost was AUD$17,089 
in 2000 (Davis, Norman et al. 2006).  In the United States, 25-50% of the costs associated 
with diabetes-related care were attributed to the care of diabetes foot ulcers National Institute 
for Health and Clinical Excellence (NICE 2011).  A Canadian study found that the cost of 
major events attributable to diabetes foot ulcers such as lower limb amputations generates a 
greater financial burden than the cost of treating the ulcer alone (Goeree, Lim et al. 2009).  
Following amputation due to foot ulceration in diabetes, mortality rates are higher than those 
rates for most malignancies (Armstrong, Wrobel et al. 2007): 13-40% mortality at 1 year, 35-
65% at 3 years and 39-80% at 5 years, in each case mainly due to cardiovascular disease 
(Singh, Armstrong et al. 2005).  The presence of a foot ulcer in a person with diabetes 
diminishes quality of life scores by 10-40% compared with the general population, indicating 
a significant social burden (Armstrong, Lavery et al. 2008).   
 
2.1.2 Care of foot ulcers in diabetes 
Standardised protocols of care using an interdisciplinary team approach have been shown to 
lower rates of complications and amputations in patients with foot ulcers in diabetes 
(O'Loughlin, McIntosh et al. 2010).  Up to a 50% reduction in the risk of major lower-limb 
amputation is seen in patients with diabetes receiving evidence-based multidisciplinary 
treatment (Van Damme and Limet 2005).  The American Diabetes Association (ADA, 1999) 
concluded that preventative care teams - that is, multidisciplinary teams that utilise patient 
education, risk assessment tools and therapeutic footwear - can reduce amputation rates by 
50-85% (Mayfield, Reiber et al. 1998).  The importance of early recognition of the high-risk 
foot is frequently underestimated in both inpatient and outpatient settings, and this is 
attributable to the asymptomatic nature of the condition and a reluctance to conduct routine 
foot screening (Boulton, Armstrong et al. 2008), with time constraints often cited as the 
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 reason for the latter.  In people with diabetes who develop a foot ulcer, the cornerstone of 
foot care is based on: careful assessment of the foot ulcer, including precipitating and 
predisposing factors, and the coordinated administration of four key elements of care:  
• pressure offloading  
• debridement and dressings and, where indicated, 
• antibiotic therapy, and/or 
• revascularisation (Kruse and Edelman 2006) 
The individualisation of such treatments to a specific patient in a balanced manner across the 
multiple health care disciplines is key to optimising foot ulcer healing in diabetes (Boulton, 
Meneses et al. 1999, Wraight, Lawrence et al.2005).  Podiatrists, the treating physicians, 
surgeons and nursing staff all need to contribute to care in a coordinated manner in 
multidisciplinary clinics, along with broader disciplines such as microbiology and radiology.  
Wound biopsy studies are a safe, reliable and effective way of assessing tissue composition 
within a wound (Panuncialman, Hammerman et al. 2010) and radiological techniques allow 
the progression of pathological processes to be better quantified so treatment can be targeted 
accordingly.  Despite these interventions and the introduction of standardised guidelines, 
many ulcers still do not heal and others are recalcitrant. It is essential that healing in wounds 
in diabetes is optimised in order to improve patient outcomes and to minimise use of limited 
health care resources.   By doing so, gold standard outcomes of ulcer healing can be achieved 
and the need for hospital admission and extensive amputation can be minimised.  
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 2.2 Pathological events in diabetic foot ulceration 
 
A comprehensive understanding of wound healing in diabetes has yet to be realised 
(Blakytny and Jude 2006; Waugh and Sherratt 2006).  However, many important factors that 
disrupt healing in people with diabetes have been identified, and are addressed in this section.   
 
The pathology in diabetic foot ulcers is primarily attributable to co-existing ‘extrinsic’ 
factors—that is, neuropathy and vascular disease (Adler, Boyoko et al. 1999).  Studies by the 
US Department of Health and Human Services, Centers for Disease Control and Prevention, 
observed that about 20% of foot ulcers in people with diabetes are caused primarily by 
peripheral arterial disease.  In ~50% of cases neuropathy is the primary underlying cause and 
in ~35% both neuropathy and peripheral arterial disease are present (Control and Prevention 
2011).  Bacterial infection is considered a complication of diabetic foot ulceration as opposed 
to a cause but is included in this section as it delays ulcer healing.  At a cellular and tissue 
level, intrinsic pathogenic factors are also implicated in the failure of diabetic wounds to heal. 
The ‘intrinsic’ pathophysiology of the diabetic wound is discussed alongside ‘normal’ wound 
healing in detail in section 2.3. 
 
 2.2.1 Peripheral arterial disease  
Peripheral arterial disease is a manifestation of systemic atherosclerosis that is associated 
with an increased risk of death and ischemic events (Hirsch, Criqui et al. 2001). It is 
commonly diagnosed when pulse waveforms are abnormal, intermittent claudication is 
reported and/or ankle brachial pressure indices (ABPI) are less than 0.9 (Hirsch, Criqui et al. 
2001).  It must be noted that the ABPI is not a definitive measurement of peripheral arterial 
disease as calcified arteries may produce abnormally high readings (Palumbo, Melton et al. 
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 1995).  More specific tests such as Doppler flow velocity can assist with diagnosis of 
peripheral arterial disease.  People with diabetes are twice as likely to have peripheral arterial 
disease as those without (Gregg, Sorlie et al. 2004; Maly, Chovanec et al.  2010).  Early 
research into wound healing in diabetes suggested that small vessel or microvascular disease 
is a major culprit in the failure of healing in diabetic wounds (Schramm, Dinh et al. 2006).  It 
was assumed that microangiopathy, with endothelial proliferation in arterioles and basement 
membrane thickening in capillaries, delayed both the entry of essential cells into the wound 
and the clearance of metabolic by-products from the wound (Siperstein, Unger et al. 1968).  
Subsequent studies have shown that whilst microvascular disease contributes to abnormal 
wound healing and may persist in the diabetic ulcer (due to abnormal vessel permeability, 
functional ischaemia and an impaired neurogenic vasodilatory response), macrovascular 
disease is also a major co-contributor to morbidity (Donnelly, Emslie-Smith et al. 2000). 
 
The prevalence of macrovascular disease is substantially elevated in people with diabetes and 
is characterised by the presence of atherosclerosis (Gaede, Jepsen et al. 2003).  Factors that 
may contribute to the increased atherosclerosis in people with diabetes include increased 
expression of endothelial adhesion factors and platelet dysfunction (Boyle and Boyle 2007).  
People with diabetes are especially predisposed to atherosclerosis in distal vessels (vessels at 
and below the knee, for example, the tibial artery), as well as the usual larger arteries such as 
those in the pelvis and proximal leg (such as the femoral artery).  Hypoperfusion resulting 
from macrovascular disease has a profoundly detrimental effect on wound healing in distal 
tissues. Table 2.1 outlines studies that have linked peripheral arterial disease to ulcer 
development and outcomes in diabetes. 
 
 
15 
 
 Table 2.1: Studies identifying risk factors for foot ulceration, amputation and mortality 
due to peripheral arterial disease in diabetic populations.  
 
 
Study Participants Outcomes Comments 
Winkley, Stahl et al. 
2007 
253 Moderate ischaemia 
(an ABPI <0.7) 
conferred a threefold 
risk of mortality to 
subjects with diabetic 
foot ulcers (HR 2.74, 
95% CI 1.46-5.14). 
Microvascular 
complications 
predisposed 
individuals to 
recurrent ulcerations 
(HR 3.34, 95% CI 
1.17-9.56). 
The sample size was 
relatively small for 
this type of study 
Eurodiale study 
(Prompers, Huijberts 
et al. 2007).   
1,088 patients from 
14 centres 
The Eurodiale study 
linked a high 
prevalence of foot 
ulceration to baseline 
ischaemia with 
Europeans who 
present with a new 
diabetic foot ulcer 
and also linked 
ischaemia to 
increased risk of 
ulceration, 
amputation and 
mortality (p<0.001) 
There was a high 
dropout rate amongst 
older patients and 
those with deep 
ulcers, suggesting 
that these ‘worse’ 
ulcers were excluded 
and the actual 
prognosis is worse 
than the report 
suggests 
North-West Diabetes 
Footcare Study 
Abbott (Abbott, 
Carrington et al. 
2002) 
 
1035 Reduced foot pulses 
(<2/4) were shown to 
confer the risk of 
new foot ulcers.   
 
Palpation of pedal 
pulses is associated 
with a high degree of 
inter-observer 
variability and high 
false 
positive/negative 
rates 
The Fremantle 
Diabetes Study 
(Davis, Norman et al. 
2006).   
531 An ankle-brachial 
pressure index 
(ABPI) <0.9 was an 
independent 
If used alone, the 
ABPI can 
underestimate 
angiographic 
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 A relatively small study of 253 subjects by Winkley et al (2007) showed that microvascular 
complications can explain recurrent ulceration (Winkley, Stahl et al. 2007).  The Eurodiale 
study (2007) linked a high prevalence of ulceration to baseline ischaemia in Europeans 
presenting with a new foot ulcer in diabetes (Prompers, Huijberts et al. 2007).  In contrast, 
some studies have failed to show a correlation between peripheral arterial disease and 
amputation (Faglia, Favales et al. 2001; Jude, Oyibo et al. 2001), but this could be attributed 
to the study pre-plan that people with severe peripheral arterial disease (ABPI) <0.5) were 
excluded.  Furthermore, some relatively minor amputations may be neglected in some 
databases, leading to an underestimate of the total number of amputations performed. 
 
predictor of lower 
extremity amputation 
(LEA) and of 
mortality in foot 
ulcer patients with 
diabetes.  
atherosclerotic 
disease due to 
arterial calcification 
and distribution of 
disease 
Jude, Oyibo et al. 
2001 
136 arteriograms 
were analysed 
People with diabetes 
had greater severity 
of arterial disease 
below the knee (p = 
0.02); people with 
diabetes were five 
times more likely to 
require an 
amputation (41.4 vs. 
11.5%, odds ratio 
[OR] 5.4, p <0.0001). 
Mortality was higher 
in the  group with 
diabetes (51.7 vs. 
25.6%, OR 3.1, p = 
0.002), and people 
with diabetes who 
died were younger at 
presentation than 
patients without 
diabetes (64.7 +/- 
11.4 vs. 71.1 +/- 8.7 
years, p = 0.04). 
High proportion of 
hypertensive patients 
in diabetic group. 
This study showed 
that whilst diabetes 
conferred certain 
risks, it failed to 
show a correlation 
between peripheral 
arterial disease 
(PAD) and 
amputation. 
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 The Fremantle Diabetes Study (2006) reported that an ABPI <0.9 is an independent predictor 
of both lower extremity amputation and mortality in people with diabetes who have a foot 
ulcer (Davis, Norman et al. 2006).  Furthermore, this study reported that other microvascular 
manifestations of diabetes—nephropathy and retinopathy—were also associated with the risk 
of amputation.   
 
Reduced foot pulse palpation (≤2/4 pulses palpable) was shown by the North-West Diabetes 
Footcare Study ( Abbott,Carrington et al. 2002) to confer increased risk of new foot 
ulceration (Abbott, Carrington et al. 2002). 
 
Peripheral oedema is not uncommon in people with diabetes, associated with heart failure, 
end-stage renal failure, and in some cases can be caused by medications (such as calcium 
channel blockers), or venous insufficiency (Apelqvist, Larsson et al. 1992).  Peripheral 
oedema was found intercurrently in almost 50% of a cohort of people with diabetes and a foot 
ulcer with severe lower limb ischaemia.  Peripheral oedema compromises vascular dynamics, 
and it precipitates tissue ischemia and impaired healing by increasing the distance required 
for diffusion of oxygen from capillaries to the ulcer.  Oedema may reduce clearance of ulcer 
metabolites and degradation products from the ulcer site and its presence is closely associated 
with amputation and death yet it remains understudied in terms of optimal wound care, 
including in the setting of peripheral arterial disease (Apelqvist, Larsson et al. 1992).  The 
evidence presented, whilst not conclusive, suggests that peripheral vascular disease is a 
contributing factor to foot ulceration in patients with diabetes 
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 2.2.2 Neuropathy 
Diabetic neuropathy is defined as “the presence of symptoms and/or signs of peripheral nerve 
dysfunction in people with diabetes, after the exclusion of other causes” (Boulton, Gries et al. 
1998).  Neuropathic effects in diabetes mellitus can involve the sensory, motor and 
autonomic systems.  Patients with loss of sensation commonly have decreased perception of 
pain.  The loss of nociception that occurs in diabetic neuropathy is a major contributor to foot 
pathology by reducing the patient’s awareness of ulceration and infection.  Some people with 
diabetes have reduced peripheral sensation; others have only painful neuropathic symptoms, 
with loss of sensation, while both conditions sometimes exist.  There is no specific treatment 
for diabetic neuropathy where loss of sensation occurs, although there are many drugs to 
improve symptoms of painful neuropathy should they be present.  Factors contributing to the 
development of diabetic neuropathy are not well understood, although some biochemical 
pathways, such as aldose reductase may mediate the effects of elevated blood glucose to 
cause nerve damage, whether this be directly on peripheral nerves or on the blood vessels 
supplying these nerves – the so-called vasa nervorum (Feldman, Stevens et al. 1997).  Other 
than chronic hyperglycameia clinical factors associated with diabetic neuropathy include 
hyperlipidaemia, hypertension, consumption of alcohol, and presence of obesity (Huizinga 
and Peltier 2007).  The association between hyperglycaemia and diabetic peripheral 
neuropathy was best established with the DCCT trial (1996) where tight control of blood 
glucose levels led to a reduction in peripheral neuropathy onset of up to 60% in people with 
diabetes (DCCT, 1996).  Various hypotheses to explain the aetiology of diabetic peripheral 
and autonomic neuropathy exist: 
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 (i) Metabolic – Increased intracellular glucose as a result of hyperglycaemia is converted to 
sorbitol and fructose, which can cause nerve cell injury; 
(ii) Vascular – Endoneural vascular resistance to hyperglycaemia results in secondary 
capillary damage and axonal degeneration; 
(iii) Autonomic – Immunogenic alteration of capillary endothelial cells; 
(iv) Neurotrophic – Deficiency of nerve support factors such as nerve growth factor (NGF) 
can result in reduced nerve proliferation and survival; 
(v) Laminin abnormalities – Laminin promotes neurite extension and its decreased gene 
expression in diabetes could result in neuropathology (Cameron and Cotter 1997; Feldman, 
Stevens et al. 1997; Boulton, Vinik et al 2005; Duby, Campbell et al; 2004). 
 
More recently through advanced neuroimaging studies the central nervous system has been 
implicated in diabetic peripheral neuropathy (Selvarajah, Wilkinson et al. 2008).  Important 
work by Tesfayes’ group (2012) has shown that peripheral neuropathy concomitantly affects 
the central as well as peripheral nervous system (Tefsaye and Selvarajah 2012).  This finding 
goes some way to explaining components of peripheral neuropathy such as allodynia, where 
pain is elicited with non-painful stimuli.  Work by Zambreanu et al (2005) has shown this to 
be attributable to abnormalities in the spinal cord (Zambreanu, Wise et al. 2005) 
 
It is probable that interplay between these factors forms the basis for the clinical features of 
diabetic peripheral neuropathy and that no single factor is responsible for diabetic peripheral 
neuropathy.  Loss of protective sensation (sensory neuropathy) is detrimental to wound 
healing as sufferers are vulnerable to physical, chemical and thermal trauma.  Ongoing, 
unnoticed trauma is a common consequence of neuropathy as is the development of increased 
areas of high pressure on weight-bearing surfaces.  Indeed it is postulated that pressure per se 
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 can accelerate cellular ageing (Wlaschek, Scharffetter-Kochanek et al. 2005).  Motor 
neuropathy can lead to foot deformity (such as hammer toes and prominent metatarsal heads) 
and subsequently to areas of increased pressure from weight bearing or from poorly fitting 
shoes. 
 
Loss of neuronal input to local vasculature (autonomic neuropathy) may result in abnormal 
vasodilation and oedema, or vasoconstriction and ischaemia (Aring, Jones et al. 2005), 
resulting in fissures, cracking and callouses, which can contribute to foot ulceration.  
Anidrotic skin changes may also reduce tensile strength of the skin making it more prone to 
ulceration.  Table 2.2 summarises the outcomes of studies investigating neuropathy as a risk 
factor for diabetic foot ulceration. 
Table 2.2: Diabetes studies identifying neuropathy as a risk factor in foot ulceration and 
ulcer outcomes including recurrence. 
 
Study Participants Outcomes Comments 
Winkley, Stahl 
et al, 2007 
 253 
Vibration perception 
threshold (VPT) of ≥ 
25 volts was a risk 
factor for ulceration 
and for mortality. 
VPT is not itself 
independently associated 
with ulcer recurrence.   
 
The Fremantle 
Diabetes Study 
(Davis, Norman 
et al. 2006).   
531 
Neuropathy was found 
to be an independent 
risk factor for foot 
ulceration. 
The data were observational 
and not collected in a 
randomised fashion, which 
detracts from its validity. 
Abbott, 
Vileikyte et al. 
1998 
1035 
People with diabetes 
with peripheral 
neuropathy (DPN) had 
an annual first ulcer 
incidence risk which 
was higher than those 
with no DPN, 
rendering DPN a key 
ulcer risk factor. 
The rate was much higher in 
the year subsequent to the 
study, indicating that 
patients were more 
compliant whilst being 
studied. 
North-West 
Diabetes 
Footcare Study 
Abbott (Abbott, 
Carrington et al. 
9710 
An abnormal 
Neuropathy Disability 
Score (NDS) of ≥6/10 
positively correlated 
with risk of new 
NDS is a composite score 
calculated by reporting 
ankle reflex, pinprick ,and 
temperature sensation, 
vibration sense tested with 
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 2002) 
 
ulceration, (1.61-3.35 
relative risk, 95% 
confidence level). 
tuning fork and 
monofilament test.  The 
authors recommend it be 
used as a screening tool 
 Peters, 
Armstrong et al. 
2007 
81 
Examining risk factors 
for recurrence of 
diabetic foot disease, 
this study found that 
whilst neuropathy 
itself was not 
responsible for ulcer 
recurrence, an index 
ulcer on the plantar 
hallux conferred risk 
for subsequent 
ulceration (p<0.05) 
It is likely that this finding is 
due to increased peak 
plantar pressures, 
attributable to DPN. The 
study is also small, likely 
with type II error. 
Abbott et al. (1998) demonstrated that people with diabetes who exhibit peripheral 
neuropathy (DPN) have an annual first ulcer incidence risk of 7.2% compared to 4.9% in a 
comparable population with no neuropathy rendering DPN a key risk factor (Abbott, 
Vileikyte et al. 1998).  Reiber et al. (1999) found that neuropathy characterised by inability to 
feel the 10g monofilament and also Vibration Perception Threshold (VPT) of ≥ 25volts, to be 
risk factors for the development of foot ulcers (Reiber, Vileikyte et al. 1999).  The Fremantle 
Diabetes Study (2006) also found neuropathy to be an independent risk factor for foot 
ulceration (Davis, Norman et al. 2006).   
 
Winkley et al. (2007) studied a cohort of 253 people with diabetes with their first foot ulcer 
and found that a diminished VPT is also a risk factor for ulceration, and also for mortality but 
that VPT is not itself independently associated with ulcer recurrence (Winkley, Stahl et al. 
2007).  Similarly a study by Peters et al. (2007), examining risk factors for recurrence of foot 
disease in diabetes found that whilst neuropathy itself is not shown to be responsible for ulcer 
recurrence, having an index ulcer on the plantar hallux confers risk for ulceration (Peters, 
Armstrong et al. 2007).  Liang (1998) identifies neuropathy as a known risk factor for toe 
amputation (Laing, 1998). It is likely that these findings are due to increased peak plantar 
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 pressures which are in turn attributable to peripheral neuropathy. Whilst there is controversy 
as to whether neuropathy is itself an independent risk factor for ulceration, the evidence 
presented suggests it is a major contributing factor to foot ulceration in patients with diabetes.  
 
2.2.3 Other risk factors for diabetic foot ulcers, delayed healing and recurrence 
Univariate predictors of healing failure, as described by the Ghanassia (2008) group include 
smoking, end-stage renal failure and popliteal stenosis.  When pooled into a multivariate 
model, smoking and renal failure were both found to be independent predictors of poor 
healing (Ghanassia, Villon et al. 2008) .   
 
Research by Lin et al. (2009) established a link between micro/macrovascular complications 
and depression (Lin, Heckbert et al. 2009).  Furthermore, Ismail et al. (2007) reported 
depression as a factor associated with worse healing outcomes for foot ulcers in diabetes 
(Ismail, Winkley et al. 2007).  Depression is often associated with poor self-care (Gonzalez, 
Peyrot et al. 2008) which may explain the positive correlation between this type of ulceration 
and depression. 
 
A cross-sectional study of 670 subjects used both odds ratio and logistic regression analysis 
to conclude that diabetes duration, cigarette smoking, aging and microalbuminuria showed a 
strong relationship with occurrence of foot ulcers in diabetes (Guerrero-Romero and 
Rodrı́guez-Morán 1998).  These factors have all been shown to cause vascular damage, 
which is itself a predictor of diabetes foot ulceration.  The findings from this study are 
supported by similar findings in several other studies (Delbridge, Appleberg et al. 1983; 
Apelqvist and Agardh 1992).  In the large Eurodiale study (2007), clinical heart failure was 
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 found to be risk factors that adversely affect foot ulcer healing rates.(Prompers, Huijberts et 
al. 2007).   
 
2.2.4  Infection 
Bacterial infection in a foot ulcer can be defined as a foot ulcer having observable clinical 
symptoms and/or signs of inflammation such as redness, swelling, heat, and when neuropathy 
is absent, pain.  At least two of these features are thought to be required for a clinical 
diagnosis of foot ulcer infection (Boulton, Meneses et al. 1999).  In addition, other features to 
indicate infection may be present such as cellulitis, purulent exudate, and/or sinus tracking 
and deep probing of an ulcer (Boulton, Meneses et al. 1999; Joseph, Lipsky et al. 2010).   
Underlying arterial insufficiency and neuropathy often diminish the classic features of 
infection of redness, heat and swelling.  Therefore, vigilant screening for infection is 
necessary.  ‘Secondary clues’ that may indicate infection including in a foot ulcer in a person 
with diabetes, are: 
- those related to the ulcer: a positive probe-to-bone test; an ulcer present for >30 days; 
friable granulation tissue presence; wound edge undermining; copious and/or malodourous 
wound exudate; and a wound caused by trauma;  
- patient related factors: history of recurrent ulcerations  especially at a single site; and end-
stage renal failure being present  (Wounds International, 2013). 
 
For many years, bacterial infection has been regarded as a complication of ulcers in people 
with diabetes and also as a factor that exacerbates ulcer healing as opposed to being a primary 
causal factor (Robson and Heggers 1970).  It is estimated that 50-80% of foot ulcers in 
people with diabetes will become clinically infected.  In addition, clinical infection portends a 
worse prognosis for healing - approximately 20% of patients with an infected foot ulcer will 
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 require an amputation (Wu, Driver et al. 2007).  Carlson and Reed (2003) found clinical ulcer 
infection even if not involving bone and especially abscess presence, or osteomyelitis to each 
be a risk factor for toe amputation (Carlson and Reed, 2003).   
 
Bacterial presence, at least to a level of clinical infection, adversely affects ulcer healing 
(Jones, Edwards et al. 2004). Robson and Heggers (1970) reported that regardless of tissue 
type, any bacteria present at a level equal to or greater than 106 organisms/g tissue will impair 
tissue healing (Robson and Heggers 1970), and this level of bacterial load is found in 
research studies when clinical infection is present (Edmonds and Foster 2004).  According to 
data from the Australian Wound Management Association (AWMA 2011) the level of 
bacterial load in an ulcer necessary to cause clinical bacterial infection is also proportionate 
to virulence of the bacterial strain (AWMA 2011). 
 
Data has linked bacterial colonising load in a wound and in its eschar with adverse outcomes.  
Chronic ulcers typically feature heavy bacterial colonisation (Schneidner, Vildozola et al. 
1983; Dowd, Wolcott et al. 2008).  Bacteria in these types of wound exist sub-clinically in 
adhesive biofilm communities.   These biofilm communities are more resistant to anti-
microbial therapy than acute wounds (Rhoads, Wolcott et al. 2008).  James et al. (2008) 
found that 60% of chronic wounds were colonised by bacteria in a persistent biofilm, 
compared with only 6% of acute wounds (James, Swoggers et al, 2008).  Foot ulcers are a 
common chronic wound which heal at a much slower rate than acute wounds, and limited 
data suggest that debriding a biofilm from a chronic wound, whether it be clinically infected 
or not, will aid ulcer healing possibly through reduction in the bacteria present in the biofilm 
(Rhoads, Wolcott et al. 2008).  It is not known whether the bacterial burden found in most 
ulcers in diabetes is a consequence of the longevity of the wound, local wound hypoxic 
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 conditions, neutrophil dysfunction as a deficit in bactericidal killing, and/or effects of the 
hyperglycaemia or its derivatives such as advanced glycation end-products (Falanga and 
Falanga 2005).  
 
It remains unclear whether antibiotic therapy should be considered in clinically uninfected 
ulcers in people with diabetes. In one study a relationship between bacterial load and ulcer 
healing in diabetes was established from bacterial colony counts on aerobic blood agar plates 
derived from wound fluid obtained from post-debridement ulcer swabs.   Results showed 
increased bacterial colony count positively correlated with reduced ulcer healing rate (Xu, 
McLennan et al. 2007). In that particular work most ulcers were infected clinically and the 
lack of high level data to support use of antibiotic treatment in clinically uninfected ulcers has 
led to recommendation  in international guidelines of such antimicrobial use, either topically 
or systemically, for only clinically infected ulcers (IDF 2005). For the research presented in 
this thesis, an infected ulcer in diabetes is one that fulfils criteria for being clinically infected 
according to the Boulton group (1999)  and stated at the beginning of this section (2.2.4) 
(Boulton, Meneses et al. 1999).   
 
2.2.5 Classification of foot ulcers in diabetes 
Systems exist to grade ulcers according to their characteristics and severity.  These can assist 
with wound monitoring, treatment planning, comparing service delivery and in predicting 
patients ulcer healing outcomes (Oyibo, Jude et al. 2001).  The table below (Table 2.3) shows 
a comparison of three commonly used wound classification systems.   
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 Table 2.3: A comparison of wound classification systems. 
System: Description Advantages/Disadvantages References 
University of 
Texas 
A 4-grade x 4-stage 
matrix to assess degree 
of infection and 
ischaemia. 
Comprehensive description of 
ulcer types. Useful 
monitoring tool.  Does not 
formally include ulcer depth. 
Armstrong, Lavery 
et al. 1998 
Wagner A 6-grade system 
assessing ulcer depth, 
perfusion and infection. 
Does not adequately address 
all aspects of infection and 
ischaemia. Some ulcers may 
fall between the 6 categories. 
Wagner 1981 
PEDIS A descriptive table 
assessing perfusion, 
size, depth, infection 
and neuropathy using 4 
grades. 
User friendly, good for less 
experienced practitioners, but 
some ulcers may fall outside 
the stated parameters. 
Schaper 2004 
 
For the purposes of the research presented in this work, the validated University of Texas 
wound classification system has been used to categorise ulcers (Armstrong, Lavery et al. 
1998).  This system is viewed as comprehensive and was already adopted in the clinic where 
the study took place, meaning that both the staff and study personnel were familiar with its 
use and reliable data could be collected. 
 
2.3 Wound Healing and impairments to the wound microenvironment commonly 
present in diabetes 
 
Cutaneous wound healing is the complex multicellular process by which the skin repairs 
itself following injury.  This process is highly organised and occurs as a series of events 
leading to barrier restoration and functional recovery of skin strength (Barrientos, 
Stojadinovic et al. 2008).  In the case of wounded skin, healing of the dermis with wound 
closure occurs through re-epithelialisation and wound contraction (Inoue, Kratz et al. 1995; 
Sardari, Dehgan et al. 2006). Following haemostasis, normal wound healing can be depicted 
schematically with serial and overlapping phases, as shown in Figure 2.2.   
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 At the cellular level, wound healing is commonly impaired in diabetes.  Some of the events 
that are dysregulated in wound healing in diabetes are depicted schematically in Figure 2.3.  
The following text section (2.3) will address these phases in detail, focusing on healing in 
both ‘normal’ and ‘diabetes’ situations. 
 
 
 
 
Figure 2.2  Schematic diagram showing the three main stages of normal wound healing 
in humans following the ‘haemostasis’ stage.  The time course reflects healing by 
secondary intention in a cutaneous wound, with re-epithelialisation occurring in the later 
proliferative phase, as described in the text section 2.3. Adapted from Falanga (Bentzen 
2006).  
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Figure 2.3: Stages of wound healing showing the predominant cell types at each stage 
including endothelial progenitor cells (EPCs).  Neutrophil and macrophage dysfunction, 
which occur in chronic wounds, are indicated by the blue arrows.  Adapted from O’Loughlin 
and O’Brien, 2011. 
 
2.3.1  Haemostasis 
The most immediate event following wounding is haemostasis.  Platelets flow from injured 
blood vessels and adhere to surfaces of the wound, especially to collagen (via carbohydrate 
molecules on the collagen surface) (Gentry 1992).  Adenosine diphosphate and 5-HT 
(serotonin) are then released from granules within platelets, allowing them to aggregate via 
expression of ‘sticky’ glycoproteins on their cell membranes (Gentry 1992).  The aggregated 
platelets are not strong enough to sustain haemostasis but this early clumping causes 
phospholipid platelet factor 3 to be revealed on the platelet surface.  Phospholipid platelet 
factor 3 is central to the conversion of prothrombin to thrombin and subsequent haemostatic 
fibrin plug formation.  The resulting plug maintains structural support prior to the deposition 
of collagen (Midwood, Williams et al. 2004). 
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 2.3.2 Inflammatory phase 
Wound inflammation is characterised by the sequential recruitment of immune cells, release 
of inflammatory chemokines and cytokines and local infiltration of leukocytes (Stadelmann, 
Digenis et al. 1998).  Inflammatory mediators such as prostaglandins and thromboxanes are 
released from ruptured cell membranes.  This causes spasm of local blood vessels, which 
stems loss of blood and prevents removal of essential inflammatory cells from the area 
(Stadelmann, Digenis et al. 1998).  After a short time lapse, the vasoconstriction is reversed, 
largely by the action of histamine, leading to vasodilation (Witte and Barbul 1997).  
Histamine also increases vascular permeability, allowing larger proteins and inflammatory 
leukocytes to cross the vessel wall.  The subsequent movement of proteins into the 
extravascular area increases the osmolarity of the wounded tissue.  Thus, water is drawn into 
the wound area along with the larger proteins, causing a localised oedema. 
 
The plasminogen activation system potentiates the early inflammatory response via intra-
cellular signalling and the induction of cytokines (Ploplis, French et al. 1998; Lighvani, Baik 
et al. 2011).  Damaged cells release intracellular components such as heat shock proteins and 
transcription factors, which act to limit blood loss and attract anti-inflammatory cells to the 
wounded area (Nathan 2002).  Under the influence of chemotactic molecules, leukotrienes 
and prostaglandins are synthesised and work synergistically to attract leukocytes, particularly 
monocytes to the site of injury (Ploplis, French et al. 1998; Lighvani, Baik et al. 2011).   
 
Various studies have reported abnormalities in chronic wounds in diabetes compared with 
acute wounds.  Reduced leukocyte numbers, especially monocytes, are noted in wounds in 
diabetes; this is attributable to defective chemotaxis and inhibition of proliferation (Pierce 
2001).   Phenotypic changes in the leukocytes for example their increased the generation of 
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 cytokines such as TNF-α, IL-1, and IL-6 and enhanced the production of O2  (Ding, Kantarci 
et al. 2007; Brownlee, Cerami et al. 1988) also contribute to impaired wound healing, 
although the underlying mechanisms are largely unknown (Loots, Lamme et al. 1998).  
Elevated levels of chemokines and proinflammatory cytokines observed in wounds in 
diabetes may result in changes in the ECM composition that impede the healing process 
(Agren, Werthen et al. 2007).  Rather than progressing through the usual phases of wound 
healing, wods in diabetes become ‘fixed’ predominantly in the inflammatory phase (Agren, 
Werthen et al. 2007).  This occurs because the normal feedback mechanisms that down-
regulate the inflammatory stage are impaired, leading to an increased and persistent 
inflammatory response. These abnormalities are explored below. 
 
Fibronectin, a major component of ECM, plays a role in the regulation of MMPs. The relative 
deficiency of fibronectin in chronic wounds is thought to be related to increased degradation 
rather than decreased synthesis.  This is illustrated by the finding that the level of fibronectin 
mRNA is stable while fibronectin degradation products are widespread in wound fluid from 
subjects with diabetes, (Ongenae, Phillips et al. 2000).  The deficiency in fibronectin results 
in an imbalance in levels of MMPs and their tissue inhibitors, the TIMPs, which contributes 
to impaired wound healing (Lobmann, Ambrosch et al. 2002).  Browse et al. (1982, 1998) 
postulated that impaired healing in chronic wounds is partially attributable to the 
development of a fibrin peri-wound cuff (Browse and Burnand 1982; Browse 1988).  The 
cuff, a result of abnormal fibrinolytic activity, prevents gaseous exchange and traps some 
leukocytes, which in turn release cytokines, growth factors and platelet activating factor at 
the wound periphery.  These factors further impair wound healing through their local effects 
on vascular permeability and by causing endothelial damage (Browse and Burnand 1982; 
Browse 1988) 
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 2.3.2.1 Neutrophil infiltration 
Neutrophils are the earliest leukocytes to infiltrate the wound site from the blood (Singer and 
Clark 1999).  They migrate rapidly, within hours, to the wounded area, attracted by 
fibronectin and growth factors including platelet-derived growth factor (PDGF) and 
transforming growth factor beta (TGF-β) released from platelets and kinins such as 
complement component 5a and platelet activation factor.  Neutrophils release pro-
inflammatory factors such as interleukins -6 and -8 and macrophage chemoattractant protein-
1, 4 to 12 hours post wounding (Kondo, Ohshima et al. 2002).  Chemoattractant release by 
neutrophils leads to an influx of monocytes, which explains the sequential appearance of 
these two types of leukocytes in acute inflammation.  The inflammatory actions of 
neutrophils are regulated by mast cells.   
 
In normal wounds, neutrophils are scarce after 72 hours; however, neutrophils persist in 
wounds in diabetes, prolonging the inflammatory state (Wetzler, Kampfer et al. 2000). The 
excess of neutrophils, combined with decreased TGF-β and insulin-like growth factor IGF-I, 
leads to a persistent inflammatory wound environment with the accumulation of excessive 
amounts of MMPs, especially MMP-1 and MMP-9 (Lobmann, Ambrosch et al. 2002).  These 
MMPs are not matched in quantity by their regulators, the TIMPs.  This inflamed, protease-
enhanced environment leads to uninhibited tissue degradation.  
 
The capability of macrophages to phagocytose neutrophils, which is typically a key landmark 
in the conclusion of the inflammatory stage, is impaired in wounds in diabetes (Lecube, 
Pachon et al. 2011).  In diabetes this deficit in wound macrophage phagocytosis of 
neutrophils is at least partly attributable to the increased presence of pro-inflammatory 
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 mediators, which as described below, maintains an inflammatory rather than a reparative 
macrophage phenotype (Lecube, Pachon et al. 2011).  
 
2.3.2.2 Macrophage infiltration 
In response to chemoattractants such as TGF-β and fragments of ECM as well as neutrophils 
in wounds, monocytes migrate into wounds where, under the influence of pro-inflammatory 
mediators, they become activated macrophages (DiPetro 1995).  In diabetes wounds exhibit a 
persistence of inflammation by neutrophils persisting in the wound and a relative lack in 
macrophages (Ochoa, Torres et al. 2007).  The macrophage lack may in part be due to 
diminished plasminogen in the early inflammatory response:  Shen et al. (2012), showed that 
administering plasminogen to diabetic mice normalised the relative inflammatory cell 
numbers (Shen, Guo et al. 2012).   
 
Macrophages in normal healing appear to be derived mainly from circulating monocytes, 
which are themselves derived from bone marrow.  Recent studies in mice by Brancato and 
Albina (2011) characterised distinct populations of circulating monocyte phenotypes that 
have the capacity to migrate to wounds.  These monocytes displayed specific macrophage 
phenotypes upon activation, according to their monocyte precursor type (Brancato and 
Albina, 2011).  Mesenchymal stem cells migrate from bone marrow to the wound area under 
the influence of various chemokines and differentiate into a variety of cells including 
macrophages (Sasaki, Abe et al. 2008).   
 
Once a monocyte has entered a normal wound it differentiates into a macrophage and 
becomes activated.  The activated macrophage has an increased oxygen requirement, it can 
bind to ECM via integrin receptors, it expresses higher levels of major histocompatibility 
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 antigens, and has increased capacity for antigen presentation (Janeway, Travers et al. 2001). 
As a consequence of differentiation and activation the ability of macrophages to proliferate is 
diminished.  Upon exposure to cytokines, danger-associated molecular patterns and 
interferons, macrophages acquire either M1 (inflammatory) or M2 (reparative) 
characteristics.  Local helper T cells are instrumental in determining the proportions of 
inflammatory/reparative macrophages in a normal wound.(Stout and Suttles 1997).  The 
inflammatory type macrophage produces interleukins -1, -6, and -12 and TNFα and other 
chemoattractants (Koh and DiPietro 2011).  As the normal wound inflammatory stage nears 
conclusion, the macrophage alters to a reparative cell state; this change is a result of ingestion 
of apoptotic neutrophils (Fadok, Bratton et al. 1998).   
 
In wounds in diabetes this act of neutrophil phagocytosis by macrophages, which would 
normally cue macrophages to reprogramme themselves from inflammatory to reparative 
cells, is diminished and therefore macrophages continue in their inflammatory state in 
diabetes and inflammation persists in these wounds (Mosser and Edwards 2010). 
 
2.3.2.3 Advanced glycation end products 
Advanced glycation end products (AGEs) cause cellular ageing and have a range of 
detrimental effects on wound healing (Schmidt, Yan et al. 1999).  AGEs are formed through a 
series of non-enzymatic reactions mainly between glucose and proteins.  Accumulation of 
AGE proteins in wounds in diabetes is directly proportional to glycaemia and high glucose 
levels.  The mechanisms by which AGEs cause cellular damage may include structural 
modification of proteins and stimulation of cellular responses via AGE receptors such as the 
receptor for AGEs, known as RAGE (Schmidt, Yan et al. 1999).  AGEs may both bind to 
ECM and modify its function. Commonly this induces cellular oxidant stress pathways 
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 (Schmidt, Yan et al. 1999).  Preclinical and clinical data indicate that AGE activity in the 
wound microenvironment in diabetes can lead to dysregulation of: cytokines, MMPs, growth 
factor expression, and inflammatory cell infiltration and function (Schmidt, Yan et al. 1999; 
Goova, Kislinger et al. 2001).  
 
2.3.2.4 Other Molecules in Wound Healing 
Various growth factors, cytokines and proteases have been shown to regulate aspects of 
wound inflammatory processes in vitro, giving rise to the concept that these different classes 
of molecules also regulate important phases of wound healing in vivo.  These molecules are 
discussed in Table 2.4. 
 
Table 2.4: Growth factors, cytokines, proteases and some key related receptors that 
regulate wound inflammatory processes. 
Molecule & 
Origin 
Function Dysfunction in Diabetes References 
Pro-
inflammatory 
Cytokines and 
Neuropeptides 
E.g. Substance P 
 
Secreted by small 
nerve fibres 
Sensitise local mast 
cells, and activate 
neutrophils and other 
leukocytes via the local 
release of histamine and 
arachidonic acid to 
produce chemokines 
and proinflammatory 
cytokines such as 
TNFα; increase the 
permeability of blood 
vessels to allow wound 
infiltration of 
macrophages.  
Substance P increases 
fibroblast proliferation 
via natural killer (NK) 
receptors, tachykinins 
promote angiogenesis in 
vivo and in vitro.  
High levels of pro-
inflammatory TNFα and 
also the neuropeptide 
substance P, persist in 
diabetic wounds. Landis 
et al. hypothesised that 
impaired neutrophil 
apoptosis could be 
attributable to elevated 
and prolonged TNFα 
expression.  
 
Pradhan, Cai et 
al. 2011; 
Kurkowski, 
Kummer et al. 
1990; Brain 
1997; Landis, 
Evans et al. 
2010; Nieto-
Vazquez, 
Fernández-
Veledo et al. 
2008. 
 
Toll like 
receptors (TLRs) 
E.g. TLR-3 
 
TLRs recognise 
invading microbes and 
promote the production 
of inflammatory 
Dasu et al. reported that 
increased TLR -2 activity 
prolonged inflammation 
in wounds in diabetes, 
Kawai and 
Akira 2006; 
Macedo, Pinhal-
Enfield et al. 
35 
 
 Part of the innate 
immune system 
cytokines, chemokines 
and interferons which 
are essential in the 
development of the 
adaptive immune 
response by upregulated 
antigen presenting cells. 
suggesting that in some 
cases TLRs in these 
wounds may be 
detrimental to wound 
healing. 
 
2007; Dasu, 
Thangappan et 
al. 2010. 
 
 
Proteases   
E.g. MMP-2 and 
MMP-9 
 
Secreted (e.g. 
collagenases, 
gelatinases, and 
stromelysins) or 
membrane-bound; 
require activation 
via catalytic 
cleavage to 
become fully 
active. 
 MMPs are synthesised 
as proenzymes. There 
are four tissue inhibitors 
of MMPs (TIMP-1 to 
TIMP-4), Leukocytes 
are both sources of, and 
targets for, pro-
inflammatory cytokines 
such as Il-1β and TNFα, 
which are themselves 
mediators of Nuclear 
factor kappa beta 
(NFκB) and ROS.  
MMP levels are 
increased in the 
inflammatory phase of 
normal wound healing 
(Madlener, Parks et al. 
1998).  During the 
inflammatory phase in, 
for example, post-
surgical wounds, 
expression of MMP-9 
pro- and active forms is 
increased and its actions 
are largely pro-
inflammatory.  Levels 
of the activated form of 
MMP-9 correlate with 
neutrophil attraction to 
wounds through its 
ability to cleave IL-8.   
The excess of neutrophils, 
combined with decreased 
TGFβ and IGF-I, leads to 
the accumulation of 
excessive amounts of 
MMPs, especially MMP-
9.  These MMPs are not 
matched in quantity by 
their regulators, the tissue 
inhibitors of 
metalloproteinases 
(TIMPs), leading to 
uninhibited tissue 
degradation.  High 
glucose concentrations 
also increase the levels of 
MMPs.   
A high ratio MMP-9 to 
TIMP-1 protein in post-
debridement wound fluid 
predicts poor wound 
healing outcomes. Bennett 
and Schultz postulate that 
increased MMP levels in 
chronic wounds are 
responsible for the 
decrease in growth factors 
due to proteolytic activity 
of MMPs. 
Madlener, Parks 
et al. 1998; 
Watelet, Claeys 
et al. 2004; 
McLennan, 
Bonner et al, 
2008; Schleicher 
and Friess 2007; 
Liu, Min et al. 
2007; Bennett 
and Schultz 
1993; Ladwig, 
Robson et al. 
2002. 
 
Reactive oxygen 
species (ROS) 
E.g. 4-hydroxy-2-
nonenal  (a marker 
of ROS). 
 
Released by cells 
in response to 
degraded tissue 
fragments. 
 
ROS have cytotoxic and 
signalling roles. They 
are crucial in wound 
healing. When present 
in high levels they cause 
oxidative stress, which 
subsequently 
exacerbates 
inflammation.  
 
In wounds in diabetes, 
ROS activate a number of 
pro-inflammatory 
pathways and cause 
defective angiogenesis in 
response to ischaemia. 
Dissemond, 
Goos et al. 
2002;   
Giacco, 
Brownlee et al. 
2010.  
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2.3.3 Proliferative phase 
Inflammatory macrophages produce several growth factors such as PDGF, basic fibroblast 
growth factor (bFGF) and TGFβ (Rappolee, Mark et al. 1988).  These attract fibroblasts and 
endothelial cells to wound sites and encourage proliferation of these cells (Katz, Alvarea et 
CCN 
matricellular 
proteins 
E.g. CCN-1, also 
known as 
angiogenic 
inducer 61 
(CYR61 known as 
CCN1),  and 
CCN2, also 
known as 
connective tissue 
growth factor 
(CTGF) 
 
Induced by 
inflammatory 
cytokines and 
chemokines 
Modulate the 
inflammatory response 
by regulating the 
activity and expression 
of chemokines and 
cytokines.   CYR61 is 
one of many factors that 
can induce macrophages 
to the MI inflammatory 
phenotype.  CCN2 is 
chemotactic, at least in 
vitro, for macrophages, 
and its regulation and 
action is described in 
detail in section 2.7, 
using the traditional 
term ‘CTGF’ for this 
protein.  
 
Intact CTGF (CCN2) 
protein is deficient in 
wound tissue of animals 
with diabetes. 
Jun and Lau 
2011; Bai, Chen 
et al. 2010; 
Chicha, Yilmaz 
et al. 1995; 
Thompson, 
McLennan et al. 
2006. 
 
Growth factors 
E.g. Platelet 
derived growth 
factor (PDGF), 
transforming 
growth factor –
beta (TGF –β). 
 
Some growth 
factors, such as 
PDGF and TGFβ, 
are released early 
in the wound 
healing cascade 
by platelets and 
also by 
monocytes.  
Attract and activate 
macrophages and 
fibroblasts.   Induce the 
production of other 
cytokines and growth 
factors such as vascular 
endothelial growth 
factor (VEGF) and 
PDGF, which then 
initiate the formation of 
granulation tissue.  
Growth factors in 
concert help progress 
the wound from the 
inflammatory phase to 
the later proliferative 
and tissue remodelling 
phases.  Growth factors 
in wound healing are 
discussed in detail in 
sections 2.5.1, 2.6 and 
2.7.  
Growth factor levels are 
decreased in chronic 
wounds and in wounds in 
those with diabetes.  
Studies suggest that 
growth factors are not so 
much deficient as 
‘trapped’ within the 
peripheral fibrin cuff that 
surrounds wound 
capillaries. They may also 
be proteolysed in diabetes 
resulting in loss of their 
bioactivity.  
(Falanga, moosa 
et al. 1987) 
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 al. 1991).  Reparative macrophages help to remodel wound ECM; they produce IGF-I and 
PDGF.  Macrophages and macrophage-derived growth factors are essential in initiating the 
formation of new tissue in wounds tissues and they assist in the transition between 
inflammation and repair (Leibovich and Ross 1975).  It is this transition that is often delayed 
resulting in impaired healing in wounds in diabetes (Tellechea, Leal et al. 2010). 
 
Macrophage signalling, especially in reparative macrophages, induces fibroplasia (Hunt, 
Knighton et al. 1984).  The majority of fibroblasts found in wounds are recruited from local 
tissues although a small proportion are bone marrow-derived.  Fibroblasts are responsible for 
the synthesis and deposition of the ECM and the remodelling of ECM into a collagenous 
matrix (Clark, Nielsen et al. 1995).  Their presence marks the onset of the proliferative stage 
of healing.    
 
A fibroblast is able to synthesise many ECM components including collagen, 
glycosaminoglycans, glycoproteins and elastic fibres.  Fibroblast migration is governed by 
growth factors, primarily PDGF, which upregulates syndecan-4 (a proteoglycan) and other 
integrins in order to attract fibroblasts to the wounded area.  In diabetes, fibroblast 
proliferation is reduced, causing a delay in healing (Loots, Lamme et al. 1999).  This extent 
of this proliferative defect is proportional to hyperglycaemia (Hehenburger, Heilbom et al. 
1998).   
 
Growth factor degradation through proteolysis is quite common in subjects with diabetes 
(Roth, Piekarek et al. 2006) reflecting the increased inflammatory and protease active 
environment in these wounds (Wetzler, Kampfer et al. 2000).  This notion is supported by 
Wlaschek et al (1997), who showed that the most prominent isoform of PDGF is degraded by 
38 
 
 wound fluid from chronic venous leg ulcers and that the loss of PDGF stability could be 
prevented by addition of specific protease inhibitors  (Wlaschek, Peus et al. 1997). 
 
Fibroblast-derived enzymes such as collagenases and stromelysin may partially proteolyse 
ECM in order to cleave pathways for cell migration.  In the latter stages of healing, 
fibroblasts differentiate into more specialised, activated cells, termed myofibroblasts, which 
have contractile and remodelling functions.  The phenotypic transition of fibroblast to 
myofibroblast is precipitated by changes in the local mechanical microenvironment (Midgley, 
Rodgers et al. 2013).  Fibroblasts are usually protected from cellular invasion by foreign 
bodies and by proteolytic degradation by cross-linked fibres within the ECM.  However, 
when tissue is injured, this protection is lost as the ECM is continuously remodelled and 
fibroblasts acquire contractile stress fibres.  The acquisition of these stress fibres is the 
intermediate step between fibroblast and myofibroblast, and at this stage the cell is commonly 
referred to as the ‘protomyofibroblast’ (Tomasek, Gabbiani et al. 2002).  When granulation is 
complete fibroblasts die by apoptosis (Akasaka, Ono et al. 2010) and the cell-rich granulation 
tissue transforms into a relatively acellular collagenous tissue. 
 
Once granulation tissue has developed, keratinocytes lose their anchorage to basement 
membranes and under the influence of multiple growth factors such as epithelial growth 
factor (EGF) and IGF-I migrate into wounds for the purpose of re-epithelialisation 
(Nickoloff, Mitra et al. 1988).  VEGF is a key growth factor in the proliferative phase.  It 
induces endothelial cell proliferation and migration and vasopermeability which is required 
for wound healing (Aiello and Wong 2000).  VEGF protein levels are reduced in chronic 
non-healing wounds due to protease activity (Lauer, Solberg et al. 2000).  Motility and 
proliferation of keratinocytes is controlled by chemicals such as nitric oxide and by growth 
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 factors (Witte, Barbul et al. 2002).  More recent studies have shown that contact with 
fibroblasts stimulates migration and proliferation of keratinocytes, and that without such 
contact keratinocyte proliferation slows significantly (Wang, Wang et al. 2012). 
 
Angiogenesis must occur concurrently with fibroblast, keratinocyte and endothelial cell 
proliferation as this proliferation is dependent on the local availability of oxygen.  
Angiogenesis involves the activation of local endothelial cells and circulating endothelial 
progenitor cells by growth factors such as VEGF.  Under the influence of these angiogenic 
factors, endothelial cells develop pseudopodia and migrate through the ECM to form new 
blood vessels.  Fibrin is a potent promoter of endothelial cell migration (Potter, Linge et al. 
2006) and has also been implicated in angiogenesis.  MMPs contribute to angiogenesis by 
digesting basement membrane, which permits cell proliferation and angiogenesis (Lansdown, 
Sampson et al. 2001).  In a hypoxic environment macrophages and platelets produce 
angiogenic factors to promote angiogenesis.  These factors are then switched off when 
sufficient blood flow is restored to reverse the hypoxia (Greenhalgh 1998).  Simultaneously 
endothelial cell migration and proliferation is reduced when perfusion is adequate. 
 
2.3.4 Wound contraction and remodelling 
Following the proliferative stage, a wound must undergo a period of remodelling in order to 
acquire tensile strength.  Collagen molecules replace the ECM proteins; the predominant type 
of collagen switches from type III in early wounding to type I later (Robins, Milne et al. 
2003).  Collagen fibrils become stabilised via inter and intra-molecular cross linking and 
proteoglycans organise the collagen and contribute to tensile strength.  This process may take 
many months and, in comparison to normal skin, the wounded area will always have a tensile 
strength deficit (Robins, Milne et al. 2003).   
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 As normal wounding is resolved, cells associated with later wound healing such as 
myofibroblasts, undergo apoptosis and are phagocytosed.  Redundant blood vessels regress 
and wound contracture is completed (Robins, Milne et al. 2003).  Wound contraction and 
remodelling is mediated by myofibroblasts, which give wound tissue muscle-like 
characteristics of contraction and resistance to deformation, as first described by 
Abercrombie (1956) (Abercrombie, James et al. 1956).  Another phenotypic hallmark of the 
myofibroblast is its expression of high levels of α-smooth muscle actin (αSMA) (Darby, 
Skalli et al. 1990).  Due to its abundance in myofibroblasts, αSMA is the most commonly 
used molecular marker for myofibroblasts.  For this reason αSMA was used as a parameter to 
quantitate wound healing in the studies reported in this thesis. 
 
In diabetes, collagen levels are markedly reduced due to both decreased collagen synthesis 
and increased collagen degradation (Spanheimer, Umpierrez et al. 1988).  This contributes to 
the delay in overall healing, and a loss of tensile strength in foot ulcers in diabetes 
(Spanheimer, Umpierrez et al. 1988).  The presence of advanced glycation of ECM in 
diabetes is thought to contribute to the increased ‘stiffness’ in intact skin and in healed 
wounds in diabetes with an associated loss of wound tensile strength (Spanheimer, Umpierrez 
et al. 1988).  
 
An overview of normal wound healing and the factors that contribute to impaired healing in 
the wound in diabetes has been presented.  The aim of this work was to explore the 
possibility of improving wound healing using topical therapies.  Currently many therapies 
exist whose purpose is to enhance wound healing in diabetes.  The following section 
discusses these therapies. 
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 2.4 Current therapies in foot ulceration in diabetes  
 
Foot ulcers in diabetes are chronic and complex wounds that often have a profound and 
sometimes devastating impact on the quality of life of the sufferer and cause a significant 
financial burden to healthcare providers.  For this reason there is an urgent need to improve 
wound healing in people with diabetes.  Current treatment regimens, as discussed in section 
2.1.2 include offloading, debridement, dressing, infection control and revascularisation 
(Kruse and Edelman 2006).  Other therapies including negative wound pressure (NWPT), 
vacuum assisted closure (VAC), skin substitutes, hyperbaric oxygen and various growth 
factor therapies (Hopf, Humphrey et al. 2001).  Autologous platelet plasma gel (Driver, Hanft 
et al. 2006), ultrasound (Ennis, Foremann et al. 2005) and various autologous engineered 
scaffoldings (Uccioli, Giurato et al. 2011) have also been investigated as potential wound 
healing therapies and are discussed in this section.  
 
In Australia the National Health and Medical Research Council (NHMRC) National 
Evidence-Based Guideline for the Prevention, Identification and Management of Foot 
Complications in Diabetes’ (NHMRC 2011) have graded the evidence of current wound 
healing interventions based on NHMRCguidelines, (NHMRC 2009).  In order for continuity 
when assigning grades of recommendation, the NHMRC has formulated descriptors of the 
type of evidence that can be attributed to each grade of recommendation.  These guidelines 
are aimed at facilitating clinical decision making for health professionals in order to optimise 
patient outcomes, and are shown in Table 2.5.   
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 Table 2.5 Definition of NHMRC grades of recommendations.  
Adapted from National Health and Medical Research Council (NHMRC 2009). 
 
 
National Evidence-Based Guideline for the Prevention, Identification and Management of 
Foot Complications in Diabetes wound care guideline is shown in Table 2.6 (NHMRC2011). 
In general, Grade A or B Recommendations are high levels of Recommendation, whilst 
Grade C or D are much weaker Grades. 
 
NHMRC guidelines state that:  
‘Grades of recommendation are intended to indicate the strength of the body of evidence 
underpinning the recommendation. This should assist users of the clinical practice guidelines 
to make appropriate and informed clinical judgments. Grade A or B recommendations are 
generally based on a body of evidence that can be trusted to guide clinical practice, whereas 
Grades C or D recommendations must be applied carefully to individual clinical and 
organisational circumstances and should be interpreted with care’ (NHMRC 2009). 
 
 
 
 
Grade of recommendation  Description  
A  Body of evidence can be trusted to guide practice.  
B  Body of evidence can be trusted to guide practice in 
most situations.  
C  Body of evidence provides some support for 
recommendation(s) but care should be taken in 
application.  
D  Body of evidence is weak and recommendation must 
be applied with caution.  
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 Table 2.6: Synopsis of NHMRC guidelines regarding established wound care practices. 
Intervention     Description                                    Level of Evidence 
Adapted from The National Evidence-Based Guidelines: Prevention, Identification and 
Management of Foot Complications in Diabetes, (NHMRC 2011). 
  
Topical hydrogel 
dressings 
May be considered for autolytic 
debridement to assist the 
management of non-ischaemic, non-
healing ulcers with dry, non-viable 
tissue. 
 
Grade B 
 
Pressure reduction Otherwise referred to as 
redistribution of pressure or 
offloading, is required to optimise 
the healing of plantar foot ulcers. 
 
Grade B 
 
Total contact 
cast or other device 
rendered irremovable 
Offloading of the wound can be 
achieved with the use of a total 
contact cast or other device rendered 
irremovable. 
 
 
 
Grade B 
Topical negative pressure 
therapy 
May be considered for foot ulcers in 
specialist centres, as part of a 
comprehensive wound management 
program. 
 
 
 
Grade B 
Hyperbaric oxygen 
therapy 
May be considered for foot ulcers in 
specialist centres, as part of a 
comprehensive wound management 
program. 
 
 
 
Grade B 
Larval therapy May be considered for foot ulcers in 
specialist centres, as 
part of a comprehensive wound 
management program. 
 
 
Grade C 
Skin replacement 
therapies 
 
• Cultured skin 
equivalents 
 
• Skin grafting 
May be considered for foot ulcers in 
specialist centres, as part of a 
comprehensive wound management 
program. 
 
 
 
 
 
Grade B  
 
Grade D 
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 As yet no therapy has attained an ‘A’ grading, indicating that the pinnacle of wound healing 
therapies has yet to be reached. These therapies along with other emerging wound treatments 
are discussed in detail in the remainder of this chapter. 
 
2.4.1 Dressings 
Most dressings are designed to create and maintain a moist wound healing environment, 
which is optimal for wound healing (Bishop, Walker et al. 2003).  Factors that must be 
considered when choosing a wound dressing include: 
• Location and size of wound 
• Amount and type of exudate 
• Type of wound tissue and periwound tissue 
• Compatibility with other therapies (e.g. casts) 
• Wound bioburden/infection risk 
• Patient pain, quality of life and wellbeing 
• Cost and ease of application  
 
The table below is a synopsis of the types of dressings available.  Briefly, alginates, foams, 
polyhexamethylene biguanide (PHMB) and silicones are useful for heavily exudating wounds 
due to their absorbent capacity.  Honey, silver, PHMB and iodine are useful for critically 
colonised wounds; however, systemic antibiotic therapy is necessary when a wound is 
clinically infected or increasing in size (Brown 2006).   
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 Table 2.7: The relative merits of commonly used wound dressing types.   Adapted from: 
International Best Practice Guidelines: Wound Management in Diabetic Foot Ulcers. 
Wounds International, (2013) (Wounds International, 2013). 
Type Actions Indications/use Precautions/contraindication
s Alginates Absorb fluid 
Promote autolytic 
debridement 
Control moisture 
Conform to the 
wound bed 
For use in moderate to highly 
exuding wounds 
Designed to be used to fill cavities, 
these dressings often exist  in the 
form of rope or ribbon and may be 
combined  with silver for 
antimicrobial activity 
Do not use on dry/necrotic 
wounds Use with caution on 
friable tissue (may cause 
bleeding) 
Do not pack cavity wounds 
tightly 
Foams Absorb fluid 
Deliver moisture 
control 
Conform to the 
wound bed 
Moderate to high exuding wounds 
Special cavity presentations in the 
form of strips or ribbon 
Low adherent versions available for 
patients with fragile skin 
Combined presentation with silver or 
PHMB for antimicrobial activity 
Do not use on dry/necrotic 
wounds or those with minimal 
exudate 
Honey Rehydrates the 
wound bed Promotes 
autolytic debridement 
Antimicrobial action 
Sloughy, low to moderate exuding 
wounds Critically colonised wounds 
or with clinical signs of wound 
infection 
May cause 'drawing' pain 
(osmotic effect) 
Known sensitivity  
Hydrocolloids Absorb fluid  
Promote autolytic 
debridement 
Clean, low to moderate exuding 
wounds Combined presentation with 
silver for antimicrobial activity 
Do not use on dry/necrotic 
wounds or high exuding 
wounds 
May encourage over-
granulation  
   Hydrogels Rehydrate wound bed 
Control moisture  
Promote autolytic 
debridement  
Dry/low to moderate exuding 
wounds Combined presentation with 
silver for antimicrobial activity 
Do not use on highly exuding 
wounds 
or where anaerobic infection is 
suspected  
May cause maceration 
Iodine Antimicrobial action Critically colonised wounds or 
clinical signs of infection 
Low to high exuding wounds 
Do not use on dry necrotic 
tissue 
Known sensitivity to iodine 
Short-term use recommended 
(risk of systemic absorption) 
Low-adherent 
wound contact 
layer 
(silicone) 
Protect new tissue 
growth Atraumatic to 
periwound skin  
Conformable to body 
t  
Low to high exuding wounds 
Use as contact layer on superficial 
low exuding wounds 
May dry out if left in place for 
too long  
Known sensitivity to silicone 
PHMB 
(polyhexamet
hylene 
biguanide) 
Antimicrobial action Low to high exuding wounds 
Critically colonised wounds or 
clinical signs of infection 
May require secondary dressing 
Do not use on dry/necrotic 
wounds Known sensitivity 
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 Odour control 
(e.g. activated 
charcoal) 
Odour absorption Malodorous wounds (due to excess 
exudate) May require antimicrobial 
if odour due to increased bioburden 
Do not use on dry wounds 
Protease 
modulating 
Active or passive 
control of wound 
protease levels is 
achieved 
Clean wounds that are not 
progressing despite correction of 
underlying causes, exclusion of 
infection and optimal wound care 
Do not use on dry wounds or 
those with leathery eschar 
Silver Antimicrobial action Critically colonised wounds or 
clinical signs of infection 
Low to high exuding wounds 
Combined presentation with foam 
and alginates for increased 
absorbency.  
    
Some may cause discolouration 
Known sensitivity 
Discontinue after 2 weeks if no 
improvement and re-evaluate 
Polyurethane 
film 
Moisture control 
Breathable bacterial 
barrier  
Transparent (allows 
visualisation of 
wound) 
Primary dressing over superficial 
low exuding wounds 
Secondary dressing over alginate or 
hydrogel for rehydration of wound 
bed 
Do not use on patients with 
fragile/ compromised 
periwound skin 
Do not use on moderate to high 
exuding wounds 
Other more advanced dressings (e.g. collagen and bioengineered tissue products) may be considered for 
wounds that are not healing adequately; these are discussed in section 2.4.6. 
 
 
 
Dressings may be useful delivery vehicles for the wound healing therapies such as those 
tested in the studies within this thesis.  Whilst wound dressings are useful in helping to 
optimise the wound environment and/or reducing bacterial burden, no single dressing fulfils 
all the requirements to heal a foot ulcer in diabetes (Hilton, Williams et al. 2004) and further 
research is warranted in this area.   
 
2.4.2 Pressure reduction and total contact casts 
As previously discussed, the feet of patients with peripheral neuropathy are subject to areas 
of high pressure forces that frequently result in ulceration.  It is important to offload at-risk 
areas of the foot and redistribute these pressures more evenly.  Total non-weight-bearing 
using crutches or a wheelchair provides effective offloading, but levels of patient compliance 
are poor.  Shoes and in-shoe devices such as orthoses and insoles are well tolerated in the 
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 ambulant patient but their offloading capacity is limited (16-52% offloading improvement 
compared to flat rubber-soled shoes) (Cavannagh and Bus 2011). 
 
It is generally accepted that the best ‘compromises’ between patient ambulation and 
offloading, are the total contact cast (TCC) and the removable cast walker (RCW).  In clinical 
trials the RCW improved offloading by 64-92% compared to control rubber-soled shoes 
(Lavery, Vela et al. 1996).  Subsequent studies by Armstrong et al. (2001) showed the TCC 
to be more effective in healing diabetic foot ulcers than the RCW or modified half shoe 
(Armstrong, Nguyen et al. 2001).  Patients with removable devices wear them less and 
ambulate more than those issued with non-removable TCCs (Armstrong, Nguyen et al. 2001).  
The irremovable TCC is therefore considered the ‘gold standard’ of offloading, but it can 
complicate dressing changes.  This problem is frequently circumvented by bi-valving the cast 
and fixing the two halves in place with bandaging, which facilitates removal of the cast for 
wound visualisation and dressing changes. 
 
2.4.3 Negative wound pressure therapy (NWPT) 
NWPT accelerates wound healing by increasing local blood flow, aiding the formation of 
granulation tissue and decreasing bacterial load (Argenta and Morykwas 1997).  Multicentre 
studies showed NWPT to be more effective than advanced moist wound therapy (hydrogels) 
in healing diabetic wounds (Blume, Walters et al. 2008).  NWPT over lower extremity 
wounds with exposed bone greatly reduced the amount of tissue oedema, thus decreasing the 
surface area of the wound as shown in in studies by DeFranzo et al. (2001) where profuse 
granulation tissue was observed to form rapidly in the wounds treated with NWPT and these 
complex wounds showed improved healing (DeFranzo, Argenta et al. 2001).  
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 Due to the expensive and cumbersome nature of NWPT systems and issues with maintaining 
a good vacuum seal around the intricate architecture of the foot, NWPT is more useful in 
large, complex wounds with an ischaemic component rather than as an everyday therapeutic 
option for less complex ulcers. 
 
2.4.4 Hyperbaric oxygen therapy (HBOT) 
The therapeutic use of oxygen under pressure is known as hyperbaric oxygen therapy 
(HBOT) and has been used to assist wound healing.  HBOT has been shown experimentally 
to improve wound tissue hypoxia, enhance perfusion, reduce oedema and down regulate 
inflammatory cytokines, whilst promoting fibroblast proliferation, collagen production and 
angiogenesis (Gill and Bell 2004).  HBOT has also been proposed as a 
bactericidal/bacteriostatic treatment through its enhancement of the effects of anti-microbial 
drugs and its ability to restore leukocyte function by increasing tissue oxygen tension (Çimşit, 
Uzun et al. 2009). 
 
There have been few trials of HBOT.  The reported trials have been largely in favour of 
HBOT (Baroni, Porro et al. 1987; Abidia, Laden et al. 2003) but they have been consistently 
flawed in design and have not provided compelling evidence, being based mostly on case 
studies.  Other limitations of these studies include small cohorts, poor therapy compliance, a 
lack of investigator or patient blinding, inadequate descriptions of the types of wounds 
enrolled, and disparities in allocation of treatment (Lipsky and Berendt 2010).  Recently the 
Cochrane review (Kranke, Bennett et al. 2012) of nine HBOT clinical trials (of which 8 
enrolled diabetic foot ulcers) concluded that: 
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  “In people with foot ulcers due to diabetes, HBOT significantly improved the ulcers healed 
in the short term but not the long term and the trials had various flaws in design and/or 
reporting that means we are not confident in the results. More trials are needed to properly 
evaluate HBOT in people with chronic wounds; these trials must be adequately powered and 
designed to minimise all kinds of bias.” (Kranke, Bennett et al. 2012). 
 
This conclusion highlights the need for further research into this controversial and expensive 
therapy.  It is likely that other topical therapies will in the long term be more cost effective 
and easier to administer than HBOT and unless HBOT shows remarkable results in high 
quality clinical trials it is unlikely to become a mainstream therapy.  
 
2.4.5 Larval therapy 
Also known as ‘maggot therapy’ or ‘biosurgery’, larval therapy is a popular tool for the 
debridement of sloughy and necrotic material, especially in painful ischaemic wounds.  
Larvae have two mechanisms of action.  Firstly their mandibular hooks mechanically break 
down tissue.  Secondly the larvae produce secretions containing proteolytic enzymes that 
further break down devitalised tissue into an ingestible form that the larvae then feed on 
(Chambers, Woodrow et al. 2003).  Larval therapy is not a cosmetically or psychologically 
acceptable treatment for some individuals; however, the ability of larvae to debride most 
wounds in 3-5 days renders them both clinically and financially attractive as a wound 
therapy.    
 
2.4.6 Skin substitutes 
Bioengineered skin substitutes have been fabricated according to specific functional 
objectives (Boyce and Warden 2002), using both artificial and natural ECM proteins (Raeber, 
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 Lutolf et al. 2005).  Examples of artificial skin substitute materials include polyethylene 
glycol macromers, polylactide and poly-ethylene terephthalate.  Natural materials used as 
artificial ECM include hyaluron, fibronectin, collagen and alginates. 
 
Balasubramani et al (2001) classified skin substitutes into three classes according to their 
preparation and composition (Balasubramani, Kumar et al. 2001): 
Class I skin substitutes consist of epidermal-equivalent-only, naturally occurring or biological 
dressing substitute, e.g. amniotic membrane or synthetic dressing substitute, e.g. synthetic 
polymer sheet (Tegaderm®, Opsite®), (Halim, Khoo et al. 2010). 
Class II skin substitutes encompass dermal components from processed skin or fabricated 
with collagen and other matrix proteins e.g. Apligraft® (Organogenesis, Inc., Canton, MA, 
USA, and Novartis Pharmaceuticals Corp., East Hanover, NJ, USA) composed of type I 
bovine collagen and allogeneic keratinocytes and neonatal fibroblasts. 
Class III skin substitutes possess distinct dermal and epidermal components and are popularly 
referred to as composite skin e.g. Dermagraft® (Advanced BioHealing, La Jolla, CA, USA) 
is a bioabsorbable polyglactin mesh seeded with allogeneic neonatal fibroblasts (Kumar 
2008). 
 
Problems and limitations with existing skin substitutes include impaired vascularisation due 
to poor anastamoses between graft and bed areas (O'Ceallaigh, Herrick et al. 2006); absence 
of differentiated structures such as sweat glands, hair follicles and pigment; and subsequent 
scarring.  Skin substitutes also suffer from the high financial costs associated with research, 
development, cell sourcing and biocompatibility (Metcalfe and Ferguson 2007). Therefore, 
this type of therapy is often overlooked in favour of less expensive topical wound treatments.  
Such scaffolds do, however, have the potential to be used as delivery vehicles for topical 
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 treatments such as growth factor therapies (Geer, Swartz et al. 2005; Wang, Leong et al. 
2008).   
 
Aside from existing wound treatments for diabetic foot ulcers, advanced wound healing 
therapies are constantly being developed as understanding of regenerative processes and 
potential interventions in wound healing advance.  The following section explores the 
evidence and strength of emerging therapies that are still in various stages of research and 
development. 
 
2.5 Emerging Wound Healing Therapies in Diabetes 
 
2.5.1 Topical growth factors as therapy 
Growth factors are polypeptide proteins that regulate cell proliferation, differentiation, organ 
growth and metabolism of target cells (Hopf, Humphrey et al. 2001).  Studies conducted to 
test the efficacy of growth factors in treating foot ulcers in diabetes are summarised in the 
table below (Table 2.8) and the biologic actions of growth factors are discussed in detail in 
Sections 2.6 and 2.7.   
 
Table 2.8: Studies of growth factors in human foot ulcer healing in diabetes. 
Intervention Study Title/Author Experimental 
design/cohort 
Outcome 
Basic 
Fibroblast 
Growth 
Factor 
(bFGF) 
Application of basic 
fibroblast growth factor 
may reverse wound 
healing impairment in 
diabetes. 
 
Robson, Phillips et al. 
1992 
 
Randomised, 
blinded, 
placebo-
controlled 
human trial. 
 
n=50 
Histologically, fibroblast and 
capillary counts were elevated in 
treated subjects, all of whom had 
longstanding pressure sores.  
More patients treated with bFGF 
achieved > 70% wound closure 
(p < 0.05). 
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  Effect of topical basic 
fibroblast growth factor 
on the healing of 
chronic neuropathic 
ulcer of the foot in 
diabetes. A pilot, 
randomized, double-
blind, placebo-
controlled study. 
 
Richard, Parer-Richard 
et al. 1995 
Pilot, 
randomised, 
double-blind 
study. 
 
n=17 
In the bFGF group, three of nine 
ulcers healed compared with five 
of eight in the placebo group 
(NS).  Percent healed area at the 
end of the study did not differ 
significantly. Topical application 
of bFGF has no advantage over 
placebo for healing chronic 
neuropathic diabetic ulcer of the 
foot. 
Epidermal 
Growth 
Factor 
(EGF) 
 
Intra-lesional injections 
of recombinant human 
epidermal growth 
factor promote 
granulation and healing 
in advanced foot ulcers 
in diabetes: 
multicentre, 
randomised, placebo-
controlled, double-
blind study. 
 
Fernandez-Montequın, 
Valenzuela-Silva et al. 
2009 
 
Multicentre, 
double-blind, 
placebo-
controlled trial. 
 
n=149 
Granulation tissue covering ≥ 
50% of the ulcer at 2 weeks was 
achieved by 19/48 controls 
versus 44/53 in the 75 µg EGF 
group [odds ratio (OR): 7.5; 95% 
confidence interval (CI): 2.9-
18.9] and 34/48 in the 25 µg 
EGF group (OR: 3.7; 1.6-8.7). 
No drug-related severe adverse 
reactions were reported;  
Granulocyte 
Colony 
Stimulating 
Factor (G-
CSF) 
Effects of granulocyte-
colony stimulating 
factor in the treatment 
of foot infection in 
diabetes. 
 
Yonem, Cakir et al. 
2001. 
Double-blind, 
placebo-
controlled trial 
 
n=30 
Duration of hospitalization (26.9 
+/- 2.0 vs. 28.3 days; P>0.05, 
NS), duration of parenteral 
antibiotic administration (22.9 
+/- 2.0 vs. 23.3 +/- 1.9 days, p 
<0.05), time to resolution of 
infection (23.6 +/- 1.8 vs. 22.3 
+/- 1.7 days, p < 0.05), and need 
for amputation (13.3% vs. 20%), 
P>0.05, NS) were similar 
between the G-CSF and the 
standard groups 
 Trial of recombinant 
granulocyte colony-
stimulating factor as 
adjunctive therapy for 
limb-threatening foot 
infection in diabetes. 
 
De Lalla, Pellizzer et 
al. 2001. 
Randomised 
prospective 
controlled trial. 
 
n=40 
The administration of G-CSF for 
3 weeks as an adjunctive therapy 
for limb-threatening diabetic foot 
infection was associated with a 
lower rate of amputation within 9 
weeks after the commencement 
of standard treatment (p<0.038).  
No significant differences in 
wound closure were observed 
between the groups. 
53 
 
 Platelet 
Derived 
Growth 
Factor 
(PDGF) 
Efficacy of topical 
recombinant human 
platelet derived growth 
factor on wound 
healing in patients with 
chronic lower limb 
ulcers in diabetes. 
 
Jaiswal, Gambhir et al. 
2010. 
Randomised, 
blinded, 
placebo-
controlled 
human trial. 
 
n=50 
At the end of 10 weeks, 18 
(72%) ulcers had healed in 
control group and 15 (60%) in 
test group (p >0.05). Three 
ulcers in the control group 
showed >75% reduction in size 
compared to 2 in the test group 
(p >0.05). There was no 
statistically significant 
improvement in ulcer healing 
rates after the use of topically 
applied rhPDGF. 
 Clinical evaluation of 
recombinant human 
platelet – derived 
growth factor for the 
treatment of lower 
extremity ulcers in 
diabetes. 
 
Steed et al. 1995. 
Double-blind, 
placebo-
controlled, 
multicentre 
study. 
 
n=118 
Twenty-nine (48%) of 61 
patients randomized to the 
rhPDGF-BB homodimer group 
achieved complete wound 
healing during the study 
compared with only 14 (25%) of 
57 patients randomized to the 
placebo group (p=0.01). The 
median reduction in wound area 
in the group given rhPDGF-BB 
was 98.8% compared with 
82.1% in the group given 
placebo (p =0.09). There were no 
significant differences in the 
incidence or severity of adverse 
events between the rhPDGF-BB 
and placebo groups. 
 Randomised clinical 
trial comparing OASIS 
wound matrix to 
Regranex (PDGF) gel 
for ulcers in diabetes. 
 
Niezgoda, Van Gils et 
al. 2005. 
 
Randomised, 
prospective, 
controlled 
multicentre trial 
at 9 outpatient 
wound care 
clinics. 
 
n=73 
After 12 weeks of treatment, 18 
(49%) OASIS-treated patients 
had complete wound closure 
compared with 10 (28%) 
Regranex-treated patients. 
 
The sample size was not large 
enough to demonstrate that the 
incidence of healing in the 
OASIS group was statistically 
superior (p =0.055). The study 
showed that treatment with 
OASIS is as effective as 
Regranex in healing full-
thickness diabetic foot ulcers by 
12 weeks. 
 Effectiveness of 
recombinant human 
platelet-derived growth 
factor for the treatment 
of diabetic neuropathic 
Retrospective 
cohort study. 
 
n=24,898 of 
whom 9.6% 
RhPDGF was more effective 
than standard therapy in both 
helping a wound to heal (relative 
risk (RR) was 1.32 [1.22, 1.38] 
and preventing amputation, RR 
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 foot ulcers. 
 
Margolis, Bartus et al. 
2005. 
 
received PDGF. 0.65 (0.54, 0.78). Its effect was 
similar to the efficacy estimates 
from previously published 
randomised controlled trials. 
 Efficacy and safety of a 
topical gel formulation 
of Recombinant 
Human Platelet-
Derived Growth 
Factor-
BB(Becaplermin) in 
patients with chronic 
neuropathic diabetic 
ulcers. 
 
Wieman 1998. 
A phase III 
randomised 
placebo-
controlled 
double-blind 
study. 
 
n=382 
 
Compared with placebo gel, 
becaplermin gel 100 µg/g 
significantly increased the 
incidence of complete wound 
closure by 43% (50 vs. 35%, p = 
0.007) and decreased the 
time to achieve complete wound 
closure by 32% (86 vs. 127 days; 
estimated 35th percentile, 
p = 0.013). 
 
 Efficacy of 
recombinant human 
platelet-derived growth 
factor (rhPDGF) based 
gel in diabetic foot 
ulcers: A randomised, 
multicentre, double-
blind, placebo-
controlled study in 
India. 
  
Hardikar, Reddy et al. 
2005. 
 
A randomised, 
multicentre, 
double-blind, 
placebo-
controlled 
study. 
 
n=111 
Efficacy evaluations carried out 
at 10 and 20 weeks showed that a 
significantly higher (p < 0.01) 
percentage of patients (40% 
higher at 10 weeks and 32% 
higher at 20 weeks) in the 
rhPDGF-based gel-treated group 
achieved complete healing 
compared to the placebo-treated 
group. The average time to 
healing was significantly shorter 
in the treatment group (46 days) 
compared to the placebo group 
(61 days) at 10 weeks (p< 0.001) 
and also significantly shorter in 
the treatment group (57 days) 
versus the placebo group (96 
days) at 20 weeks (p < 0.01). 
The incidence of adverse events 
was low in both groups. 
 Treatment of 
nonhealing foot ulcers 
in diabetes with a 
platelet-derived growth 
factor gene-activated 
matrix (GAM501): 
Results of a Phase 1/2 
trial. 
 
Mulder et al. 2009. 
Pilot study to 
evaluate 
the safety, 
maximum 
tolerated dose, 
and preliminary 
biological 
activity of 
GAM501. 
 
n=15 
Following treatment with a 
replication-defective adenovirus 
encoding (PDGF)-B, there were 
no apparent differences in wound 
closure between the doses. 
However, the study was 
underpowered. 
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  Recombinant human 
platelet-derived growth 
factor-BB 
(becaplermin) for 
healing chronic lower 
extremity ulcers in 
diabetes. 
 
Embil, Papp et al 2000. 
Open-label 
clinical 
evaluation. 
 
n=134 
Complete healing of ulcers was 
achieved in 57.5% of patients, 
with a mean time to closure of 63 
days and a recurrence rate of 
21% at 6 months. Of the 
potential factors affecting ulcer 
healing, only drug compliance (p 
< 0.001), dressing compliance (p 
< 0.01), the presence of infection 
(p < 0.01), baseline ulcer area (p 
< 0.05), and baseline total wound 
evaluation score (p < 0.05) were 
significantly associated with 
healing. Results of this study 
further confirmed the efficacy 
and safety of becaplermin gel for 
the treatment of lower extremity 
diabetic ulcers. 
 Efficacy and safety of 
becaplermin 
(recombinant human 
platelet-derived growth 
factor-BB) in patients 
with nonhealing, lower 
extremity diabetic 
ulcers: a combined 
analysis of four 
randomised studies. 
 
Smeill, Wieman et 
al.1999 
Combined and 
separate 
analyses of four 
multicentre, 
randomised, 
parallel group 
studies 
 
n=922 
Becaplermin gel-100 µg/g 
significantly increased (p=0.007) 
the probability of complete 
healing compared with placebo 
gel.  Becaplermin gel-100 µg/g 
significantly decreased (p=0.01) 
the time to complete healing 
compared with placebo gel.  
Therefore, it is effective and well 
tolerated in patients with full 
thickness lower extremity ulcers 
in diabetes. 
 
 
In general, it has been difficult to maintain full bioactivity of proteins applied to wounds due 
to protein instability in the protease-rich environment of the wound  (Choate and Khavari 
1997).  This field of therapy has realised some clinical outcomes and holds promise 
(Buchberger, Follmann et al. 2010), but so far only one growth factor derived treatment, 
PDGF, has Therapeutic Goods Administration (TGA) approval.   
 
PDGF-BB (marketed as Regranex) has FDA (Food and Drug Administration) approval in the 
US for the treatment of ‘lower extremity diabetic neuropathic ulcers that extend into the 
56 
 
 subcutaneous tissue or beyond, and have adequate blood supply’ (Dailymed, 2011).  A 
multicentre trial concluded that treatment with PDGF-BB-containing becaplermin gel at a 
dose of 100 µg/g once daily, in conjunction with good ulcer care, is an effective and well 
tolerated wound therapy in patients with diabetic foot ulcers.  The treatment improved both 
the total number of ulcers healed and the overall wound healing rate (Smiell, Wieman et al. 
1999; Embil, Papp et al. 2000; Senet 2004).  Some studies have questioned the efficacy of 
PDGF-BB (Mandracchia 2001), including in a non-clinical trial, post-marketing setting  
(Papanas and Maltezos 2010).  PDGF-BB has not been compared with other additional 
treatment modalities, especially bioengineered skin substitutes and extracellular matrix 
proteins (Papanas and Maltezos 2010).  Growth factor in a liquid or gel form might not be the 
best approach to target the growth factor to the cells directly involved in wound healing 
(Margolis, Crombleholme et al. 2000).  Studies incorporating PDGF with an adeno-
associated viral vector have shown that this method of delivery can result in a prolonged and 
more localised delivery.  Improved distribution of growth factors to wound sites may enhance 
their efficacy in the future (Chen and Giannobile 2002, Koria2012) 
 
A post-marketing retrospective case-control study involving 1622 becaplermin initiators and 
2809 matched control subjects did not indicate concern in long term (more than 6 years) 
follow-up (RR, 1.0; 95% CI, 0.5-2.3) the adjusted rate ratio for cancer mortality among those 
who received three or more tubes relative to those who received none was 5.2 (95% 
confidence interval 1.6-17.6) (Ziyadeh, Fife et al. 2011).  The level of evidence in such 
studies is not high, due particularly to lack of randomisation and inadequate power.  As an 
increased mortality rate secondary to cancer was reported in patients treated with more than 
three tubes of becaplermin, a boxed Product Information Warning for Regranex (becaplermin 
gel) has been required by the FDA (Papanas and Maltezos 2010).  Current recommendations 
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 indicate this agent should be used only when the anticipated benefits outweigh the potential 
harm, and it should be used, if at all, with caution in those with diagnosed systemic 
malignancy (Papanas and Maltezos 2010).  These findings should be taken into account when 
developing other growth factors as wound therapies.    
 
2.5.2 Autologous Platelet Rich Plasma (PRP) 
Platelet-rich plasma (PRP) is defined as the portion of the plasma fraction of autologous 
blood having a platelet concentration above baseline (Mehta and Watson 2008).  PRP has 
also been referred to as platelet-rich concentrate, autologous platelet gel, platelet-enriched 
plasma, and platelet releasate.  It is a rich source of chemotactic and mitogenic growth factors 
(Steed, Goslen et al. 1992).  Being autologous, PRP is safe to use as it is produced from the 
patients own blood as required (Lacci and Dardik 2010).  
 
Few PRP studies exist that are scientifically rigorous; however, small-scale trials showed that 
PRP-treated wounds healed more quickly than controls (Knighton, Ciresi et al. 1986; Driver, 
Hanft et al. 2006; Saad Setta, Elshahat et al. 2011).  Limitations to these studies included 
small sample size, manufacturer sponsorship and compliance issues.  More research is 
warranted in this field. 
 
2.5.3 Stem cells 
The ability of stem cells to self-renew and give rise to subsequent generations of cells has led 
to them being targeted as therapies in many situations where regeneration is required, with 
varying degrees of success (Weissman 2000).   
 
58 
 
 Stem cells have yet to be studied in human wound healing in diabetes.  Studies in diabetic 
rats have shown that topical transplantation of a clonal population of embryonic stem cells 
(5 × 106) by injection enhanced diabetic wound healing during the early stage of healing.  The 
rats also showed markedly elevated VEGF, EGF and fibronectin, suggesting that some of the 
effect of the embryonic stem cells was through induction of growth factors (Lee, Choi et al. 
2011).  Kim et al. (2012) found mesenchymal stem cells significantly enhanced diabetic 
wound healing and that topical proinflammatory reaction and suppression of CD45 
expression was reduced in the mesenchymal stem cell group (Kim, Zhang et al. 2012).  
VEGF and EGF were also increased, in line with the findings of Lee et al. (2011) (Lee, Choi 
et al. 2011). 
 
This promising data could, if confirmed, lead to wound regeneration through stem cell 
therapy in humans in the future, including autologous therapy.  However, a greater 
understanding of the mechanisms of human stem cell differentiation is needed before such an 
approach using stem cells will be widely accepted as a wound healing therapy. 
 
2.5.4 Other Peptides/Proteins 
Some bioactive peptides have been shown to successfully stimulate wound healing in 
diabetes: a selection of those that have been deemed to show potential in early stage 
development are discussed below. 
 
2.5.4.1 Activated protein C 
Activated protein C (APC) is a plasma protease derived from its precursor, protein C, which 
circulates in plasma. APC has anti-inflammatory and pro-apoptotic properties and contributes 
to wound healing, particularly in the granulation and remodelling phases (Jackson, Xue et al. 
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 2005; Whitmont, Fulcher et al. 2013).  A pilot study showed APC to be an effective treatment 
for longstanding venous ulcers that were resistant to conventional treatment (Whitmont, Reid 
et al. 2008).  Recent studies have shown diabetic wounds to have low levels of protein C 
compared with controls (Whitmont, Fulcher et al. 2013).   This finding combined with the 
known pro-angiogenic properties of APC (Xue, Thompson et al. 2006)  makes it a 
particularly attractive treatment for complex diabetic and ischaemic ulcers.  
 
2.5.4.2 Vitronectin complexes 
The ECM protein vitronectin is an adhesive glycoprotein, abundant in blood plasma and 
different ECM sites. Particularly upon tissue injury/repair and remodelling, vitronectin acts as 
a potent matricellular factor, coordinating cell migration with pericellular proteolysis and 
growth factor signalling at sites of tissue remodelling (Preissner and Reuning 2011; Upton, 
Cuttle et al. 2008).   
 
Upton et al. (2011), hypothesised that because wound healing is driven by interactions 
between ECM proteins and growth factors, not just by growth factors alone, a 
vitronectin/growth factor complex might enhance wound healing (Upton, Wallace et al. 
2011).  A single arm pilot study using chronic wounds supported this hypothesis (Upton, 
Wallace et al. 2011) 
 
2.5.4.3 Nor Leu 
NorLeu3-A(1-7) is an analogue of the naturally occurring peptide, angiotensin 1-7.  Its 
mechanisms of action when administered topically include induction of progenitor 
proliferation (such as epidermal stem cells and hematopoetic proginators which then 
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 differentiate into different, more specialised cell types) and accelerated vascularisation, 
collagen deposition and re-epithelialisation (Rodgers, Verco et al. 2011).  
 
NorLeu3-A(1-7) increased flap survival in a nicotine-induced mouse skin wound model by 
promoting angiogenesis (Baykan, Gunay et al. 2012).  Administration of NorLeu3-A(1-7) 
peptides in diabetic mice accelerated collagen deposition by 2- to 6-fold, increased rates of  
re-epithelialisation and induced angiogenesis.  Increased infiltration of the wound by 
macrophages and neutrophils was also observed at day four (Rodgers, Roda et al. 2003). 
 
These positive animal studies led to a human pilot study, which concluded that topical  
NorLeu3-A(1-7) is safe and effective in the healing of foot ulcers in subjects with diabetes 
and that a larger scale, higher level of evidence study of this therapy is justified (Balingit, 
Armstrong et al. 2012). 
 
2.5.5 Anti-inflammatory therapies in foot ulceration in diabetes  
Given that inflammation typically persists in diabetic foot ulcers, there is much interest in 
anti-inflammatory therapies.  However there is no history of large-scale human trials of 
primary anti-inflammatory therapy for diabetic foot ulcers (Falanga and Falanga 2005; Eldor, 
Raz et al. 2004).  Topical agents that have mainly anti-inflammatory effects and that have 
been examined in limited pilot studies in human diabetic foot ulcers include curcumin 
(Appendino, Belcaro et al. 2011),  bark extract Bensal HP (Jacobs and Tomczak 2008) and 
natural honey (Makhdoom, Khan et al. 2009).  In each case, the agent was quite well 
tolerated, but due to study design and numbers enrolled, no firm conclusions about efficacy 
could be made. 
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 Many therapies directed at healing diabetic wounds are currently in development, and other 
existing therapies such as NWPT and HBOT show potential but lack robust clinical evidence 
of a therapeutic effect in wound healing.  Such therapies are frequently prohibitively 
expensive and logistically difficult to administer.  It is therefore logical to investigate 
therapies that are less costly and can be easily administered as a topical agent.  This thesis 
seeks to test two such therapies, the growth factor CTGF and the bee-hive product propolis, 
which are discussed in sections 2.7 and 2.8.    
 
The following section discusses the role of growth factors in wound healing in order to 
provide context to the rationale for testing CTGF as a wound therapy. 
 
2.6 Roles of growth factors in wound healing in diabetes 
 
As an immediate response to injury, platelets release a variety of growth factors.  These 
growth factors then attract essential cells and proteins to the wound area and thus stimulate 
tissue regeneration.  During wound healing, growth factors are secreted by various cells such 
as macrophages, fibroblasts and endothelial cells and, as well as being important chemotactic 
agents, they regulate mitogenesis, angiogenesis and matrix production.  Studies using a 
combination of PDGF and IGF-I topically applied to partial thickness porcine wounds, 
provide evidence that growth factors work synergistically in wound healing (Lynch, Colvin et 
al. 1989; Greenlagh, Albertson et al. 1993). 
 
Growth factor levels are decreased in chronic wounds and wounds in diabetes.  This is 
primarily due to protein degradation or sequestration, rather than reduced gene expression or 
a translational defect in protein production (Dvonch, Murphey et al. 1992; Brown, Breeden et 
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 al. 1994; Bitar and Labbad 1996).  Bennet and Schultz (1993) postulated that increased MMP 
levels in chronic wounds are responsible for the decrease in growth factors through 
proteolysis (Bennet and Schultz 1993).  However, other studies have suggested that growth 
factors are not so much deficient as ‘trapped’ within the peripheral fibrin cuff that surrounds 
wound capillaries (Falanga, Moosa et al. 1987).  Regardless of whether growth factors are 
absolutely deficient or merely trapped, there is much interest in the potential of exogenous 
growth factors to accelerate wound healing.  
 
PDGF is released from the α-granules of platelets.  It is a major mitogen, induces fibroblast 
and smooth muscle cell proliferation, is chemotactic to leukocytes, and has the ability to 
upregulate ECM deposition through stimulation of fibronectin and collagen synthesis (Heldin 
and Westermark 1999).  As discussed in section 2.5.1, PDGF was the first growth factor to be 
approved for use in a wound, (Knighton, Ciresi et al. 1986), but it has attracted some 
controversy due to its carcinogenic potential and poor outcomes in some wound healing 
studies. 
 
2.6.1 Basic fibroblast growth factor (bFGF) 
bFGF has been approved in China for topical therapeutic wound use.  It is chemotactic for 
inflammatory cells such as macrophages and neutrophils, and mitogenic to fibroblasts and 
keratinocytes (Fu, Sun et al. 2000).  Importantly, it also has a pro-angiogenesis role via its 
proliferative effect on vascular smooth muscle and endothelial cells (Robson, Phillips et al. 
1992).   
 
Animal models of excisional wound healing by Hebda’s (1990) and Stenberg’s (1991) groups 
indicated the potential of bFGF to enhance wound healing and to overcome the inhibition to 
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 wound contraction caused by bacteria in a healthy porcine model (Hebda, Klingbeil et al. 
1990; Stenberg, Phillips et al. 1991).  bFGF promotes the proliferation of almost all cells 
associated with wound healing (Richardson, Trinkaus-Randall et al. 1999).  A gelatine sheet 
containing bFGF promoted neo-epithelialisation, granulation, angiogenesis and wound 
closure in mice (Miyoshi, Kawazoe et al. 2005).  Reductions in angiogenesis and granulation 
tissue formation were observed in burn wound and infection wound models of diabetic mice 
compared to normal mice, and bFGF treatment restored these functions significantly 
(Okumura, Okuda et al. 1996). 
 
2.6.2 Vascular Endothelial Growth Factor (VEGF) 
In wounds, VEGF is produced by neutrophils, platelets and macrophages.  Acting primarily 
through tyrosine kinase receptors expressed on endothelial cells, its primary function in 
wounds is the induction and maintenance of wound vasculature (Carmeliet 2000).  Actions of 
VEGF include increases to the influx of inflammatory cells, migration and proliferation of 
endothelial cells, and vascular permeability.  There are five isoforms of VEGF: VEGF, 
VEGF-b, VEGF-c, VEGF-d and Placenta Growth Factor (Saaristo, Tammela et al. 2006).  
The bioactivity of VEGF is decreased in diabetic wound, which is thought to be a 
consequence of the highly proteolytic wound environment in such wounds (Roth, Piekarek et 
al. 2006). 
 
Diminished production of VEGF and decreased angiogenesis are thought to contribute to 
impaired tissue repair in diabetic patients (Galiano, Tepper et al. 2004).  In one study, VEGF-
treated wounds in diabetic mice demonstrated increased epithelialisation, increased matrix 
deposition and enhanced cellular proliferation, which was associated with double the rate of 
healing compared to untreated mice (Galiano, Tepper et al. 2004).  These findings were 
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 supported by Saaristo et al. (2006) who showed that VEGF-c enhanced angiogenesis and 
lymphangiogenesis in wounds in diabetic mice and significantly accelerated wound healing 
(Saaristo, Tammela et al. 2006). 
 
It is likely that as well as acting directly on the local vasculature, VEGF mobilises bone 
marrow-derived endothelial progenitor cells, which also contribute to angiogenesis (Asahara, 
Takahashi et al. 1999).  The function of endothelial progenitor cells is compromised in people 
with diabetes, which contributes to the higher rate of vascular defects in such patients 
(Tepper, Galiano et al. 2002).  Therefore, it seems plausible that VEGF therapy in diabetics 
might be able to reverse deficits in the function of endothelial progenitor cells function.   
 
2.6.3 Epidermal growth factor (EGF)   
EGF  is an essential growth factor for epithelial cell proliferation and wound healing (Huo, 
Qiu et al. 2009).  Released initially from α-granules of platelets and subsequently by 
macrophages and keratinocytes (Loot, Kenter et al. 2002) EGF promotes mitogenesis of 
fibroblasts, endothelial cells and keratinocytes.  EGF in gelatine-microsphere dressings 
improved healing in both diabetic and non-diabetic rats (Dogan, Demirer et al. 2009).  A US-
based study showed topical EGF to have a moderately positive effect on wound healing, 
enhancing burn wound healing by 1-4 days (Brown, Breeden et al. 1994).  However, a similar 
study by Cohen et al. (1995) found that EGF had no demonstrable accelerative effect on 
healing (Cohen, Crossland et al. 1995).  
 
2.6.4 Transforming growth factor –beta (TGF-β) 
TGF-β has been implicated widely in wound healing. It has a broad spectrum of actions, 
including cell migration and proliferation, synthesis of ECM, angiogenesis and remodelling 
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 (Amento and Beck 1991).  TGFβ affects all cell types that are involved in wound healing and 
is present in high concentrations in platelet α-granules and it is also present in T-lymphocytes 
and monocytes (Wang, Han et al. 2006).  Of its three isoforms, TGFβ type 1 is most common 
in human wounds (representing 85% of TGFβ found in wound fluid).  It is notable that the 
type 2 isotype predominates in fetal tissues which do not scar (Longaker, Bouhana et al. 
1994).  Cowin et al. (2001) found low levels of TGF-beta1 and TGF-beta2 in fetal murine 
wounds compared with adults and corresponding low rates of scarring in the fetal tissue 
(Cowin, Holmes et al. 2001).  This indicates that the expression of TGF-beta and its receptors 
in adult and fetal wounds could be important in the absence of scar formation that is observed 
in the fetus.  TGFβ has perhaps the most broad spectrum of action of all the known growth 
factors.  It plays a central role in angiogenesis by recruiting and activating inflammatory cells 
that secrete endothelial mitogens.  TGFβ-mediated chemotaxis leads to the influx and 
activation of inflammatory cells.  TGFβ also has a key role in the elaboration of matrix by 
contributing to the synthesis of matrix proteins and by controlling the secretion of proteases 
so as to favour the accumulation of ECM proteins (Ksander and Olsen 1993).  Expression of 
TGFβ by fibroblasts is impaired in diabetic foot ulcers (Jude, Blakytny et al. 2002).  Studies 
using aminoguanidine to block AGE formation have been shown to restore TGFβ levels; it is 
therefore likely that AGE accumulation in the diabetic ulcer contributes to the impaired 
TGFβ levels (Yavuz, Tugtepe et al. 2005). 
 
TGFβ is a powerful inducer of CTGF in connective tissue cells but not in some other cell 
types such as epithelial cells (Bradham, Igarashi et al. 1991; Frazier, Williams et al. 1996).  
Following brief exposure to TGFβ, fibroblasts are able to express CTGF for prolonged 
periods (Grotendorst, Okochi et al. 1996), studies by Igarashi et al. (1996) showed that  
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 CTGF mRNA is not observed in the absence of exogenous TGFβ (Igarashi, Nashiro et al. 
1996) indicating a link between these two factors.  
 
TGFβ has multiple direct effects mediated by Smad and mitogen-activated protein kinase 
pathways.  Smad3-null mice show impaired chemotaxis of inflammatory cells in response to 
TGF-β1 therapy and decreased ability of inflammatory cells to auto-induce TGFβ (Lakos, 
Shu-Jen et al. 2004 ; Yang, Letterio et al. 1999).  It is probable that the effects of TGFβ are 
also partly due to the downstream effects of CTGF.  
 
Animal models have been used to evaluate the efficacy of exogenous TGFβ in wound repair.  
Topical application of TGFβ has consistently been shown to increase the tensile strength of 
incisional wounds in rats and to accelerate healing (Ammann, Beck et al. 1990; Jones, 
Curtsinger et al. 1991; Beck, DeGuzman et al. 1993).  Dosing profiles indicate that the 
efficacy of TGFβ follows a bell curve profile.  The tensile strength of TGFβ-treated punch 
biopsy wounds in pigs and guinea pigs was also increased following healing by secondary 
intention (Ksander, Chu et al. 1990).  Intravenous injection of TGFβ up to 24 hours prior to 
wounding has been shown to enhance wound healing.  TGFβ-treated wounds also show  
increased collagen content, as measured by Picrosirius red staining (Pierce, Tarpley et al. 
1992).  This increased wound tensile strength and collagen indicate that TGFβ is a key 
growth factor in wound healing.    
 
TGFβ-1 knockout mice showed accelerated re-epithelialisation during incisional wound 
repair, in comparison with wild-type mice (O'Kane and Ferguson, 1997; Koch, Roche et al. 
2000).  Conversely, overexpression of TGFβ in an animal model accelerated the rate of 
wound closure in partial thickness wounds by promoting keratinocyte migration (Tredget, 
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 Demare et al. 2005).  In full-thickness wounds transgenic mice overexpressing the TGFβ-1 
transgene in keratinocytes exhibited delayed healing after burn injury and TGFβ-1 slowed the 
rate of wound re-epithelialisation (Yang, Letterio et al. 2001).  This conflicting data suggests 
that improved wound-healing outcomes may be achieved by selectively blocking the negative 
effects of TGFβ, although it does potentially limit the role of TGFβ-1 as a therapy to aid 
overall cutaneous wound healing. 
 
2.6.5 Other growth factors 
Other growth factors that may ameliorate wound healing and that are deficient in chronic 
wound milieu include placenta growth factor (PGF), insulin-like growth factors (IGFs) and 
hepatocyte growth factor (HGF).   
 
An adenoviral vector containing placenta growth factor (PGF) showed it to significantly 
accelerate healing in diabetic wounds, improving granulation tissue formation, maturation, 
vascularisation and monocyte recruitment (Cianfarani, Zambruno et al. 2006).  PDGF, FGF2, 
and VEGF mRNA levels were also increased, suggesting a synergistic effect of PGF with 
induced endogenous growth factors to aid wound healing. 
 
Circulating IGF-I and IGF-II are transferred from blood to local sites of production via a 
sequence of binding proteins.  It has been postulated that alterations in levels of these binding 
proteins and increased levels of IGF antagonists are associated with defective wound repair in 
diabetes (Loot, Kenter et al. 2002).  Topical IGF-I therapy has been shown to aid wound 
healing when used alone (Beckert, Haack et al. 2007) and also when used in combination 
with other growth factors (Lynch, Colvin et al. 1989). 
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 HGF stimulates proliferation and migration of epidermal keratinocytes and melanocytes.  It 
also increases MMP-2 and -9 levels and their related activities (cell migration, angiogenesis 
and ECM remodelling) (Yoshida, Matsumoto et al. 2004).  Transgenic overexpression of 
HGF in mice resulted in increased vascularisation and granulation tissue formation, (Toyoda, 
Takayama et al. 2001) while incisional wounds in Wistar rats showed enhanced healing 
following intradermal administration of HGF (Ono, Yamashita et al. 2004). 
 
Growth factors have the potential to heal human diabetic wounds, as discussed in section 
2.5.1.  PDGF –BB is the only growth factor treatment currently approved by the FDA, and it 
is expensive, controversial and not available in Australia.  The current literature lacks robust 
research to determine whether the growth factor CTGF is a safe and effective agent in healing 
diabetic wounds.  CTGF has, however, shown potential as a wound healing therapy in a 
Baboon burn model (Liu, Shi et al, 2007).  Its structure, function and wound healing potential 
is described below. 
 
2.7 Connective Tissue Growth Factor 
 
2.7.1 Structure and regulation in normal skin 
First identified as a secreted protein in 1991, (Bradham, Igarashi et al. 1991), CTGF, also 
known as CCN2, is a 32-38 kDa member of the CCN family, a group of proteins that share a 
common modular structure (Bork 1993).  CTGF comprises 349 residues and is organised into 
a signal peptide and four domains (Figure 2.4) designated as: 
 
- Insulin-like growth factor binding protein domain at the amino-terminus; 
- Von Willebrand factor type C module domain; 
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 - Thrombospondin repeat type 1 domain; 
- C-terminal module domain (CT) (Yoshida and Munakata 2007). 
 
This structural organisation suggests that different domains of CTGF might be responsible for 
different signals in the modulation of biological activities.  
 
Figure 2.4: CTGF structure  
The five exons of CTGF, which encode the single peptide (SP) and four domains (Adapted 
from Gupta, Clarkson et al. 2000).        
 
CCN2 is induced during normal wound healing in the absence of diabetes.  This includes in 
preclinical models, in a transient manner in keratinocytes some 7 or more days after skin full 
thickness porcine wound generation (Wang, Olsen et al. 2001) and in dermal fibroblasts in 
murine models of wounding including stented excisional wounds and PVA subcutaneously 
implanted sponge models of wounding (Alfaro, Deskins et al. 2013).  The CTGF promoter 
appears to be activated in such wounding in normal rodent skin (Kapoor, Liu et al. 2008).  In 
contrast to normal wound healing, excessive skin CTGF is implicated as a causal factor in 
skin scarring including hypertrophic scar and keloid formation (Igarashi, Nashiro et al. 1996) 
and in skin diseases dominated by sclerosis such as systemic sclerosis (Fonseca, Lindahl et al. 
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 2007), where in each case CTGF over-expressed compared with levels in normal skin and in 
normal, non-scarring wound healing. 
 
2.7.2 CTGF bioactivity 
Whilst the mechanism of action of CTGF has yet to be fully understood, a picture of its 
functions does exist: a series of studies have shown that CTGF stimulates fibroblast 
proliferation and differentiation, thus enhancing ECM production (Daniels, Van Bilsen et al. 
2009).  CTGF induces ECM proteins such as collagen and fibronectin (Frazier, Williams et 
al. 1996).  CTGF promotes cell adhesion through an integrin-heparin sulphate proteoglycan 
dependent pathway.  The specific integrin used in this pathway by CTGF varies between 
different cell types (Babic, Chen et al. 1999).  In addition, CTGF has chemotactic and 
mitogenic properties and can promote cell differentiation (Bradham, Igarashi et al. 1991; 
Yosimichi, Nakanishi et al. 2001).  CTGF can induce cell migration and proliferation by 
upregulating integrin expression on target.  Other integrins, induced by reactive oxygen 
species, have been shown to inhibit CTGF-mediated migration (Chang, Shih et al. 2004).  
Therefore local factors (such as oxygen levels) are likely to influence the actions of CTGF 
(Chang, Shih et al. 2004). 
 
CTGF may also influence angiogenesis.  Shimo et al. (1999), demonstrated that CTGF 
promotes angiogenesis in vivo (Shimo, Nakanishi et al. 1999).  However transgenic mice that 
constitutively overexpress CTGF show decreased expression of VEGF and decreased 
angiogenesis at growth plates (Ivkovic, Yoon et al. 2003).  As discussed above, it is probable 
that local conditions in target tissues determine the effects of CTGF. 
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 Despite considerable research, a specific signalling receptor for CTGF has not been identified 
(Leask, Abraham et al. 2003).  Chen et al. (2001) demonstrated that CTGF is secreted 
through the Golgi and degraded in the endosome via a low density lipoprotein receptor 
(Chen, Segarini et al. 2001).  However, it is not clear whether this is a true signalling reaction 
or merely a mechanism by which excess CTGF degraded.  Wang et al. (2010) hypothesised 
that CTGF could signal in some cells through the nerve growth factor receptor, tyrosine 
kinase A (Wang, McLennan et al. 2010). 
  
CTGF acts as a regulator of other growth factors but may in turn be regulated by such factors 
(Arnott, Nuglozeh et al. 2007).  CTGF regulates the expression of VEGF under certain 
conditions (Nishida, Kondo et al. 2009).  Abreu et al.(2002) showed that binding of CTGF to 
TGF-β led to enhanced TGF- β mediated gene transcription in Xenopus cells (a genus of 
frogs widely used as a model for molecular and cell biology studies), (Abreu, Ketpura et al. 
2002), while  Igarashi et al. (1993) demonstrated that TGF-β was able to induce CTGF in 
human skin fibroblasts, thus lending weight to the co-regulatory concept (Igarashi, Okochi et 
al. 1993).  
 
2.7.3 CTGF regulation by exogenous agents 
Exogenous substances have the ability to affect the expression of CTGF.  This was explored 
by Gressners group, (2008), who established that caffeine was able to inhibit TGF-β-
stimulated CTGF expression in hepatocytes through effects on the PPAR-gamma and SMAD 
2/3 pathways (Gressner, Lahme et al. 2008).  Other exogenous regulators such as the 
saturated fatty acid palmitate and cigarette smoke have been shown to induce CTGF (Churg, 
Tai et al. 2006; Yu, Birke et al. 2012). 
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 2.7.4 CTGF as a biomarker, predictor and mediator of disease in diabetes 
Elevated CTGF gene expression and protein levels have been reported in the tissues of people 
with diabetes (Riser, Denichilo et al. 2000).  Jaffa et al. (2008) demonstrated that elevated 
plasma CTGF-N fragment was a predictor of macrovascular disease in type 1 diabetes, 
indicating a strong link between CTGF and some diabetic complications (Jaffa, Usinger et al. 
2008).  Similarly, CTGF has been implicated in the development of diabetic nephropathy, 
hepatopathy, cardiomyopathy and retinopathy (Wang, Denichilo et al. 2001;Twigg, Cao et al. 
2002; Paradis, Perlemuter et al. 2001; Rachfal and Brigstock 2003; Candido, Forbes et al. 
2003; Way, Isshiki et al. 2002; Tikellis, Cooper et al. 2004) and expansion of the ECM 
occurs within tissues in diabetes.  It has been postulated that this ECM aberration is largely 
responsible for the diabetes-related complications mentioned above.  The mechanisms by 
which CTGF is able to influence ECM accumulation are not well understood and multiple 
mechanisms may be involved.  
 
Specific diabetes-related stimuli have been found to induce CTGF expression in vitro.  These 
include metabolic factors such as AGEs (Twigg, Chen et al. 2001), ROS (Park, Kim et al. 
2001) and high blood glucose levels (Murphy, Godson et al. 1999).  Candido et al. (2003) 
showed that by treating diabetic animals with a breaker of AGEs, CTGF levels were reduced 
to normal (Candido, Forbes et al. 2003).  The increased low-density lipoproteins commonly 
associated with hyperlipidaemia have also been shown to induce CTGF expression in vitro 
(Sohn, Tan et al. 2006).  CTGF induction has therefore been implicated not only as a marker 
but as a potential mediator of pathology in tissues in diabetes where excessive fibrosis may 
occur, such as the kidney, heart, liver, complicated atheromatous plaques and the diabetic eye 
(Twigg and Cooper 2004).   
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 In contrast to the many tissues affected by fibrosis in diabetes, in which CTGF is induced, 
CTGF appears to be deficient in wounds in diabetes.  In baboon studies, CTGF levels were 
reduced in sterile subcutaneous wound tissue of diabetic animals compared with non-diabetic 
controls (Thompson and McLennan, 2010).  Interestingly, in this work, CTGF mRNA levels 
in the wound tissue were not different between diabetic and control animals.  Also in this 
work wound fluid from diabetic animals was found to proteolyse CTGF (Thompson and 
McLennan, 2010), suggesting that CTGF in diabetic wounds may undergo proteolysis.  In 
wounds in diabetic animals the theme of growth factor degradation through proteolysis is 
quite common (Roth, Piekarek et al. 2006) reflecting the increased inflammatory and protease 
active environment in diabetic wounds (Wetzler, Kampfer et al. 2000). 
 
The MMPs, their TIMPs and CTGF appear to be linked in a serially regulated manner 
involving feedback mechanisms.  For example, MMPs are secreted by endothelial cells in 
response to CTGF (Kondo, Ohshima et al. 2002) and, in other systems, CTGF induces 
MMPs, such as MMP-1 (Ishibuchi, Abe et al. 2010) and MMP-2 (Chintala, Liu et al. 2012).  
In turn, CTGF degradation is induced by a number of MMPs, including MMP-9 (Hashimoto, 
Inoki et al. 2002).  CTGF induces the MMP natural inhibitor TIMP-1 in renal mesenchymal 
cells (McLennan, Wang et al. 2004) and, of more relevance to skin, recombinant human 
CTGF (rhCTGF) increases each of TIMP-1 to TIMP-4 in porcine skin fibroblasts 
(Hashimoto, Inoki et al. 2002).  If this same mechanism exists in wounded skin then it could 
contribute to the benefits of CTGF wound healing therapy by limiting CTGF degradation.  
 
As previously discussed, the ability of CTGF to regulate the bioactivity of other growth 
factors (such as TGF-β) may contribute to its role wound healing.  CTGF expression in 
dermal fibroblasts is induced potently by TGF-β through an elaborate interplay between 
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 various transcriptional factors (Shi-Wen, Leask et al. 2008).  It has also been postulated for 
many years that CTGF is required for, or possibly synergistically augments TGFβ actions in 
fibroblasts (Grotendorst 1997).  Indeed, in a mouse model, subcutaneous injection of either 
CTGF or TGF-β resulted in only transient granulation but a more persistent response was 
observed when these two factors were injected in combination (Mori, Kawara et al. 1999).  
This supports the concept that fibroblast proliferation, activation and migration, which 
characterise granulation and, therefore, ECM accumulation, are influenced by CTGF.      
 
CTGF induces αSMA in fibroblasts, converting them to a myofibroblast phenotype.   
Activated fibroblasts - or ‘myofibroblasts’ - express αSMA, which has been shown to 
ameliorate wound contraction and remodelling (Chen, Shi-Wen et al. 2005).  As discussed in 
section 2.3.3, αSMA induction in diabetic wounds is reduced and this contractility and 
remodelling is delayed.  Conversely, contractility is protracted in fibrotic conditions such as 
scleroderma in which the αSMA-producing myofibroblast phenotype persists (Whitfield, 
Finlay et al. 2003).  
 
2.7.5 CTGF levels in wound fluid of human diabetic foot ulcers 
 A series of studies examined CTGF levels in post-debridement human wound fluid from 32 
human subjects with chronic diabetic foot ulcers by Western immunoblot over a prolonged 
period of wound healing (>3 months).  Demographic information describing the cohort is 
shown in Table 2.9.  High CTGF protein levels in wound fluid correlated with improved 
wound healing rates in diabetic foot ulcers Dr L. Lo (personal communication, July 2008) as 
indicated in Figure 2.5.  Data were calculated with n=38, for all ulcer aetiology (with 
p<0.001), and with n=32 after excluding post-surgical ulcers (also p<0.001).  Together with 
the known bioactivities of CTGF—chemotactic for macrophages, pro-angiogenic, induction 
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 of SMA, and ECM accumulation—the finding that high levels of CTGF correlates with 
increased ulcer healing in human diabetic foot ulcers further supports the rationale that 
applying rhCTGF to wounds may improve healing in diabetic foot ulcers. 
Table 2.9: Demographics of subjects and ulcer type in study analysing CTGF in wound 
fluid of diabetic foot ulcers by Western immunoblot, using in-house anti-CTGF 
antibody. 
Patient demographics  
Study subject number (n) 32 
Age (years)* 64.1±1.8 
Diabetes duration (years) 17.6±1.9 
Gender (% male) 75 
Ulcer type   
     Neuropathic only 29 
     Neuro-ischemic 3 
* all data are mean ±SD 
 
Figure 2.5: Wound healing rate and CTGF in wound fluid. 
Plot showing % change per 10 days in CTGF in wound fluid post-debridement and wound 
healing in the human diabetic foot ulcers described in Table 2.9.  Each data point represents a 
patient in the study and typically three analyses were performed in each patient across a 12 
week or longer period.  Linear regression shows a highly significant trend towards wound 
healing rate correlating with rate of increase in CTGF in human foot ulcer fluid (p<0.001). 
The data for n=32 (without the post-surgical ulcers) is shown.  
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 Topical application of CTGF has not yet been studied in any diabetic wound model. It is 
notable, however, that topical application of rhCTGF to acute burns in monkeys resulted in 
accelerated cutaneous wound closure and granulation tissue induction (Liu, Shi et al. 2007). 
Thus considering the known bioactivities of CTGF, its relative deficiency in wounds in 
diabetes, that it is induced as wounds heal in human diabetes, and that CTGF therapy 
accelerated wound healing in a monkey burns model (Liu, Shi et al. 2007), there is a rational 
basis to consider CTGF as topical therapy in cutaneous wounds in diabetes.   
 
Whilst CTGF is an endogenously produced factor which could, which has properties that may 
be favourable to wound healing in diabetes, the following section introduces the concept of 
substances that occur within nature, but not within the human body which may hold 
therapeutic value.  In particular the bee-derived product propolis is in order to provide 
context for its testing as a wound healing therapy in diabetic foot ulcers within this thesis. 
 
2.8 Neutraceuticals 
 
Many innovative therapies are being developed to treat diabetic wounds.  As previously 
discussed, many are prohibitively expensive and/or logistically difficult to deliver.  NWPT 
and HBOT are two prime examples of therapies that are both costly and logistically 
challenging to deliver.   
 
To improve healing rates in recalcitrant diabetic wounds in a cost effective manner, it is 
rational to investigate natural products, which are inexpensive and readily available.  The 
relatively low cost of developing existing natural products or ‘neutraceuticals’ into wound 
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 healing therapies makes them particularly attractive.  Such therapies generally have low side 
effect profiles as they are often already used for human consumption—for example, as foods.   
 
2.8.1 Bee-derived wound therapies 
Since ancient times bee-derived products have been used as medicines and as wound healing 
therapies (Najafi, Vahedy et al. 2007).  Recently there has been a revival of interest in bee-
derived products, but to date the role of these products in diabetic wound healing has not 
been studied.  Bee or ‘Apitherapy‘ products are of particular interest as they have established 
anti-bacterial and anti-inflammatory properties, are inexpensive and generally well tolerated.  
 
Bees nest in colonies that are headed by a single fertile female, the queen, who is usually the 
only egg layer in the colony.  Tasks such as foraging for nectar to make honey, producing 
royal jelly to feed the queen and larvae, cleaning, removing debris from the hive, and 
producing the resinous substance called propolis to protect the hive from pathogens are 
carried out by the worker bees, which are all female.  These clearly defined functions are 
thought to have enabled the bee to survive a variety of evolutionary challenges.   Apitherapy 
products are produced by bees and can be harvested from their nests.  Of these products, only 
four—honey, propolis, royal jelly and bee venom—have been researched for their potential 
as wound healing therapies.  Their composition is shown overleaf in Table 2.10 
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 Table 2.10:  Composition of apitherapy products used in wound healing. 
Bee Product Composition 
Honey 20% water, 70–75% reducing sugars, 5-10% 
sucrose (Grembecka and Szefer 2013). 
Royal Jelly 60% water, 5% lipids, 15% protein, 20% 
sugars (Xu and Gao 2013). 
Propolis 50% resin and vegetable balsam, 30% wax, 
10% essential oils, 5% pollen and 5% 
organic debris (Bankova 2005; Menniti-
Ippolito, Mazzanti et al. 2008). 
Bee Venom 88% water, 6% melittin, 6% combination of 
other enzymes and amino acids, 
carbohydrates, phospholipids and 
physiologically active amines (Alia, Laila et 
al. 2013). 
The composition of bee products shows a large amount of regional variation, depending on 
the local species of bee, the plants that they feed on, and climatic and environmental 
conditions (Gheldof and Engeseth 2002; Righi, Negri et al. 2013).    The most well studied 
and commonly used bee products are derived from the honey bee (Apis mellifera), which is 
native to Europe, Africa and western Asia. This species has also been introduced to other 
continents, starting in the 17th century, and is now found all around the world, including east 
Asia, Australia and North and South America (Winston, Dropkin et al. 1981). 
 
Apis mellifera has several sub-species or regional varieties, including the Italian bee (Apis 
mellifera ligustica), European dark bee (Apis mellifera mellifera) and the Carniolan honey 
bee (Apis mellifera carnica). Each species differs in its ability to produce the various types of 
bee products, with some subspecies being better suited to producing certain bee products than 
others.  For example, the Russian honey bee yields more propolis than the Irish honeybee.  
However, most colonies are capable of producing at least some of each of these products.  
The principal components of the various bee products are shown in Table 2.10.  They vary 
quite markedly in composition, particularly water and carbohydrate content. 
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 The occurrence of chronic foot ulcers in persons with diabetes is, as previously discussed, 
due to several inter-related factors that cause local wound related abnormalities (Sibbald and 
Woo 2008).  Some of the factors that prevent diabetic foot wounds from healing, such as 
persistent inflammation and increased bacterial burden could potentially be ameliorated with 
apitherapy/bee products.  Preclinical research into the use of apitherapy products in wound 
healing suggests that honey, propolis, royal jelly and bee venom have the potential not only 
to promote healing in ‘normal wounds’ but also to attenuate the chronic inflammation, 
oxidative stress, bacterial burden and immunodeficiency that thwarts healing in diabetic 
wounds.  
 
Within the hive ecosystem, honey and royal jelly are foodstuffs, bee venom is involved in 
defensive roles (killing intruders) and signalling (releasing pheromones that warn other bees 
of attack) and the prime function of propolis is to protect bees against disease.  Bees coat the 
internal walls of their hives with a thin layer of propolis to sterilise the comb and keep their 
hives free of bacteria.  Given this specific function and its proven efficacy in preclinical 
wound healing studies, it is likely that propolis, out of all the bee products, holds the greatest 
potential as a wound healing product.   
 
2.8.2 Propolis 
Propolis is a resinous hive product produced by bees (Figure 2.6).  The name derives from the 
Greek words Pro (defence of) and Polis (city), and the name reflects the importance of this 
substance as a hive protectant.  Propolis consists of plant buds that are collected on the hind 
legs of worker bees and then masticated.  Bee salivary enzymes are added through this 
process and the resulting product is then mixed with wax (Ghisalberti 1979; Bankova, de 
Castro et al. 2000).  Within the hive, propolis is used to fill cracks and crevices to prevent 
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 insect invasion (Daugsch, Moraes et al. 2008).  It is also used to ‘embalm’ hive invaders that 
the bees are able to kill but cannot transport out of the hive, thus preventing problems 
associated with decomposition (Sforcin 2007).   
 
 
Figure 2.6:  Propolis in situ in a commercial beehive. 
Photograph courtesy of Yves Ginat, Apiarist, Woodbridge, Tasmania 
 
Propolis has been used in ‘medicine’ since the time of the Pharaohs (Lamprecht 1994).  It is 
collected from the hive superstructure by scraping, usually performed in autumn following 
honey extraction.  Propolis is sticky when freshly collected and at a hive temperature of 
35°C. It hardens as temperatures drop and is quite brittle at 5°C (Ghisalberti 1979).  
Following collection, propolis must be evaluated and processed before therapeutic use.  
Excess wax is removed by cold water washing.  The propolis is then dissolved in a solvent 
(usually 95% ethyl alcohol) and filtered to remove large particles and foreign bodies 
(Burdock 1998).  Propolis can be administered orally or topically.  Photoacoustic 
spectroscopy has shown penetration of propolis into wounded skin to be excellent (Sehn, 
Hernandes et al. 2009).  In contrast to honey, which also has antibacterial properties (Al-
Waili, Salom et al. 2011), propolis is not prone to cause maceration around the wound edge 
and it also has potent antibacterial and anti-inflammatory properties (de Moura, Negri et al. 
2011, Ramos, Miranda et al, 2007) . 
Propolis 
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 2.8.3 Composition and toxicity 
The composition and colour of propolis vary according to the region from which it originates.  
(Bankova 2005; Menniti-Ippolito, Mazzanti et al. 2008).  However, whilst the composition of 
propolis may show regional variation, its biological properties appear to remain similar 
regardless of origin.  
 
The composition of propolis is complex.  Over 200 constituents of propolis have been 
identified (Marcucci 1995).  The most biologically-active fractions of propolis are flavanoids 
and esters of caffeic acid (Russo, Longo et al. 2002).  These substances also occur naturally 
in foodstuffs, and studies show that the amount introduced into the body by ingestion or 
topical application of propolis is negligible by comparison.  Flavanoids are easily 
metabolised, and no flavanoid residues accumulate in the body after oral or topical 
administration of propolis (Havsteen 1983; Havsteen 2002).   
 
No adverse effects were observed when propolis was administered to rodents in relatively 
large doses (700 mg/kg) (Dobrowolski, Vohora et al. 1991).  Avouret-Grand et al. (1993)  
reported the oral lethal dose of propolis in mice to be >7340 mg/kg, which indicates a low 
toxicity (Arvouet-Grand, Lejeune et al. 1993).  Irritancy testing on guinea pig skin showed 
that even at its highest dilution of 20%, propolis was not an irritant (Hausen and 
Wollenweber 1988).  Human data on contact allergens in persons with leg ulcers showed 
propolis to have a relatively low sensitisation rate (4%) compared to 21% for wool tar and 
10% for Balsam Peru (both used in fragrance).  The preponderance of occupational allergic 
contact dermatitis seen in apiarists (Hausen and Wollenweber 1988; Gulbahar, Ozturk et al. 
2005) is thought to be due to caffeic acid derivatives found in propolis and for this reason 
propolis should be used with caution in people with an allergic disposition. 
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 2.8.4 Actions of propolis 
As a topical agent propolis is reported to be an effective treatment to aid resolution of cuts 
and abrasions (Okonenko 1985) and inflamed throats (Pang and Chen 1985).  Its mechanisms 
of action, which may have relevance to wound healing in diabetes are discussed in the 
following section. 
 
2.8.4.1 Anti-inflammatory activity of propolis 
The anti-inflammatory effects of propolis are well-established (Ledon, Casaco et al 1997; 
Mirzoeva and Calder 1996; Sforcin 2007) and are largely attributable to caffeic acid 
(Grunberger, Banerjee et al. 1988; Chan, Wen et al. 1995).  Studies by Jin et al. (2005) 
showed that caffeic acid phenyl ester (CAPE) in propolis is a potent inhibitor of MMP-9 (Jin, 
Chung et al. 2005).  Temiz et al. (2008) hypothesised that propolis-treated rat colon 
anastomoses would heal more quickly and showed increased bursting strength due to 
decreased collagenolysis attributable to CAPE action on MMP-9 (Temiz, Aslan et al. 2008).  
Propolis treatment has been shown  to reduce the persistent inflammation that characterises 
diabetic wounds by normalising neutrophil and neutrophil elastase levels (McLennan, Sakar 
et al. 2009).  It has been proposed that propolis reduces inflammatory exudates in diabetic 
rodents and improves the wound closure rate in diabetic wounds through its widely reported 
anti-oxidant effects (Vieira, Laranjinha et al. 1998; Nagaoka, Banskota et al. 2002; Mercan, 
Kivrak et al. 2006).   
 
Reduced inflammatory cell infiltration was observed in propolis-treated rabbit corneal 
injuries compared to controls; this anti-inflammatory effect was comparable to that achieved 
with dexamethasone   induction of cytokine production by spleen cells, thus demonstrating 
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 the potential of propolis to reduce chronic inflammation such as that observed in diabetic foot 
ulcers (Missima and Sforcin 2008). 
 
2.8.4.2 Antimicrobial activity of propolis 
The exposed subcutaneous tissues of wounded skin are prone to contamination and 
colonisation by a variety of microorganisms.  Robust evidence exists to support the anti-
microbial properties of propolis (Bonvehi, Coll et al. 1994; Kosalec, Pepeljnjak et al. 2005, 
Marghitas, Mihai et al. 2010; Ozklap, Ozcan et al, 2010).  The inhibitory concentration of 
propolis is 400 times greater than that of tetracycline against E. coli and more than 50 times 
higher against S. aureus and B. subtilis.  The composition of propolis determines its efficacy 
against  P. aeruginosa in vitro (Pepeljnjak and Kosalec 2004), with the extracts of propolis 
being particularly effective (Aliyazıcıoglu, Sahin et al. 2011).   
 
To test the anti-microbial activity of propolis, its activity against Micrococcus luteus was 
assessed using microcalorimetric analysis of bacterial cultures in different growth phases.  
The addition of propolis extracts to these cultures resulted in a strong decline in heat 
production, a prolongation of the lag phase and the introduction of a second lag phase, 
indicating that propolis is both bacteriostatic and bactericidal (Lamprecht 1994).  The anti-
bacterial activity of propolis especially against P. aeruginosa  and S. aureus, is thought to be 
largely attributable to the phenolic acid fraction (Lamberte, Cabrera et al. 2011; Bankova, 
Christov et al. 1995).   For example, no antibacterial activity against S. aureus was observed 
in a batch of propolis with a low phenol count, unlike batches with a higher phenol count, 
which had substantial antibacterial activity (Bankova, Christov et al. 1995).   
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 Propolis has also been shown to inhibit the proliferation of fungal elements such as Candida 
(at concentrations of 3-10 mg/mL) (Metzner, Schneidewind et al. 1977) and viruses.  Propolis 
mediated inhibition of the HIV (human immunodeficiency virus) virus has also been 
observed.  The mechanism of propolis’ HIV antiviral property in CD4+ lymphocytes occurs 
via, inhibition of viral entry (Gekker, Hu et al. 2005).  
 
2.8.5 Propolis in wound healing 
Several studies have examined the potential of propolis to promote wound healing.  Propolis 
has been deemed to have a low-allergen profile which makes it particularly suitable to study 
as a wound healing therapy (Menniti-Ippolito, Mazzanti et al. 2008).  In excisional rat 
wounds, propolis improved wound contraction rates compared to petroleum jelly treated 
controls (Pillai, Palsamy et al. 2010).  The wounds treated with propolis had higher levels of 
hydroxyproline (indicating collagen formation), hexosamines and uronic acid (responsible for 
ECM accumulation and chemoattraction).  There was also a significant increase in DNA, 
RNA and protein in the wound at day 7 in the propolis treated animals, indicating accelerated 
hyperplasia associated with wound healing.  Similar findings of improved wound healing and 
increased hydroxyproline levels were observed in propolis-treated rat colon anastamoses 
(Temiz, Aslan et al. 2008).  
 
The altered cell composition in the wounds of propolis treated animals was shown to favour 
healing.  As described above, topical propolis treatment prevented the persistent elevation in 
neutrophil levels otherwise seen in a diabetic rat model of impaired wound healing 
(McLennan, Sakar et al. 2009) and increased fibroblast proliferation in rat colon wounds 
(Temiz, Aslan et al. 2008).  Sehn et al.(2009) observed that propolis treatment promoted 
wound healing by stimulating keratinocyte proliferation (Sehn, Hernandes et al. 2009).   
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  A small-scale observational human study comparing thrice-daily application of propolis skin 
cream to silver sulfadiazine in the treatment of burns showed some beneficial effects 
(Gregory, Piccolo et al. 2002).  Time to wound closure was reduced in the propolis group 
(9.09 days versus 10.96 days) and inflammation was reduced.  Whilst bacterial colony counts 
in wound samples were not different between the two groups, those treated with propolis 
were anecdotally found to have decreased discomfort, possibly due to analgesic properties 
that have been previously associated with propolis (Ledon, Casaco et al. 1997; Paulino, 
Dantas et al. 2003).  The study authors also noted that propolis is less expensive than silver 
sulfadiazine cream and does not confer such a risk of allergy that is associated with silver 
sulfadiazine therapy. 
 
2.8.6 Propolis as an investigational therapy 
Investigation into the properties of propolis has been largely confined to animal models.  
There have been few clinical studies on the therapeutic efficacy of propolis.  Furthermore, 
even though the main actions of propolis appear consistent across sources from various 
geographic regions and countries, propolis is not a standardised product and its composition 
is largely determined by its geographical area of origin 
 
 The mode of action of propolis is controversial and that whilst its wound healing properties 
are largely associated with its anti-microbial and anti-inflammatory actions, rather than acting 
as a pure tissue regenerator, propolis may have other healing properties that might be derived 
from fatty acids, vitamins and minerals that have yet to be fully investigated (Burdock 1998).  
A lack of large-scale, well-conceived, robust clinical trials precludes bee products from 
becoming more accepted as wound therapies.  Given the magnitude of the problem of 
diabetic foot ulceration, there is an urgent need to systematically study bee products in human 
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 diabetic foot ulcers to determine if they may improve healing outcomes.  Propolis in 
particular could be of value in wound healing in diabetes because it is known to have potent 
anti-inflammatory and anti-bacterial properties and it is known that diabetic foot ulcers fail to 
heal largely because of excessive inflammation and excessive bacteria which propolis might 
ameliorate. 
 
The burden conferred by a diabetic foot ulcer in terms of both financial and social costs has 
been outlined as have the abnormalities in the diabetic wound microenvironment and the 
probable causative factors of these abnormalities.  Using this understanding, many therapies 
are emerging that aim to accelerate healing in diabetic wounds. This work aims to explore the 
potential of two therapies, CTGF and propolis, to improve healing in diabetic wounds and to 
normalise the wound environment. 
 
2.9 Hypotheses and aims of this thesis 
 
Diabetic foot ulcers are a significant cause of morbidity and mortality and are characterised 
by persistent inflammation and a dysregulated wound microenvironment.  The growth factor 
CTGF has a multitude of biological actions. Its expression is induced in wound tissue and 
increases in human wound fluid as the wounds heal.  Prior to this work the effect of topical 
rhCTGF on wound healing had not been tested in a wound model in diabetes. 
 
In an experimental rodent model of diabetes, the beehive protectant propolis has already 
shown by our research group to improve wound healing.  A logical extension of this existing 
work was to test the safety and efficacy of topical application of propolis in a cohort of 
people with diabetes who have foot ulcers.  
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 Study hypotheses:  
1. CTGF improves cutaneous wound healing in a diabetic rodent model. 
2. Propolis is a well-tolerated treatment for human foot ulcers in diabetes. 
3. Propolis will improve healing in human diabetic wounds. 
 
Study Aims 
The overall, integrated aims of this series of studies were to investigate the capacity of topical 
therapies (CTGF and propolis) to improve healing in wounds in diabetes and to gain an 
understanding of their effect on the wound microenvironment.  The objectives related to the 
respective hypotheses were:   
 
1. To determine the effect of topical administration of rhCTGF on wound closure, 
strength and wound histology in non-diabetic and diabetic cutaneous wounds in an 
experimental rodent model. 
2. To trial topical propolis in a small-scale human feasibility study of foot ulceration in 
diabetes, observing safety, acceptability and patient tolerability and side effect profile, and 
conducting a preliminary analysis of wound closure rates compared with historic controls, 
including to calculate sample size requirements for a full scale randomised control trial of this 
therapy. 
3. To undertake analysis of wound fluid CTGF, MMP’s -2 and -9, and viable bacterial 
load in propolis-treated wounds compared with historic controls. 
 
Collectively, the outcomes from this novel work could advance understanding in the wound 
microenvironment and in the future development of topically applied therapies to improve 
healing in foot ulcers in diabetes. 
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 Chapter 3 
 
METHODOLOGY 
 
3.1  Introduction 
 
This series of studies in my PhD explores two wound therapies in diabetes - the growth  
factor CTGF and the bee-hive protectant propolis.  CTGF has not previously been trialled in 
diabetic wounds, so this study will be conducted in a rodent model of wound healing.  
Propolis has shown promise as a therapy to heal rodent diabetic wounds so will be tested in a 
small-scale human study of foot ulcers in diabetes.  This section explores the methodologies 
used to test the study hypotheses. 
 
3.2  Experimental models of wound healing 
 
An experimental animal model can be defined as “a living organism with an inherited, 
naturally acquired or induced pathological process that, in one or more respects closely 
resembles the same phenomenon in humans” (Isselhard 1986).  To substantiate the ability of 
any factor to ameliorate wound healing, in vivo experimentation is necessary.  Ethical 
constraints largely prohibit studies of wound therapies in humans that have not been 
examined in non-human settings, especially when such therapies may well have adverse 
effects, such as in the case of protein growth factors.  Thus, the use of animal models of 
wound healing in the diligent search for improved wound care is inevitable. 
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 Ideally, a perfect analogue of the human clinical situation would be used in a preclinical  
wounding study, including in diabetes.  Unfortunately such an analogue has not yet been 
established (Dorsett-Martin and Dorsett-Martin 2004).  The choice of model in wound 
healing depends upon several factors such as type of investigation, stage of investigation 
(acceptable degree of simplification), outcome measurement and recruitment criteria.  
Logistical constraints such as species availability, housing facilities, husbandry requirements, 
time and budget must also be considered (Gottrup, Agren et al. 2000).   
 
3.2.1  Species and breeding 
Animal models of wound healing have been developed in many species including the rat, 
mouse, hamster, guinea pig, pig and dog (Greenhalgh and Greenhalgh 2005).  Small animals 
such as rodents are more easy to procure and less difficult to maintain than a larger animal 
such as a fully grown pig.  For this reason the rat was chosen for this work.  However, this 
animal has its limitations, in imitating the true clinical picture, which are addressed in the 
following section. 
 
3.2.2  Selection of wounding models 
The choice of wounding model is dependent on the type of healing and/or the stage of the 
healing process that is to be investigated (Gottrup, Agren et al. 2000).  A factor that often 
confounds attempts to mimic human wound healing in animal models is wound contraction.   
Many of the animals used in wound healing studies are ‘loose skinned’—that is, they have a 
subcutaneous panniculous carnosus muscle which contributes to repair via contraction and 
collagen formation (Cross, Naylor et al. 1995).  Indeed, it has been reported that 90% of 
rodent model wound closure can be attributed to contraction (Levenson, Geever et al. 1965).  
The human is not loose skinned and caution must be exercised when drawing parallels with 
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 other animal models.  The pig has skin similar to human skin and is, therefore, often the 
animal of choice in cutaneous wound studies.  However, its major drawback is that pig skin 
often heals too rapidly to study the effect of wound healing interventions.  In addition, 
financial and ethical considerations may prohibit use of porcine models (Winter 1962).  For 
the purposes of this work a rat model was used and wounds were splinted with a transparent 
film to minimise wound contraction so that healing more closely approximated the human 
state. 
 
3.2.3  Wound models 
Several wound models enable measurement of granulation tissue and wound contraction and 
are therefore more akin to the clinical situation.  These can be grouped as ‘tissue models’, 
which mimic clinical wounds (incisional, excisional, burn), or ‘artificial models’, which 
create an artificial defect using a foreign implanted material (chambers, sponges etc.).  
 
Cutting of the skin with a sharp blade will inflict an accurate, reproducible wound.  In the 
landmark 1929 paper “The healing of wounds as determined by their tensile strength”, Howes 
and Harvey (1929) described the incisional wound model as four phases through which the 
histology and biochemistry of the wound alters over time and wound tensile strength 
increases  progressively, reaching a maximum at around the 60-80th day postoperatively 
(Howes and Harvey 1929).  Subsequently, the approach has become a benchmark in the 
evaluation of breaking and bursting strength in skin and other tissues.  However, this model 
has limitations in wound healing studies as the skin defect is relatively small and quick to 
heal. 
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 Split thickness models are less commonly used.  These scrape-type lesions are not readily 
reproducible in hairy animals and healing is often too rapid to determine clear differences 
between treatment groups in the porcine model; nor do they imitate the deeper wounds seen 
in human diabetic foot ulcers.  Another partial thickness wound, the blister, has been used 
extensively to evaluate epidermal regeneration (Kiistala and Mustakallio 1964).  Blisters are 
easily reproducible, but have little pertinence to the deeper dermal wounds that are clinically 
problematic. 
 
An excisional wound is created when a more significant volume of target tissue is removed 
(Falanga, Schrayer et al. 2004; Reid, Said et al. 2004).  The filling of the resulting void 
allows for more detailed histological and biochemical analysis.  In addition, this type of 
wound lends itself to the topical application of wound agents and subsequent study of their 
value and was therefore chosen for the animal studies in this work.  This model more closely 
approximates the human foot ulcer than an incisional model.  Following wound closure, 
scarring and strength can also be quantitated.  The major disadvantage of this model is that 
the wound heals by contraction as well as by re-epithelialisation from the wound edges, but 
this can be minimised with splinting techniques.   
 
The chronic wound is uncommon in laboratory animals.  Therefore, various animal models 
have been adapted to reflect the local and systemic conditions that might prevent a wound 
from healing in humans.   
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 3.3  Diabetes 
 
Diabetes contributes significantly to the morbidity and mortality associated with chronic 
wounds (Boulton and Vilekyte 2005, 2001; Goodson and Hung 1977).  It is therefore 
unsurprising that many animal models of diabetes have been developed for the purpose of 
studying wound healing.  These models fall into two categories of induced diabetes: genetic 
or chemically-induced diabetes.   
 
3.3.1  Genetic models of diabetes 
Several research groups have used the db/db mutant mouse to study the effects of diabetes in 
wound healing.  Clinical signs of diabetes exhibited by this animal include obesity, 
hyperphagia, hyperinsulinaemia and hyperglycaemia (Tsuboi, Shi et al. 1992).  Diabetes in 
the genetically diabetic mouse known as the db/db mouse is due to a single gene mutation on 
the leptin receptor on chromosome 4.  Db/db mice are infertile, which necessitates that 
heterozygous carriers be used to propagate the mutation.  This model also exhibits an 
abnormal immune system, which is perhaps its major shortcoming (Bell and Hye 1983). 
 
The ob/ob mouse is another genetic model of diabetes in which the animal is genetically 
predisposed to overeating and becomes obese.  In contrast to the db/db mouse, no other 
abnormalities have been observed in this model.  Whilst initially obese, hyperinsulinaemic 
and hyperglycaemic, this state does not persist and the animal eventually achieves 
normoglycaemia (Genuth 1969).  The transient nature of diabetes in this model renders it less 
useful in long-term wound studies. 
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 Genetically diabetic strains have also been characterised in other species including guinea 
pigs, Celebes apes (Macaca Nigra), Yucatan swine, Keeshond dogs, outbred baboons, and 
South African hamsters.   
 
3.3.2  Chemically-induced models of diabetes 
Animals can be rendered diabetic by chemical treatment.  Two agents—alloxan and 
streptozotocin (STZ)—are commonly used for this purpose, both of which selectively destroy 
pancreatic beta cells.  Both substances cause toxic glucose analogues to preferentially 
accumulate in pancreatic beta cells causing their death (Lenzen 2008).  The action of alloxan 
is more rapid than that of STZ.  For this reason, STZ was the preferred agent in the studies 
within this thesis as ketosis is less likely to occur with its use.  Our laboratory has used a 
variety of models across the years in cutaneous and subcutaneous wound healing in diabetes; 
in particular, despite its short duration of wound healing, we have found that full thickness 
dorsal skin wounds in STZ-induced diabetic wild-type rats (after 6 weeks of diabetes) 
provide a good model to study topical application of therapies (McLennan, Bonner et al. 
2008).  For this reason, the STZ-induced diabetic rat was used in the studies within this 
thesis.   
 
3.3.3 Rationale for the preclinical wounding model chosen in this thesis 
Following due consideration, the studies of rhCTGF in diabetic wound healing were 
undertaken in a rat model of STZ-induced diabetes, studying full thickness skin wounds.  
This decision was made because: the model is widely recognised as a reliable model of 
diabetes mellitus; the cutaneous model of excisional biopsy is also widely recognised and has 
been established and published in our research laboratory, including in studies of ulcer 
closure and dermal changes; and the cutaneous model enables direct application of rhCTGF 
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 to the wound. Some potential disadvatanges of the model are that it is of type 1 diabetes 
rather than the more common type 2 diabetes; that rat skin differs significantly from human 
skin, with wounds healing to some degree by contraction, which does not occur in healing 
human skin wounds; and that the wound healing defects in diabetic rats in this model are 
relatively mild, with only small differences compared with ulcers in non-diabetic control rats. 
By splinting the ulcers using a reliable, established method using the dressing Tegaderm 
(Chung, Peplow et al. 2010) and by following an established, published protocol for 6 weeks 
of diabetes induction, then wounding and monitoring healing in our research laboratory 
(McLennan, Bonner et al. 2008), many of the negatives of this model can be overcome, thus 
enabling a reliable study of rhCTGF in diabetic skin wounds.  
 
3.4 Types of clinical investigation to address the utility of an investigational agent 
 
Evidence-based medicine aims to close the gap between research and everyday clinical 
practice (Sackett, Rosenberg et al. 2007).  The risks and benefits of scientifically developed 
treatments need to be assessed in a clinical arena to predict outcomes and merit in medical 
practice. 
 
Clinical evidence is rated or ranked according to a number of parameters, including freedom 
from biases, which reduce quality and impact of research.  Several rating systems exist but, in 
general, evidence falls into one of the five categories described below. 
 
3.4.1  Randomised controlled trials 
Randomised controlled trials (RCTs) are considered the gold standard of evidence-based 
medicine (Britton, McKee et al. 1998).  Blinding, randomised allocation of treatment/placebo 
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 and strict inclusion/exclusion criteria are used to minimise bias.  However strict 
inclusion/exclusion criteria may limit generalisation in a study i.e. the study group may be a 
homogenous cohort but not representative of a real, more generalised population (Lovato, 
Hill et al. 1997; McKee, Britton et al. 1999). 
 
3.4.2  Observational studies 
Observational type studies provide weaker empirical evidence, greater potential for 
confounding bias and are therefore most valuable in generating preliminary evidence to be 
used in future studies rather than as stand alone evidence (Concato, Shah et al. 2000). 
 
3.4.3  Case control studies 
Case control studies are limited as stand alone evidence as they are often retrospective, which 
in itself can confer bias, and methodology may be flawed.  These studies are, however, 
valuable in establishing research direction in poorly researched areas or areas where large 
studies are not feasible, such as rare complications (Towler 2001; Vandenbroucke and Pearce 
2012). 
 
3.4.4  Expert opinion 
Expert opinion based on clinical experience, descriptive studies, or reports of expert 
committees have been shown to be a more powerful tool for changing clinical practice than 
national evidence-based guidelines (Lomas 1991); however, the evidence they provide is not 
robust and must be treated with caution (McManus, Wilson et al. 1998). 
 
 
 
96 
 
 3.4.5    Pilot or feasibility studies 
A pilot or feasibility study is a small scale version or ‘trial run’ of a full scale study 
(Anderson and Prentice 1999; Bowen, Kreuter et al. 2009).  Such studies may be indicated 
when scant studies/data exists within the study field, partnerships need to be forged and 
tested, no in depth information into the intervention or target population is available, or 
previous similar studies have not worked (troubleshooting).  Pilot or feasibility studies are 
usually used as justification for a subsequent RCT (internal study) but can also be a stand 
alone piece of work (external study) (Lancaster, Dodd et al. 2004).  In the latter case, external 
controls can be used, such as appropriate historic controls, albeit with recognition of the 
potential biases introduced by such an approach as articulated by the Therapeutic Goods 
Administration (TGA 2001).  
 
The major reason to conduct a pilot study is to determine sample size necessary to power a 
larger trial (Browne 1995; Feldman and Fleischer 1999).  The pilot study can also be viewed 
as a feasibility study if aspects of the study design need to be examined prior to undertaking a 
larger randomised controlled trial.  A general rule is that approximately 30 participants in a 
study will allow estimation of a parameter (Browne 1995).   A pilot/feasibility study may also 
be used to test the integrity of a study methodology (Shih, Ohman-Strickland et al. 2004) and 
to test questions that pertain to recruitment, sampling, instrumentation, analysis and 
interpretation.  
 
The analysis of a pilot study should be mostly descriptive (Loscalzo 2009).  It is important 
not to place too much emphasis on statistical analysis (Arain, Campbell et al. 2010), and the 
results from such a small scale study should be interpreted with caution.  In particular, a 
decision to proceed or terminate evaluation of an intervention based on the results of a pilot 
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 study is hazardous because it is possible that the decision will be derived from false positive 
or false negative results (Type 1 or 2 error) (Fain 2010).  After propolis was found to have 
wound healing properties in a diabetic rodent model, (McLennan, Bonner et al. 2008) the 
next logical step was to run a pilot study to test it in human studies, following the 
recommendations of Browne, 1995, including to permit further estimations for larger scale 
RCT parameters (Browne, 1995).  
 
3.5 Logistics of clinical trials 
 
The most important principle of clinical trial design is to answer one question well.  
Secondary questions and analyses should be reserved for generating subsequent hypotheses 
(Kestle 1999).  The study question should be a single sentence and is key to the study (Beitz 
2006).  The sample of subjects to be studied should be clearly defined using 
inclusion/exclusion criteria.  Underlying pathophysiology must also be clearly defined.  In the 
case of wounds, this would include wound assessment criteria, which in these studies was 
defined as percentage change in wound area from original size, determined from wound 
tracings. 
 
Appropriate ‘standard care’ must also be determined.  Several wound studies have been 
criticised for using inappropriate standard care—for example, Steed compared becaplermin, a 
topical preparation containing PDGF, with saline-soaked gauze dressings, although the latter 
was widely considered an outdated therapy and therefore not an appropriate control (Steed, 
1995).  For this reason, it was decided that propolis-treated pateints would receive usual care 
(debridement, topical and systemic anti-microbial therapies and pressure offloading as 
necessary).  This approach minimised bias when compared to control subjects who received 
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 similar therapy, but without propolis, and ensured that subjects were not deprived of what is 
currently regarded as the gold standard of care. 
 
3.6 Outcomes 
 
Endpoints and surrogate endpoints in any clinical study must be clearly defined,  and 
methods of analysis should be established (Stanley 2007).  The primary outcome should be 
specifically defined (Kestle 1999); in these studies, complete wound healing was the primary 
outcome.  For wound care therapeutics, FDA guidelines require all wound care products to 
heal a wound (Armstrong, Boulton et al. 2009), which was the basis for choosing complete 
wound healing as the primary endpoint.   
 
Successful wound healing is often a series of smaller triumphs, such as a reduction of local 
pressure or wound healing across a fixed time. Wound therapies should perhaps be 
considered in terms of intermediate/surrogate endpoints (Pocock, Geller et al. 1987; Gandhi, 
Murad et al. 2008). Surrogate outcomes such as wound healing rate after the first four weeks 
of care have been shown to be excellent predictors of subsequent wound healing (Margolis, 
Kantor et al. 2000; Sheehan, Jones et al. 2003).  Such endpoints are therefore useful in some 
studies, especially smaller scale pilot studies, which tend to be of shorter duration.  Therefore, 
rate of wound healing at all time points was used as a surrogate endpoint, as was analysis of 
wound cellular content (such as collagen and macrophages in animal studies) and markers of 
healing (such as MMPs) in human wound fluid. 
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 3.7  Rationale for the method chosen for the clinical intervention 
 
After careful consideration, the decision was made to use a feasibility/pilot study to 
investigate the effects of propolis, and to use an external historical control group.   As 
described in the literature review in this thesis, topical application of propolis has not been 
studied systematically in human diabetic foot ulcers. In fact, only one case study could be 
found in which it was applied in a diabetic foot ulcer, and this was in combination with other 
agents (Lofty, Badra et al. 2006).   
 
It was decided that as a single centre study, the historical controls could be identified pre-hoc 
from the same Diabetes High Risk Foot Service as for the propolis study, based on the study 
selection criteria. This approach was justified because the methods of treatment and the 
senior medical staff in the clinic had not changed in recent years, thus allowing a valid 
control group to be identified. This method enabled series of study subjects for the propolis 
topical application to be examined in an appropriate time interval from the single site, High 
Risk Foot Service. 
Retrospective or historical data has been used successfully in many studies (Lawrence, 
Wraight et al. 2004).  Indeed, analysis of cancer studies by Vickers et al. (2007) showed that 
over half of all phase II trials required historical data to determine a null response rate 
(Vickers, Ballen et al. 2007).  
“In the absence of important biases in the study setting, the retrospective method could be 
regarded, according to sound statistical method, as the study method of choice”  (Mantel and 
Haenszel 1959) 
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 In order to support the quantitative endpoints described above in the propolis human foot 
ulcer study in diabetes, qualitative data was collected and ranked so the clinicians’ 
experiences of the propolis study could be quantitatively described.  I determined the Likert 
scale to be the most appropriate technique to collect, analyse and summarise individual 
clinicians’ opinions as to whether propolis is a safe, tolerated and practical therapy and 
whether the study design was suitable to be used for a randomised controlled trial. The Likert 
scale is regarded as the most appropriate, accurate method of enquiry and analysis of such 
data.  The strength of the Likert scale lies in its capacity to provide a quantitative means of 
understanding what essentially is qualitative data (i.e. individual rankings) as articulated by 
(Uebersax, 2012). 
 
The major disdvantage of a feasibility/pilot study is that in the absence of randomisation and 
large study subject numbers, efficacy can only be inferred.  Therefore there will almost 
certainly be a lack of homogenicity between the two patient cohorts in a pilot study. 
Controlled trials tend to overestimate efficacy of test therapies and tests of statistical 
significance carried out in such studies are less reliable than in randomised trials (Jadad, 
Moore et al.1996; TGA 2001). Specifically, as described earlier in this chapter, biases, both 
conscious and subconscious, can be introduced into a study when external controls are used.  
 
These biases were limited in degree (TGA 2001) by the following approaches that were 
adapted in this current feasibility/pilot study: the historic control group entry criteria were 
defined at the study design phase; the control group, as historic controls external to the 
prospective propolis study, were derived from the same clinic and similar patient phenotypes 
and under the same treatment conditions as per the propolis treated group; application of the 
propolis was not undertaken by the regular clinic staff, and any loss of continuity in their 
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 regular care of patients was minimised; and the main study efficacy end-point of ulcer 
healing with reduction in ulcer area was objective and documented real-time in the controls 
and the propolis study subjects by the regular treating staff using the same method of acetate 
tracings.  
 
While the work hours and intensity required to undertake the pilot/feasibility study was 
expected to be highly demanding for a single Ph.D. student, especially in the absence of a 
research nurse or assistant dedicated to the clinical study, it was concluded that a 
pilot/feasibility study could be addressed through one site.  In addition, exploratory studies of 
the effect of propolis on the wound microenvironment by examining the stored wound fluid 
post-debridement was undertaken through use of the Endocrinology Research Laboratories, 
University of Sydney facilities by me as the Ph.D. student (FH).  In addition, microbiological 
analysis of the wound fluid was undertaken as a collaboration with Dr Geraldine McKew at 
the Microbiology facilities and Royal Prince Alfred Hospital, Camperdown. 
 
3.8 Statistics 
 
Results are expressed as mean ± standard error of the mean (SEM) or mean ± standard 
deviation (SD), each where indicated.  Statistical advice for analyses undertaken was 
provided by a statistician employed by the Cental Clinical School in Sydney Medical School, 
Dr Anne-Sophie Veillard. Statistical significance was determined using Number Crunching 
Statistical Software package (NCSS, Kaysville, Utah, USA).  Methods used where 
appropriate, were: Student’s t–test for single comparisons, analysis of variance (ANOVA) for 
multiple comparisons, and the Chi squared test for small groups with discrete data, or the 
Mann Whitney U-test for non-normally distributed data. Post-hoc correction for multiple 
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 comparisons was undertaken by Bonferroni multiple comparison test. Statistical significance 
was accepted at p<0.05. 
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 Chapter 4 
 
RECOMBINANT HUMAN CONNECTIVE TISSUE GROWTH FACTOR 
THERAPY IN A DIABETIC RODENT MODEL OF WOUND HEALING  
 
4.1 Abstract 
 
Some topical growth factor therapies, such as PDGF, have shown utility in diabetic wounds.  
CTGF is a 32-38 kDa member of the CCN family, a group of proteins sharing a common 
modular structure.  Also known as CCN-2, CTGF is capable of promoting cell adhesion; is 
chemotactic for inflammatory cells, especially macrophages; is mitogenic; and promotes cell 
differentiation enhancing ECM production including in skin (Daniels, Van Bilsen et al. 2009)  
. CTGF levels are increased in human wound fluid as wounds heal including in diabetes Dr L. 
Lo (personal communication, July 2008 and section 2.7.5) whereas it is decreased in baboon 
wound tissue in diabetes compared with controls without diabetes (Thomson, McLennan et 
al. 2010 ). CTGF applied topically has shown efficacy in preclinical models of cutaneous 
burns (Liu, Shi et al. 2007) but to date its role has not been studied in diabetic wound healing, 
including in preclinical settings.  
 
This chapter addresses the laboratory production of rhCTGF, the rodent model of delayed 
wound healing and the effects of rhCTGF as topical therapy in the model.  
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 4.2 Introduction 
 
CTGF is a 32-38 kDa member of the CCN family, a group of proteins that sharing a common 
modular structure.   In non-human primates (baboons), recent studies have recently shown 
that intact CTGF protein is deficient in diabetic wound tissue compared with wound tissue in 
non-diabetic animals (Thomson, McLennan et al. 2010 ).  In this study, the levels of pro-
inflammatory mediators and proteases were increased in the wounds of diabetic animals and 
CTGF protein accumulation in wounds was found to be delayed.  To date, the effect of 
topical application of CTGF to diabetic wounds has not been described in any animal model.  
 
The aims of this study in a preclinical model of wound healing in diabetes were to:  
(i) examine whether topically applied rhCTGF improves wound healing rate; and 
(ii) determine whether CTGF treatment improves wound cellular content and breaking 
strength in a well-defined model of diabetic rodent skin wounding.  
 
Ethics approval for induction of diabetes in animals and creation of wounds was obtained 
from the Animal Research Ethics Committee, Sydney South Western Area Health Service 
(SSWAHS), # 2D10024. 
 
4.3 Methods and materials 
 
4.3.1 Cell culture and rhCTGF protein production 
The rhCTGF for treatment of wounds was produced using an adenoviral vector (Agilent 
technologies, La Jolla, CA, USA).  The process being described in detail in a previous 
publication (Tan, McLennan et al. 2008).  The CTGF cDNA open reading frame was cloned, 
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 sequenced and inserted into the AdEasy vector (Agilent technologies, La Jolla, CA, USA) 
using the BamHI and Kpn1 sites.   
 
After insertion of the vector, the recombinant adenovirus was then replicated in mammalian 
cells.  The adenoviral vector was transfected into cells from the 911 cell line that had 
previously been cultured in RPMI and at 37°C and 5% CO2.  At confluence, the cells were 
subdivided by trypsinisation and grown to 75% confluence.   At this point the cells were 
transfected by addition of the adenoviral vector containing CTGF to cells in Dulbecco’s 
Modified Eagles Medium (DMEM; Sigma-Aldrich Co, Castle Hill NSW) and 0.05% BSA.  
The cells were maintained at 37°C in 5% CO2.  The medium, which contained rhCTGF, was 
collected at 24 and 48 hour intervals and filtered using a 0.2 µm Ministart filter (Sartorius 
AG, Goettingen, Germany). 
 
4.3.2 Purification of rhCTGF 
A heparin-sepharose affinity column (Hi Trap Heparin HP, Amersham Biosciences, Uppsala, 
Sweden) was used to purify CTGF from the conditioned medium.  The column firstly was 
equilibrated with phosphate-buffered saline (PBS) and then the filtered medium was allowed 
to pass through the column at a rate of 0.2 ml/min.  The unbound protein was washed from 
the column using PBS.  The rhCTGF that had bound to the column was then eluted using a 
high salt solution (0.1M NaCl in PBS) and fractions of 1 ml were collected.  Excess salt was 
removed from the fractions by dialysis overnight in 4l PBS using molecular porous 
membrane tubing (molecular weight cut-off 12 000 – 14 000; Spectra/por, Spectrum Medical 
Industries, Los Angeles, CA).  The dialysed fractions were stored at -80°C prior to 
quantification of rhCTGF protein concentration and verification of CTGF biological activity. 
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 4.3.3 Quantitation of rhCTGF 
To determine the concentration of the purified rhCTGF protein, 20 µl of each fraction was 
loaded into individual lanes of a 12.5% solution of sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) gel and run under standard conditions (120V for 1 hour or 
until the dye front reached the bottom of the gel).  The resulting protein bands were 
visualised with Coomassie blue dye.  A Phoretix image analysis system (Nonlinear 
Dynamics, Newcastle-Upon-Tyne, UK) was used to determine the concentration of CTGF at 
the 38 kDa band.  This was compared with a protein of known concentration (BSA standard). 
 
4.3.4 Assessment of rhCTGF bioactivity 
To quantify the bioactivity of the rhCTGF, its capacity to stimulate fibronectin production in 
cultured fibroblasts was investigated.  Normal human fibroblasts (ATCC, Manassas, VA, 
USA, cat. CRL1474) were grown to confluence in RMPI containing 10% FCS.  The cells 
were then trypsinised and plated into 6-well plates.  Forty-eight hours later the media was 
removed and replaced with RPMI containing 0.1% albumin and rhCTGF in prescribed 
concentrations (100, 250, 500, 1000 ng/ml).  After a further 48 hours the media was removed 
and the RNA extracted from the cell layer using Tri Reagent (Sigma-Aldrich).  The RNA was 
reverse transcribed with Superscript III (Invitrogen, Mt Waverley, VIC) and fibronectin gene 
expression measured by quantitative real-time PCR using primers previously validated (Tan, 
Mc Lennan et al. 2008).  The CTGF used in this study was shown to induce fibronectin 
expression by -four fold at 48 hours which was comparable to the CTGF synthesised by Tan 
et al. 2008 in which bioactivity had been proven (Tan, McLennan et al, 2008). 
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 4.4 Rodent wounding studies 
 
4.4.1 Induction and maintenance of diabetes in Sprague-Dawley rats 
Male Sprague-Dawley rats (n=52) aged between 6-7 weeks were purchased from Australian 
Laboratory Supply (Perth, Australia), this number had previously proved adequate to yield 
meaningful data in similar treatment vs. control rodent wound healing experiments 
(McLennan, Bonner et al. 2008).  Type 1 diabetes was induced in 26 animals using STZ (60 
mg/kg i.p., Calbiochem, Sydney, Australia) over 3 consecutive days. Animals whose blood 
glucose measurements were greater than 15 mmol/L after 3 consecutive days of STZ 
administration were considered diabetic, and those that did not achieve this (n=3) were 
excluded from the study.  Subsequently, animals were maintained on 2-4 IU of insulin 
(Mixtard, Novo-Nordisk, Malmo, Sweden) every second day to prevent weight loss and 
ketoacidosis. The insulin was administered every second day, according to blood glucose 
levels determined with a blood glucose meter, to maintain a target blood glucose level of ~15 
mmol/L.  All animals had access to standard chow and water ad libitum. 
 
4.4.2  Skin wounding 
Seven weeks after the induction of diabetes, diabetic (n=23) and control (n=29) animals were 
anesthetised using ketamine (85 mg/kg, Pfizer, Sydney, Australia) and xylazine (5 mg/kg, 
Bayer, Leverkusen, Germany). Dorsal skin was shaved and depilated (Veet depilatory cream, 
Reckitt Benckiser, Hull, UK).  In order to prevent bacterial infection the dorsum of each 
animal was swabbed with solution of 10% povidone-iodine prior to wounding.  In each 
animal a total of four full-thickness skin wounds were created using an 8mm biopsy punch 
(Stieffel Laboratories, NSW, Australia) with two wounds on each side of the midline, as 
shown in Fig. 4.1. The wounds included the panniculus carnosus exposing the underlying 
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 dorsolateral skeletal muscle fascia.  At the time of wounding all animals were treated with a 
single dose of parenteral antibiotic (ampicillin: 50 mg/kg).   
 
 
Figure 4.1: Wounding locations on rat dorsum. 
Full thickness wounds were created using an 8mm punch biopsy. 
 
4.4.3  CTGF treatment 
The rhCTGF used for this study was prepared as described in detail in section 4.3 (Tan, 
McLennan et al. 2008).  To examine the effect of CTGF on wound healing, 1µg of the 
purified rhCTGF in PBS was applied to each of two wounds:one each in an antero-right 
location and one postero-left.  The remaining two wounds were treated with PBS only.  The 
wounds were occluded with a transparent film dressing (Tegaderm, 3M, NSW) which was 
secured on all sides using Hypafix tape (Smith and Nephew, Victoria). 
 
After an interval of 24 hours the animals were anaesthetised (section 4.4.2 of this chapter) 
and treated with a second dose of CTGF or PBS vehicle to the same wounds.  The wounds 
were again occluded using Tegaderm and Hypafix tape.  This dosing schedule was chosen 
because the CTGF had to be made in house in a long, low yielding process and was therefore 
scarce but this dose had previously be shown as efficacious in previous in vitro studies.  
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 CTGF is important in initiating healing, firstly by ‘priming’ the wound and secondly to 
potentiate healing.   On this basis administration at early time points was deemed appropriate. 
4.4.4 Wound visualisation and retrieval 
In one series of experiments, the effect of CTGF on wound closure was determined by tracing 
the circumference of the wounds onto transparencies on the day of wounding and at twice-
weekly intervals thereafter (days 1, 3, 7, 10, 14 and 21), or until terminated.  This time frame 
was used as it has been shown to produce data reporting wound closure accurately up to day 
14, at which time most wounds have healed.  In a parallel series of experiments, rats from 
each group were terminated at day 21 specifically tissue for breaking strength analysis.  The 
tissue containing the wound was excised and either  
(i) fixed in paraformaldehyde (4% in PBS) for immunohistochemical analysis; or  
(ii) snap frozen in liquid nitrogen for determination of wound breaking strength, thus 
yielding one treated and one untreated wound for each assay.  
  
4.4.5 Wound area measurement 
Wounds were observed during closure and serial wound area measurements were taken.  
Various methods of wound area measurement were trialled. Visitrak, (a portable digital 
device marketed by Smith and Nephew for wound measurement (Smith & Nephew Surgical 
Pty Limited, North Ryde, NSW)), was found in my preliminary work to be insufficiently 
sensitive to measure wounds less than 10 mm diameter (data not shown).  The ARANZ 
Silhouette system (Merivale, Christchurch, New Zealand), which is designed to capture 
digitally wound photographs, measurements and clinical notes, was ineffective in this 
preclinical study due to difficulty in keeping the animals adequately still for routine 
photography purposes. However, acetate tracings quantitated using Image J software were 
found to be an efficient method of wound area analysis.  It is noted that this method has also 
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 been used for monitoring diabetic wound healing in foot ulcers in diabetes high risk foot 
clinics such as at Royal Prince Alfred Hospital and for animal wounding studies and found to 
be a robust method attributable to its reproducibility  (Thomson, McLennan et al. 2010).  
 
Wound circumference tracings were translated into computer images using pen-tablet 
software (Bamboo, Wacom, USA) for quantification of wound area using ImageJ software 
(Research Services Branch, NIMH, USA).  Wound closure was then determined and 
expressed as a percentage of the original wound size. 
 
4.4.6 Breaking strength 
For the measurement of wound breaking strength, healed excised wounds from day 21 were 
cut into rectangular strips with the width being the diameter of the healed wound area and the 
length being the diameter of the wound area plus one centimetre on each side to allow 
attachment to the tension meter.  The width, length and thickness of wound pieces were 
measured using calipers.   
 
To measure tensile strength, the tissue was first glued to balsa wood pieces and then the 
tissue and the balsa wood pieces were clamped into the jaws of an Elf 3400 tension meter 
(BOSE EnduraTec, MN, USA).  A constant load (45N) at a crosshead speed of 10 mm/min 
was then placed on the skin until it failed causing the skin to rupture.  The cross-sectional 
area of the skin was measured before the load was applied. The stress and strain required to 
break the wound and Young’s modulus (tensile strength) was calculated using these values. 
 
 
4.4.7 Analysis of wound cellular content 
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 The excised paraformaldehyde-fixed, paraffin-embedded wounds were sectioned (5 µm 
sections) perpendicular to the wound surface.  Sections obtained at day 7 and 14 were stained 
with specific antibodies for CTGF, CD68, collagen IV, αSMA or PCNA (proliferating cell 
nuclear antigen) (Abcam, Cambridge, MA).  Following antigen retrieval, the slides were 
incubated in a solution of 3% hydrogen peroxide for 10 minutes and washed in Tris-buffered 
saline (TBS).  Non-specific binding was blocked by incubation in 10% v/v goat serum and, 
after washing with TBS, the sections were incubated for 60 minutes at room temperature 
(RT) with primary antibodies diluted in TBS.  A further TBS wash was carried out before 
incubation with a secondary antibody for 30 minutes.  Cells were visualised using 
peroxidase-conjugated secondary antibodies followed by 3,3’-diaminobenzidine chromogen 
(Vector Laboratories, Burlingame, CA).  The antibodies used, supplied by Vector 
Laboratories, Ca, USA are shown in Table 4.1. 
Table 4.1: Primary and secondary antibodies used in immunohistochemical staining 
 
 
 
 
 
 
 
 
 
 
 
 
Primary antibody Concentration Supplier 
 
Secondary antibody 
 
Anti-CTGF 1: 400 
 
In house (ab196) 
(Tikellis, Cooper et 
al.2004) 
Goat anti-rabbit 
 
Anti-Collagen IV 
 
1: 200 Abcam (ab86042) Goat anti-mouse 
 
Anti-CD68 
 
1: 800 Abcam (ab955) Goat anti-mouse 
 
Anti-αSMA 
 
1: 400 Abcam (ab5694) Goat anti-rabbit 
 
Anti-PCNA 
1: 500 Abcam (ab15497) Goat anti-rabbit 
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 4.4.8 Analysis of cell density and staining intensity  
The mean staining intensity of CTGF in epithelial and granulation tissue was assessed semi-
quantitatively by two independent observers blinded to animal condition and wound 
treatment status using the following scoring system:  
0 = no staining;  
1 = weak staining;  
2 = moderate staining; and 
 3 = strong staining.   
The same scoring system was used to analyse the intensity of collagen IV staining and αSMA 
staining in fibroblasts and epithelial cells.  The number of macrophages (CD68 stained) in 20 
sequential fields of each section was determined (at 100x magnification under oil) by a single 
observer blinded to condition and treatment status.  The number of PCNA-positive cells was 
counted in three sequential fields of each section within each wound and the number of 
positive keratinocytes on the epithelial edge was recorded as a percentage of total 
keratinocytes in a section from each wound, again by a blinded observer. 
 
4.5 Results 
 
4.5.1 The effect of CTGF on wound closure in diabetic and control rats 
To test the therapeutic effects of CTGF on wound healing, full-thickness wounds were 
established in diabetic and non-diabetic rats and then treated with topical CTGF. Wound 
healing was assessed over a 14-day period with wound breaking strength examined on day 
21.  Data for the measurement of macroscopic wound closure expressed as percentage change 
in the initial wound area at selected time points is shown at Table 4.3.  
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 Table 4.2 Abbreviations and n values for the wound closure rate studies. 
Abbreviation Day 7  
n= 
Day 14 
n= 
Treatment Type 
C + PBS  58 44 Control + Phosphate Buffered Saline 
C + CTGF  58 44 Control + Connective Tissue Growth Factor 
DM + PBS 46 26 Diabetes + Phosphate Buffered Saline 
DM + CTGF 46 26 Diabetes + Connective Tissue Growth Factor 
 
 
 
Table 4.3: Epithelial closure rates. 
 
Wound Closure (% of initial wound size) 
Results are expressed as percentage of initial wound size (mean ± SEM), *p<0.05 compared 
with untreated diabetic wounds (DM + PBS alone), each at the same time point, by ANOVA.   
 
Wound closure was slower in diabetic animals (DM) than in control (non-diabetic) animals 
(C); (at day 7, C = 25.2 ± 0.9 % original size, DM = 31.0 ± 1.1 %  original size; mean ± SEM 
*p<0.05.  In CTGF-treated diabetic rats, macroscopic wound closure was significantly 
enhanced on days 7, 10 and 14 compared to the non-treated diabetic group (Table 4.3 and 
Fig. 4.2).   In contrast to the effect of CTGF in diabetic wounds, non-diabetic wounds treated 
with CTGF did not show improved closure rates relative to controls (Fig.4.2). 
 
Group DAY 1 DAY 3 DAY 7 DAY 10 DAY 14 
C+PBS 85.7±1.5 57.7±2.1 25.2±0.9* 18.0±0.6 13.0±0.4* 
C+CTGF 81.7±1.4* 52.2±1.8* 25.6±0.9* 16.5±0.4 13.2±0.3* 
DM+PBS 92.8±1.6 61.7±1.7 31.0± 1.1 20.7±0.8 15.9±0.5 
DM+CTGF 85.4±1.4 57.5±2.2 28.4±1.2* 16.1±0.7* 13.6±0.4* 
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Figure 4.2 Wound area reduction after cutaneous wounding and CTGF effects. 
Wound area reduction was significantly enhanced on days 7, 10 and14 in the CTGF-treated 
diabetic group (DM+CTGF) compared with the vehicle treated diabetic group (DM+PBS), 
*p<0.05 by ANOVA. For clarity, only these significant differences are shown in the figure. 
All statistically significant differences and SEM data are shown in Table 4.3.  
 
4.5.2    The effect of CTGF on wound breaking strength in diabetic and control rats 
The effect of CTGF on the wound breaking strength was measured at day 21 when the 
wounds were healed (control n=30 wounds, diabetes n=30 wounds).  As shown in Table 4.4, 
analysis by ANOVA showed that untreated diabetic wounds tolerated lower levels of final 
strain before breaking than either CTGF-treated or untreated control wounds (*p<0.005) 
(average 2.20 MPa compared to 3.08 and 3.45 MPa respectively), indicating that diabetic 
wounds are less robust.  These results are shown in Table 4.4 (A). 
 
C + PBS 
C + CTGF 
DM + PBS 
DM + CTGF 
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 Differences between the amounts of strain levels required for the wound to fail was assessed 
by comparing grouped data from diabetic animals (whether treated with CTGF or PBS) and 
controls (whether treated with CTGF or PBS).  Control wounds were able to tolerate a greater 
strain before breaking than diabetic wounds (˜p<0.05, Student’s t-test).  In tear strain and 
final strain measurements, diabetic wounds required less strain to fail than control wounds 
(tear strain 0.79 MPa compared to 1.11 MPa *p<0.01; ˜p<0.05 for final strain 2.25 MPa 
compared to 3.27 MPa; using Student’s t-test) (Table 4.4 (B)). The diabetic wounds tended to 
have a lower mean Young’s modulus than the control wounds.  Thus whilst they may be less 
stiff, the data is not statistically significant. 
 
Data was collated into groups of PBS- or CTGF-treated (regardless of diabetic status) (Table 
4.4(C)). Young’s modulus (or stress in proportion to strain) was found to be greater in CTGF-
treated wounds than untreated wounds (*p<0.05 by unpaired t-test) indicating that healed 
CTGF-treated wound sites were more stiff and less extendable than the untreated wounds 
(Table 4.4 (C)).  
 
Table 4.4: Breaking strength of wound sites. 
 
(A) Breaking strength 
ANOVA 
    
 Modulus Tear Strength 
Tear 
Strain 
Ult. 
Strength 
Final 
Strain 
C + PBS 0.93 ± 0.09 0.56 ± 0.06 1.17 ± 0.10 1.06 ± 0.01 3.45 ± 0.22 
DM + PBS 0.87 ± 0.13 0.46 ± 0.05 0.71 ± 0.06 0.81 ± 0.13 2.20 ± 0.16* 
C + CTGF 1.21 ± 0.11 0.53 ± 0.05 1.04 ± 0.10 0.89 ± 0.06 3.08 ± 0.27 
DM + CTGF 1.01 ± 0.17 0.53 ± 0.05 0.87 ± 0.18 0.86 ± 0.10 2.32 ± 0.22 
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 Breaking strength 
Student’s t-test 
 Modulus Tear Strength 
Tear 
Strain 
Ult 
Strength 
Final 
Strain 
ALL 
CONTROLS 
1.06 ± 0.07 0.49 ± 0.21 1.11 ± 0.07 0.98 ± 0.06 3.27 ± 0.17 
ALL 
DIABETES 
0.94 ± 0.10 0.49 ± 0.16 0.79 ± 0.09* 0.84 ± 0.08 2.25 ± 0.13˜ 
         
        (C)          Breaking strength  
 
       Student’s t-test 
               
 Modulus Tear 
Strength 
Tear Strain Ult 
Strength 
Final 
Strain 
ALL PBS 
ONLY 0.90 ± 0.07 0.52 ± 0.04 0.99 ± 0.07 0.97 ± 0.05 2.96 ± 0.19 
ALL CTGF 
TREATED 1.13 ± 0.09* 0.53 ± 0.03 0.97 ± 0.09 0.88 ± 0.05 2.78 ± 0.20 
 
 (A) Data from the four groups are as shown; by ANOVA, *p<0.01 compared with untreated 
control and also with CTGF-treated control; (B) Collated data are shown for all non-diabetic 
(control) rats and all diabetic rats; by Student’s unpaired t-test, *p<0.01 vs non-diabetic 
controls (for tear strain); ˜p<0.05 vs non-diabetic controls (for final strain). (C) Collated data 
are shown for all PBS-treated rats and all CTGF-treated rats; by Student’s unpaired t-test, 
*p<0.05 vs all PBS treated animals (for Modulus). Results are expressed as mean ± SEM. 
 
4.5.3  The effect of CTGF on wound tissue composition in diabetic and control rats  
The effect of CTGF on cells involved in wound healing including macrophages, activated 
fibroblasts and endothelial cells was investigated.  The intensity of staining of collagen-IV as 
a marker of wound healing was examined along with, PCNA as a marker of cell proliferation 
and CTGF protein in the wound tissue. 
 
4.5.3.1  Macrophage counts in wound tissue 
By ANOVA, no differences in macrophage number were observed across the four groups 
(Fig. 4.3).  The number of macrophages, identified by CD68 staining, was deed to be greater 
in CTGF-treated animals (control and diabetes combined) than in non-CTGF treated animals 
(control and diabetes combined) at day 7 (p<0.05 by ANOVA).  The macrophage count 
(B) 
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 declined in both treated and untreated groups by day 14, and no statistically significant 
differences between the groups were observed at this timepoint (Fig.4.3B). 
(A)           (B) 
 
Figure 4.3: Macrophage count averaged per 20 fields in rat wounds. 
Tissue macrophages were counted in 20 fields per wound in each of the experimental groups. 
No statistical difference was observed across each of the groups at day 7 or 14 (panel (B)). 
Results are expressed as mean ± SEM. 
 
4.5.3.2 The affect of CTGF treatment on activated fibroblasts and mature vascular 
endothelial cells in wound tissue in diabetic and control rats. 
Intensity of staining by α-SMA, a marker of activated fibroblasts and endothelial cells, was 
measured at days 7 and 14.  There were very few activated fibroblasts in diabetic wounds at 
day 7, either treated with CTGF or untreated.   Compared with untreated diabetic animals at 
day 7, CTGF-treated control animals showed significantly more intense fibroblast staining 
(Fig 4.4) compared with both treated and untreated non-diabetic animals (*p<0.05 by 
ANOVA) indicating that healing was more advanced in the CTGF treated control group. 
Other comparisons were not statistically significant for α-SMA scores. 
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  (A)            (B) 
Figure 4.4: Alpha smooth muscle actin staining scores in fibroblasts in  respective 
wounds. The α-SMA staining scores in wound fibroblasts in control and diabetic rats, with 
and without CTGF treatment is shown at (A) day 7 and (B) day 14. *p<0.05 vs DM +PBS, 
and DM + rhCTGF by ANOVA.  Results are expressed as mean ± SEM. 
 
There were no differences in α-SMA staining in blood vessels in the four experimental 
groups (Fig. 4.5). However, when the groups were combined, reduced staining was observed 
at day 7 in diabetic (treated and untreated combined) compared to control animals (treated 
and untreated combined) (*p<0.05 by unpaired t-test). 
(A)              (B) 
 
 
 
 
 
 
Figure 4.5: Alpha smooth muscle actin staining scores in blood vessels of wounds. 
Wounds from diabetic and non-diabetic rats treated with CTGF or PBS were stained with α-
SMA and staining scores in the endothelial cells was assessed. (A) Day 7 and (B) Day 14 
Results are expressed as mean ± SEM. 
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 4.5.3.3            The effect of CTGF treatment on collagen-IV content in wound tissue in 
diabetic and control rats. 
 
Collagen-IV staining was decreased in untreated diabetic wounds at day 7 (*p<0.05 vs. 
control+CTGF treated rats).  At day 14, CTGF-treated diabetic wounds showed more 
collagen-IV staining compared with all other groups (untreated diabetic wounds and CTGF-
treated and untreated controls) (***p<0.005 by ANOVA), (Fig. 4.6).  Representative images 
are shown (Fig. 4.7).  Increased levels of collagen are typical of wound healing. 
 
(A)            (B) 
 
Figure 4.6 Collagen-IV staining in  wound tissue. 
Intensity of collagen-IV in wounds in control and diabetic rats treated with PBS or CTGF. 
(A) At day 7 and (B) at day 14. *p<0.05 compared to control + CTGF treated animals; 
***p<0.005 compared to the other groups. Data were analysed by ANOVA and results are 
expressed as mean ± SEM. 
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     Control + PBS       Control + rhCTGF                D + PBS                 D + rhCTGF  
Figure 4.7: Representative images of collagen-IV staining in wound tissue.  
 
4.5.3.4  The effect of CTGF treatment on expression in wound tissue in diabetic and 
control rats. 
PCNA is a marker of proliferating cells and has been measured in preclinical models 
elsewhere to examine wound healing (Liu, Shi et al. 2007).  The number of PCNA-positive 
and PCNA-negative cells in the total wound (both epidermis and dermis) was measured by 
immunohistochemical staining. The staining data were expressed as the total number of 
PCNA-positive cells and as a percentage.  Cell counts were made by a single observer who 
was blinded to the tissue source of the wounds.  
 
The data indicated that diabetic wounds showed no clear differences in PCNA nominally (Fig 
4.8) or as total number of positive cells (Fig. 4.9), across any of the groups. 
 
 
 
 
Day 7 
Day 14 
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   (A)       (B) 
 
Figure 4.8: Percentage of PCNA-positive cells in wound tissue. 
PCNA-positive cells expressed as a percentage of the total number of cells in wounds from 
diabetic and non-diabetic rats treated with PBS or CTGF. (A) Day 7 and (B) day 14.  Results 
are expressed as mean ± SEM. 
 
 
(A)          (B) 
 
Figure 4.9: Mean number of PCNA-positive cells. 
Total number of PCNA-positive cells in wounds from diabetic and non-diabetic rats treated 
with PBS or CTGF. (A) Day 7 and (B) day 14.  Results are expressed as mean ± SEM. 
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 4.5.3.5  CTGF protein in wound tissue of diabetic and control rats. 
CTGF protein was examined in wound tissue macrophages, fibroblasts and endothelial cells 
by immunohistochemistry.  Intensity of CTGF staining was measured (as described in section 
4.3.7) and CTGF tended to be marginally deficient in diabetic animals compared with control 
animals but this was not statistically significant.  Treatment with rhCTGF tended to increase 
CTGF protein in both treated groups at day 7 and 14 compared to controls, although  the 
relative increase of CTGF protein in the treated groups was not statistically significant at day 
7 or 14, after the CTGF was applied as per protocol on days 1 and 2 only.  This result 
suggests that the application of topical rhCTGF to a wound may cause only a , small non-
sustained, transient increase in CTGF levels and that the CTGF measured at days 7 and 14 
was produced endogenously.   
 
(A)         (B)  
 
Figure 4.10:  rhCTGF in wound tissue samples. 
CTGF staining intensity score in wounds of diabetic and non-diabetic rats treated with PBS 
or CTGF.  Results are expressed as mean ± SEM. There were no significant differences 
between the groups, as determined by ANOVA. 
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 4.6 Discussion 
 
In diabetic wounds, several abnormalities can contribute to impaired healing including; 
prolonged inflammation, impaired angiogenesis, decreased synthesis of collagen and 
defective macrophage function (Wang, Li et al. 2009).  CTGF already has been shown to 
hold potential value in contributing to wound healing (Chang, Shih et al. 2004) and can 
accelerate the healing rate of burns in rhesus monkeys (Liu, Shi et al. 2007). 
 
The data from this chapter demonstrate that rhCTGF applied topically accelerates parameters 
of wound healing including wound closure in vivo and collagen-IV induction in particular. 
CTGF is known to act through signalling pathways to induce fibroplasia (Sonnylal, Shi-Wen 
et al. 2010).  Previous studies have shown CTGF can significantly induce collagen protein 
expression (Gore-Hyer, Shegogue et al, 2002). TGFβ which is mediated by CTGF is also able 
to induce collagen. Topical application of CTGF improves wound healing towards normal in 
a diabetic rodent model of full thickness cutaneous wound healing.  The main endpoint, rate 
of epithelial closure as a percentage of original wound size, was accelerated in the diabetic 
rats treated with CTGF. Some other wound healing end-points were not affected significantly 
by CTGF treatment, including CTGF staining, α-SMA and PCNA, and the breaking strength 
of wounds.  
 
Occlusion of wounds using a semi-permeable film dressing ‘Tegaderm’ further validated the 
model used, as occlusion enabled more accurate visualisation of the wound since no scab or 
foreign matter distorted or contaminated the wound.  Furthermore, in diabetic rodent models 
the film dressing exerts a ‘splinting’ effect on wound margins and also on contraction. This 
promotes healing through re-epithelialisation (Chung, Peplow et al. 2010) which 
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 approximates human wound healing, rather than through contraction which predominates in 
non-splinted rodent wounds. 
 
CTGF did not affect wound closure rates in control rats suggesting that CTGF is able to 
normalise certain deficits found within diabetic wounds without affecting healing in normal 
wounds.  It is thought that CTGF may normalise wound healing through the augmentation of 
chemotaxis and mitosis and/or through up-regulation of downstream mediators such as TGF-
β.  These actions might attenuate the persistent inflammation that is detrimental within the 
diabetic wound.  
 
The beneficial effect of rhCTGF therapy on epithelial closure was found to occur quite early 
on in wound healing - a significant effect on diabetic wounds was observed by day 7 after 
wounding.  In this current work, macrophage numbers were increased in wounds treated with 
CTGF, regardless of diabetes status and may have contributed to the enhanced healing 
observed in the diabetic wounds.  
 
The CTGF effect may have contributed to macrophage induction in diabetic wounds: 
increased macrophage infiltration observed within CTGF treated diabetic wounds at day 7 co-
segregated with accelerated healing in these wounds. Indeed, the influx of macrophages may 
contribute to healing, for example the application of macrophages to diabetic rodent wounds 
has been shown to accelerate wound healing and epithelial closure (Waugh, Sherratt et al. 
2006).  CTGF is expressed transiently in wounds and this is probably why CTGF protein was 
not increased at days 7 and 14.  The relatively mild differences in macrophages between 
treated and untreated groups was relatively mild probably due to the modest dosing of CTGF 
and limited study power.  Macrophages upregulate healing through their inflammatory and 
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 reparative phenotypes and the balance between inflammatory and repair macrophages is 
crucial for successful healing (DiPietro, 1995).  Inflammatory macrophages synthesise a 
range of growth factors which in turn attract fibroblasts and endothelial cells and promote 
their proliferation (Stout, Jiang et al. 2005).  Reparative macrophages also support ECM 
remodelling (DiPietro, 1995). 
 
The finding that Young’s modulus (a numerical description of the ability of a material to 
withstand changes in length under tension or compression in one direction, in this case 
tension), was found to be lower in the diabetic animals than in the controls is consistent with 
recent literature (Greenwald, Shumway et al. 1993).  Young’s modulus was found to  
increase ( t-test p<0.05) in the group of animals treated with CTGF (regardless of diabetes 
status) with attendant increase in tensile strength observed.  The observed increase in 
collagen-IV after CTGF treatment may contribute to the greater tensile strength of the wound 
sites.  Collagen contributes to wound strength and its increased accumulation in the wound 
would reasonably explain the increased strength and strain observed in CTGF-treated 
wounds.  These observations are similar to studies with other growth factors. For example, 
PDGF treatment was shown to induce collagen and cause increased strength in corneal tissue 
wounds (Murali, Hardten et al. 1994). 
 
Collagen-IV was increased in CTGF-treated diabetic ulcers when compared with untreated 
diabetic ulcers and controls.  Collagen-IV is found primarily in basement membranes, its 
formation shows progression of the wound to remodelling and therefore end stage repair.  
Collagen-IV peptides have been shown to promote cell adhesion and migration in corneal 
epithelial cells suggesting that it can contribute directly to the wound healing process 
(Cameron, Skubitz et al. 1991).  The collagen content of a wound is determined by the 
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 balance between collagen production and degradation (Stadelmann, Digenis et al. 1998) with 
MMP-9 being a key regulator of collagen-IV degradation (Falanga and Falanga 2005).  The 
direct effects of CTGF on MMP activity have not been studied extensively, although it has 
been reported that CTGF upregulates the expression of TIMP-1, an MMP inhibitor, in 
mesangial cells (McLennan, Wang et al. 2004).  Therefore, one possible mechanism for the 
increased collagen content in the diabetic wound is CTGF-mediated upregulation of TIMPs 
leading to inhibition of MMP-9 and reduced collagen degradation.  
 
Fibroblasts derived from foot ulcers in type 2 diabetes patients show diminished proliferative 
capacity and hypertrophy (Loots, Lamme et al. 1999).  This cellular hypertrophy is 
characterised by a halt in the cell cycle at the G1 phase, with continued production of cellular 
proteins, leading to an increase in the overall size of the cell (Wolf and Ziyadeh 1999).  
Previous cell cycle analysis has revealed that prolonged exposure to high concentrations of 
glucose arrests mesangial cells in the G1 phase with the concomitant induction of 
hypertrophy (Wahab, Weston et al. 2002).  The process is initiated in response to exposure to 
high concentrations of glucose.  While it might be expected then that PCNA measures in the 
current work may have exposed differences in cell proliferation however none were observed 
across wounds in rats with or without diabetes and no rhCTGF effect was observed on this 
end-point. In addition cell-cycling and phase of tissue cells were not examined.   
 
Relatively small changes in epithelial closure between control and diabetic untreated animals 
were observed in these studies.  Nonetheless, CTGF was effective at accelerating wound 
closure in diabetes.  Future studies may benefit from adopting alternative animal models with 
greater differences in epithelial closure between diabetic and non-diabetic wounds e.g.a pig 
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 model, which has tighter skin than a rat; or an ischemic model.  Ethical and logistical issues 
prevent the use of these models at this University’s facilities at this stage.   
 
The novel rodent data described in this chapter which indicates the efficacy of topical 
rhCTGF to induce wound healing in a diabetic rodent model of cutaneous wound healing, 
complements other data related to CTGF in wounds in diabetes. As described in the literature 
review section 2.7.5, research colleagues in the same laboratory have found across a series of 
samples in 32 study subjects with diabetes and foot ulcers,  a positive association between 
immunoreactive CTGF in post-debridement ulcer fluid and ulcer healing. Published data in a 
primate (baboon) model of wounding in diabetes indicates that CTGF is deficient in wound 
tissue in diabetes (Thompson, McLennan et al. 2010). On the basis of the current results 
using CTGF as therapy in a rat cutaneous model in diabetes, combined with the work of 
others addressing endogenous CTGF regulation in human and non-human primates with 
diabetes, it is suggested that early-phase studies of topical CTGF in human foot ulcers in 
diabetes, should now be considered. 
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 Chapter 5 
 
A PILOT STUDY OF PROPOLIS AS A WOUND HEALING THERAPY 
IN A COHORT OF HUMAN DIABETIC FOOT ULCERS 
 
5.1 Abstract 
 
Propolis has potent anti-inflammatory and anti-bacterial properties and previous small animal 
studies have indicated its potential to heal cutaneous diabetic wounds.  Propolis has a low 
side-effect profile and is TGA approved for therapy of abrasions, however, no systematic 
study of the use of propolis in humans with diabetic foot ulcers has been published. In this 
chapter, the results of a pilot study are presented for 24 subjects with chronic diabetic foot 
ulcers who received six consecutive weeks of topical propolis treatment applied post-
debridement, (in addition to standard care), followed by six weeks of follow-up in monitoring 
of wounds and patient progress.  
 
5.2  Introduction 
  
The beehive protectant propolis has been shown to have anti-inflammatory and antibacterial 
actions (Aliyazıcıoglu, Sahin et al. 2011).  The complex composition (comprising over 200 
compounds) and regional variation in propolis (Marcucci 1995) means it is not possible to 
determine its active ingredients exactly.  However, an extensive literature implicates caffeic 
acid poly-ester compounds (CAPE) and phenols as probable mediators of at least some of its 
anti-inflammatory and anti-bacterial properties (Bankova, Christov et al. 2005). 
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Propolis-treated diabetic rats showed improved wound healing and normalised neutrophil 
count, and the treatment was safe and well-tolerated treatment (McLennan, Sakar et al. 2009).  
This novel data indicated propolis to accelerate wound healing in a rodent model of diabetes 
(McLennan, Sakar et al. 2009).  As far as it has been possible to ascertain with any degree of 
certainty that is the only published study to show that propolis has efficacy in diabetic 
wounds, albeit in a preclinical environment.  
 
Considering the efficacy of propolis in rodent diabetic wounds and that topical administration 
has been well-tolerated (section 2.8.5) (Menniti-Ippolito, Mazzanti et al. 2008), it was 
determined that propolis should be trialed in human diabetic foot ulcers.  as propolis has not 
been systematically examined in human diabetic wounds, it was decided that the correct 
approach was an initial pilot study to test the study methodology as well as the acceptability, 
tolerability and safety of topical propolis. 
 
5.3 Methods and materials 
 
5.3.1 Study subjects 
Patients with type 1 or type 2 diabetes who attended the High Risk Foot Clinic at Royal 
Prince Alfred Hospital, Sydney, and who fitted the study inclusion criteria (outlined below) 
were approached to take part in this study between January and June 2011.  
 
The protocol was approved by the ethics committee of Sydney South West Area Health 
Service (SSWAHS) ( study ID: X10-0266, and HREC/10/RPAH/473) NSW, Australia, and 
informed consent was obtained from each enrolling patient .   
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 Thirty patients were recruited of whom six patients were subsequently removed from the 
study, four of whom failing to attend appointments and did not reschedule. A further patient 
was removed from the study when their wound deteriorated requiring a VAC (Vacuum 
Assisted Closure) NWPT system, which clinic staff considered sufficiently severe to justify 
that patient’s exclusion from the study.  Three other patients declined to take part in the study 
and several others were ineligible because they did not fulfill the study criteria.  The final 
number of serial consenting patients successfully taking part in and completing the study was 
twenty four. 
 
In general, the control subjects and the propolis-treated subjects were similar in demographic 
and ulcer characteristics (Table 5.1).  Notably patient age, diabetes duration and gender 
distribution were not different nor were the HbA1c levels documented at the time of clinic 
therapy or the history of past foot ulceration (by student’s t-test). The ulcer area (mainly 
forefoot site), University of Texas staging and grading of ulcers were also similar in the 
propolis and control groups (Table 5.1).  However, the propolis group had a ~two-fold higher 
rate of historic amputation (usually a digit), (p<0.01 by student’s t-test) and a greater than 
two-fold greater prevalence of neuro-ischaemic ulceration compared with the control group 
(p<0.05 by student’s t-test).  The control group had a higher rate of recurrent ulceration but 
this was not statistically significant (Table 5.1).  In both groups, the predominant ulcer 
location was on the plantar surface of the forefoot or a digit.  
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 Table 5.1: Demographic details of propolis-treated and historic control populations.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Data expressed as mean ± SD. 
 
A foot ulcer of four weeks duration or more was classified as a chronic ulcer, as per the 
American Diabetes Association (ADA 1999).  The exclusion criteria included severe 
ischaemia as these wounds are unlikely to heal in the absence of revascularisation 
(Stadelmann, Digenis et al. 1998; Prompers, Huijberts et al. 2007) and, on reviewing the 
        Control      Propolis 
Patient number (n)  84 24 
Males (%)  76.2 84.0 
*Age (years)   63.1±13.7 58.1±11.2 
*Type 2 diabetes (%)  86.9 77.3 
*Diabetes duration (years)   17.7±16.5 18.3±9.2 
Smoker (%) - current or past 62.3 63.6 
*HbA1c level (%)   8.8±2.0 8.2±1.6 
Previous amputation (%) Yes 15.7 32.0 
Previous foot ulcer (%) Yes – any 59.6 56.0 
*Ulcer area (mm2)  219±326 240±561 
Texan grade (%) I 71.3 77.3 
 
II or III 28.7 22.7 
Texan stage (%) A 21.3 31.8 
 B 65.0 54.5 
 
C or D 13.7 13.7 
Ulcer type (%) Neuropathic 79.2 68.3 
 Neuro-ischaemic 10.0 22.7 
 
Post-surgical or 
pressure/trauma 
10.8 9.0 
A recurrent ulcer site (%) Yes 21.5 13.6 
Antibiotic therapy - oral  (%) 80 75 
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 literature, propolis is not shown to have anti-ischaemic or angiogenic properties.  Ischaemia 
was determined as an ABPI of <0.8 or where vessel calcification was suspected, determined 
on the result of diagnostic Doppler testing.   Since propolis’ anti-microbial properties have 
not previously been tested on wounds in human subjects with diabetes, individuals with 
severe infection (defined as requiring IV antibiotics/hospital admission) were excluded from 
the study.   This was based on the advice of senior clinical staff who deemed it inappropriate 
to enrol patients requiring intensive antibiotic interventions at the early pilot stage of a 
clinical trial.  Participants with wounds that were deemed clinically infected by clinic staff 
but did not require IV antibiotics and did not have evidence of osteomyelitis were permitted 
to enrol in the study and to continue with oral antibiotic therapy as prescribed by the 
attending physician.  This was  consistent with the control group (described below). 
 
As an external control, ulcer healing results were compared with a cohort of recently-treated 
historical controls (n=84) from Royal Prince Alfred Hospital High Risk Foot Clinic patients 
with ulcers who were subject to the same inclusion/exclusion criteria and were receiving 
ongoing care in the same foot clinic.  Notably, the standard care provided in the foot clinic 
was the same for the historic controls as it was for the propolis study. All study subjects who 
would have qualified for the propolis study and who were treated in the same foot clinic in 
the recent years (2008-2010) prior to study recruitment for the were included as controls.  
The standardised approach to treating diabetic foot ulcers in the clinic was the same in 2008-
2010 as it was during the period of the propolis study (2011-2012) and so permitting a valid 
comparison between these two cohorts. Similarly, the attendant senior medical, nursing and 
allied health staff were in continuity across the period 2008-2012 and had previously been 
shown to have a high inter-tester reliability when measuring wound areas for research 
purposes (Xu, McLennan et al. 2007).  
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 Experienced clinical staff comprising (title; initial): 
Endocrinologist ST 
Nurse Manager TB 
Podiatrist  VN 
Podiatrist  DV 
Podiatrist  AH 
collaborated with the researcher (FH) to establish study inclusion/exclusion criteria that were 
consistent with ethical requirements—that is to enrol patients who were able to provide 
informed consent and were deemed low risk for side effects (such as allergy) and adverse 
events.   Standard care (as described in section 5.3.5) was maintained so as not to 
disadvantage participating patients by withdrawing what is currently considered to be the 
gold standard of care and also to maintain continuity with the control group.  The study 
design was structured so that the trial could be undertaken with minimal disruption to the 
daily activities within the clinic 
 
5.3.2  Study entry inclusion criteria 
1. Aged 18-80 years inclusive. 
2. Type 1 or type 2 diabetes mellitus. 
3. A diabetic foot ulcer of four weeks or greater duration. 
4. Must provide written informed consent. 
 
5.3.3  Study entry exclusion criteria 
1. Severe pedal ischaemia indicated by an ankle brachial pressure index (ABPI) <0.7. 
2. Severe lower limb sepsis requiring IV antibiotics and/or hospital admission. 
3. Current enrolment in any other investigational clinical drug trial. 
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 4. Known allergy to propolis, honey, royal jelly, Elastoplast, fragrance mix, or balsam of 
 Peru.  
5. Female subjects who were pregnant or lactating. 
6. History of any clinically significant disease as determined by the chief investigator. 
 
5.3.4 Investigational therapy 
Propolis (Honey Spring Variety, batch number 7232, Vastrade, Lidcombe NSW), which has 
TGA approval in Australia for use on wounds and abrasions, was administered topically each 
time the patient attended the clinic for 6 weeks or until the ulcer healed, whichever occurred 
first.  For any non-healing ulcers where surgery was indicated, propolis therapy was ceased 
prior to surgery.  Each subject was followed up for a further 6 weeks after propolis treatment 
ceased or until their wound healed, whichever occurred first.  The study was conducted over 
a 12 week period as this is a well-recognised and documented time frame in wound healing 
studies (Marrgolis, Kantor et al. 1999).  At each visit, wound area was measured post-
debridement using acetate tracing (described in section 5.3.6).  Results were compared to 
historical controls previously described.  
 
Propolis is a brown, odoriferous agent and it was not possible to blind the study subjects or 
investigators to its treatment.  A thin and even coating was painted onto the entire wound 
surface with a sterile cotton bud, ensuring that the entire wound bed was covered.  Due to the 
fluid consistency of propolis, it was deemed inadvisable to apply a large amount of the agent 
to the wound as it would run off and soil the dressings, which could increase the frequency of 
dressing change and therefore cause a difference between the treated subjects and their 
comparator controls.  The study investigator (FH) who applied the propolis was not involved 
in ongoing patient care (described in section 5.3.5) or in determining ulcer area.  The propolis 
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 was applied at the conclusion of each scheduled treatment, just prior to application of 
dressings, to minimise any potential bias that could arise from a change in routine care.  On 
average the wounds were seen in the clinic every 10.5 days, which was in keeping with the 
average time between Foot Clinic attendances for the control group (10.4 days). 
 
Figure 5.1: Propolis bottle – the variety used in the study  
 
5.3.5 Standard care 
The average time between visits was 10.5 days, with most individuals being seen weekly or 
fortnightly for standard care, as is usual practice in the Foot Clinic.  This timeframe of 
application was maintained for the study in order not to interfere with standard care and to 
achieve consistency with the historic controls.  Patients in both groups received routine 
wound debridement and appropriate optimised offloading for ulcers (offloading types 
included CAM walkers, post-op shoes, felt padding, orthopaedic grade footwear and total 
contact orthoses) (Liu, Min et al. 2009 ).  The types of dressings used in the two groups were 
also similar with almost all patients in each group receiving foam dressings (mainly Biatain) 
and, occasionally, anti-microbial dressings (mainly Iodosorb) (Liu, Min et al. 2009 ).  
Antibiotics were prescribed as deemed appropriate by the clinical staff (including an 
endocrinologist, podiatrist and nurse) who were highly experienced in judging signs of local 
wound infection such as redness, swelling, discharge and heat, in addition to systemic signs 
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 such as fever, increased body temperature and malaise.  Wound swabs were used to culture 
bacteria on these occasions where there was uncertainty as to whether a wound was infected.   
 
There was little variation in oral antibiotic therapy between the control and propolis treated 
groups (Table 5.2), with 80% and 75% of patients (n= 66 and 18), respectively, being on oral 
antibiotic treatment at study recruitment.  Anti-Staphylococcus aureus antibiotic therapy 
predominated in each group with 66 of 84, and 18 of 24, (75.5 and 75% respectively), in each 
group receiving this treatment.  
 
Table 5.2:  Antibiotic therapy used predominantly during the course of study period. 
Antibiotics Control Propolis 
Yes % 80 75 
No % 20 25 
Antistaph (A/S) only % 34.5 50 
A/S + Anaerobic (An) % 12 5 
A/S + Gram –ve % 18 15 
A/S + An + Gram -ve % 6 5 
Gram -ve only % 3 0 
An only % 1.5 0 
A/S + Anti-MRSA (MR) % 1.5 0 
A/S + Anti- Pseudomonas % 1.5 0 
A/S + MR + An % 1.5 0 
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 5.3.6  Wound area measurement 
Wound area was measured using acetate tracings.  Two pieces of acetate paper were cut to a 
size slightly larger than the wound.  One piece of paper was swabbed with Hibiscrub 
(Molnlycke, Frenchs Forest, NSW) to prevent wound contamination and placed over the 
wounded area whilst the second sheet of acetate was placed on top of the first and an outline 
of the wound area traced using a permanent marker pen with a 2mm tip.  The acetate tracings 
were scanned onto a PC and wound area was quantitated using Bersoft image software 
(Lunenburg, Nova Scotia, Canada).  This system superseded the ImageJ system used in 
Chapter 4 as it was able to measure multiple scanned acetate images simultaneously.  These 
measurements were used to calculate percentage change in wound area per wound per visit 
during the trial period.  
 
Wound healing, for the purposes of this study, was defined as epithelialisation of the entire 
wound area, as defined by the clinic staff.  This definition was based the work of Lazarus et 
al. (1994) who described a minimally healed wound as  ‘characterised by the restoration of 
anatomic continuity, but without a sustained functional result’ (Lazarus, Cooper et al. 1994).  
Within the time frame of the study it would be unlikely that wounds would heal to the point 
of full functionality and therefore minimal healing, defined as epithelialisation, was accepted 
as the healing parameter. 
 
5.3.7 Clinical staff questionnaire 
Staff (n=4; nursing and main podiatry staff) who were involved in the patient care of the 
propolis treated cohort, but not propolis administration, were asked to complete a 
questionnaire using a 7-point Likert scale.  The questionnaire reproduced at Table 5.3 was 
designed to provide feedback regarding the study design and execution.  
138 
 
 Table 5.3: Likert scale questionnaire administered to foot clinic staff (n=4). 
Question Strongly agree     Neither   Strongly 
disagree 
Trial design 1 2 3 4 5 6 7 
The study inclusion/exclusion criteria were 
appropriate 
              
Ultra-vulnerable populations may have been 
under-represented in the study 
              
Trial participants received usual wound care as 
well as Propolis 
              
The comparator group (patients seen in the same 
clinic within the previous 5 years) would have 
received similar standard care 
              
The wound assessment tools (Texas 
grade/stage/tracings) are accurate/validated 
              
Clinic staff are adequately experienced and skilled 
to carry out wound assessment 
              
               
Propolis therapy               
Adverse side effects were reported               
Propolis had a positive effect on wound healing               
Propolis treated wounds showed deterioration in 
wound area/border 
              
Propolis appears to be easy to apply               
Propolis had an unpleasant odour               
Propolis treated wounds became malodourous               
Propolis was a safe treatment               
Propolis was well tolerated by patients               
Propolis is suitable for use over exposed tendons               
Propolis is suitable for use over exposed bones               
Propolis is suitable for use in patients with 
osteomyelitis 
              
Propolis is suitable for use in patients with severe 
PVD (ABPI <0.7) 
              
Cost is important when choosing a wound therapy               
At $8 for 50ml, propolis represents good value as 
a wound therapy 
              
I would consider using propolis as a diabetic foot 
ulcer treatment 
              
I would consider using propolis as a diabetic foot 
ulcer treatment following the results of larger 
scale trials 
              
 Further research may enhance the scope for using 
Propolis (e.g. On more critical wounds) 
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 Further exploratory endpoints such as wound closure rate, bacterial count and wound protein 
composition in terms of key MMPs and CTGF were also examined in orderto determine 
whether or not it was feasible to subsequently consider a larger, more comprehensive study of 
propolis as a topical wound healing therapy, and the results from these studies are outlined in 
Chapter 6. 
 
5.4 Results 
 
5.4.1 The effect of Propolis treatment on wound healing. 
Weeks 1 and 3 (the second and fourth weeks after treatment with propolis was commenced, 
the first week being week 0) propolis treated ulcers showed a significantly improved healing 
rate compared to historical controls, (*p<0.005 and **<0.05 respectively by Mann-Whitney 
U-test) (Fig.5.1 (A)).  The percentage of patients whose ulcers were fully healed at weeks 4, 5 
and 7 was higher in the propolis treated group than the controls (*p<0.05) by Chi-squared test 
(Fig.5.1 (B)).   
 
Table 5.4: Number of active participants at each time-point during the propolis trial 
Week 0 1 2 3 4 5 6 7 8 9 10 11 12 
Control 84 84 84 83 81 81 81 79 73 67 62 54 53 
Propolis 24 24 24 23 22 22 22 21 19 18 17 15 15 
Numbers reduce as wounds heal 
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Figure 5.2: Percentage wound area compared to original size and percentage wounds 
healed in propolis vs historic control populations.  (A) Percentage wound area. *p<0.005 
and **0.05 by Mann-Whitney U-test.  (B): Percentage of patients whose ulcers had healed 
per week.  *p<0.05 by Chi-squared test. Results in A are expressed as mean ± SEM. 
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(A) 
 
 
 
 
  
(B) 
 
 
 
 
 
Figure 5.3:  Representative image of a neuropathic ulcer  
Panel (A) shows initial size at week 0 and panel (B) shows a reduction in size by 64% at 
week 4 following topical treatment with propolis. 
 
5.4.2  The effect of Propolis on wound healing in patients treated with antibiotics 
Patients were divided into two groups: 1) those who were being treated with antibiotic 
therapy and 2) those who were not and were therefore not considered to be clinically infected.   
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Figure 5.4: Wound healing rate of propolis and control wounds with and without 
concurrent antibiotic therapy. (A) Percentage wound area compared to original size in 
propolis vs. historic control populations who were receiving concurrent antibiotic therapy.  
*p<0.001 and **p<0.05 by Mann-Whitney U-test.  (B)  Percentage wound area compared to 
original size in historic control populations who were receiving concurrent oral antibiotic 
therapy compared with those who were not.  **p<0.05 by Mann-Whitney U-test.  (C) 
Percentage wound area compared to original size in propolis-treated populations who were 
receiving concurrent oral antibiotic therapy compared to those who were not.  No differences 
were observed between the groups.  All results are expressed as mean ± SEM. 
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 Wounds of patients who were receiving systemic antibiotic therapy and topical propolis 
showed improved healing at weeks 1, 3 and 4 compared to wounds that received systemic 
antibiotics only (*p<0.001 at week 1 and **p<0.05 at weeks 3 and 4 by Mann Whitney U-
test) (Fig. 5.4 (A)).  No such differences were seen when the non-antibiotic treated control 
and propolis treated groups were compared.  Control wounds receiving no antibiotics showed 
accelerated healing at weeks 2 and 3 compered to antibiotic treated wounds ( **p<0.05 by 
Students t-test, Fig. 5.4 (B)).  No differences were observed between healing rates of 
antibiotic and non-antibiotic treated, propolis-treated groups as shown in Fig. 5.4 (C).  
 
No adverse effects of propolis therapy were reported by patients enrolled in the propolis 
study, thus none were reported in progress ethics reports. 
 
5.4.3 Clinical staff questionnaire 
The four clinical staff addressing a Likert scale questionnaire, gave quantitative responses to 
questions posed about: 
i) the trial design; and 
ii)  the propolis therapy.   
 
These responses were graded 1-7, with 1 indicating strong agreement with the statement and 
7 indicating strong disagreement, and are summarised in Fig. 5.5 (A and B). The total of the 
scores for each respondent is given for each answer. Overall a score of less than 16 indicates 
a tendency to agreement, a score of 16 is neutral across the group, and a score of greater than 
16 indicates a tendency to dis-agree with the respective statement made.  The staff responses 
were, in general similar between respondents for each question with the exception of 
respondent 2 whose responses were quite different to the other 3 respondents for the 
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 questions: ‘Ultra vulnerable populations may have been underrepresented’ and ‘Adverse side 
effects were reported’.  Whilst respondent 2 did not disagree with these statements as 
strongly as their colleagues, their responses were more neutral than their colleagues.  Given 
that no adverse effects were reported or communicated to research staff it is most it is likely 
that this staff member was indicating that their opinion regarding the study population and 
adverse effects was neutral, and not negative.  
   
Overall, the staff  were satisfied with all aspects of the trial design, suggesting that the 
selection criteria, methods of wound assessment, patient care and experience of clinical staff 
in assessing the wounds were adequate (Fig. 5.5(A)).  They also opined that, in their 
observation, the propolis trial group was comparable to the historical control group (Fig. 
5.5(A)). 
 
In terms of the therapy itself, staff indicated through their responses that they believed 
propolis to generally be a safe, well-tolerated treatment that was easy to apply and they would 
consider using again (Fig. 5(B)).  It did not cause significant harm to the wound border or bed 
nor did it have an unpleasant odour profile (Fig. 5(B)).     
 
Clinical staff responses indicated that they would be reluctant to apply propolis onto exposed 
tendon or bone or in areas with an osteomyelitic and/or severe ischaemic component due to 
the paucity of evidence regarding the safety and efficacy of propolis in more ‘high risk’ 
pateints at this time.  It was considered that more research is needed into propolis as a therapy 
and if this research was undertaken, then the clinical staff would be more inclined to use it 
more broadly as a wound therapy.  The staff did not consider propolis to be expensive, but 
nor was cost a significant detriment when choosing a wound therapy (Fig. 5.5).     
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 Response 
Strongly Agree                                                     Strongly disagree 
 
 
 
 
 
Figure 5.5: Graphical representations of the total Likert scale responses from 4 clinical 
staff members. 
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 5.5  Discussion 
This chapter has examined the feasibility of topical propolis as a therapy in diabetic foot 
ulceration.  Propolis was found by patients and Foot Clinic allied health staff to be a well-
tolerated and very acceptable therapy.  The lack of adverse effects in patients receiving 
propolis therapy is not surprising considering that the treatment is generally thought to have a 
low side effect profile in the general population and it is available over the counter both as a 
topical preparation and as an oral preparation.  
 
Propolis has been used since ancient Greek and Roman times for its medicinal properties.  As 
a topical agent it is reported to be an effective treatment to aid resolution of cuts and 
abrasions (Okonenko 1985) and also to treat inflamed throats (Pang and Chen 1985).  It has 
not been systematically studied in diabetic foot ulcers. Some years ago, our laboratory 
reported that propolis topical therapy as a single application improved ulcer healing rate in 
full-thickness skin wounds in diabetic rats (McLennan, Bonner et al. 2008).  In that study, the 
healing rate was improved to levels similar to those seen in non-diabetic animals.  This 
current research took this therapy one step further in conducting a pilot study into propolis 
therapy for human diabetic foot ulcers.  
 
To gauge the potential efficacy of propolis, ulcer healing rate was measured and compared 
with a cohort of historic controls. The data suggest that propolis may have a beneficial effect 
on ulcer closure rate.  The change in ulcer area favouring propolis was consistent with the 
known bioactivity of propolis and its time course of administration in that greater differences 
in healing rate were observed in the first six weeks of the study when Propolis was 
administered (Fig.5.2(A)).  The rate of healing slowed when propolis therapy ceased after 6 
weeks treatment, further supporting the role of propolis in wound healing.  This finding 
147 
 
 suggests that the action of propolis is relatively transient and that more frequent or persistent 
dosing may increase its effects.  Considering the potent anti-inflammatory action of propolis 
it is notable that the improved ulcer healing was seen most clearly after an initial dose of 
propolis therapy (Fig.5.2(A)).   The finding of increased epithelial closure in propolis-treated 
wounds compared to controls is consistent with the animal work previously undertaken in a 
rat model, where one application of topical propolis normalised ulcer closure in the diabetic 
rats with full thickness ulcers (McLennan, Bonner et al. 2008). 
 
In the control group, healing rates were improved at weeks 2 and 3 in the wounds that did not 
receive antibiotic therapy.  It is logical that these wounds heal more rapidly, as they lack the 
complicating factor of infection.  In contrast, the healing rate between the antibiotic treated 
and non-antibiotic treated propolis-treated wounds was similar.  This finding suggests that the 
anti-bacterial properties of propolis prevented a delay in healing that otherwise would occur 
in infected wounds.  This is particularly salient in light of the recent finding that propolis 
potentiates the potency of most antibiotics, especially those active against S. aureus 
(Wojtyczka, Dziedzic et al. 2013).  Future studies should examine these preliminary data in a 
larger RCT design. 
 
This study was not intended to definitively determine if propolis was effective in foot ulcer 
healing, however, it did show that propolis was safe, well-tolerated and easy to use.  Sheehan 
et al (2003) reported that achieving 50% wound healing by week 4 is a robust predictor of 
long-term healing prognosis: these authors found that if a wound was not 50% healed at week 
4 then there was only a 9% chance of it healing within 3 months (Sheehan, Jones et al. 2003).  
Power calculations based on this pilot study show that in order for propolis-treated wounds to 
show a 25% improvement in healing compared to wounds receiving standard care at week 4 
with a 90% confidence interval (CI) (that is, for the propolis-treated group to be 42% of 
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 original size and control wounds to be 56% of original size), 68 subjects would need to be 
recruited in each arm of the study (propolis/control). For a higher confidence interval of 95% 
(that is, for the propolis-treated group to be 30% of original size and control wounds to be 
50% of original size), 103 subjects would need to be recruited in each arm of a randomised 
controlled study.  Both of these calculations assume variance as in this study, with 80% 
power needed to indicate a statistically significant difference in treated vs untreated groups. 
 
Clinical staff involved in the trial reported that propolis had a positive effect on wound 
healing.  This assumption would have been made based on a series of casual observations as 
clinical staff were not directly involved in analysing the data.  It is nevertheless encouraging 
that feedback was positive.  The main contention discernable from the Likert scale responses 
was that the clinical staff indicated they would be reluctant to use propolis as a therapy on 
wounds that are considered more ‘critical’—that is, wounds that probe to bone/tendon or that 
have an element of osteomyelitis or ischaemia.  It is not surprising that clinical staff adopted 
this conservative stance given the preliminary nature of the evidence to support propolis at 
this early stage, and that such wounds were excluded from the study desigen.  It is 
encouraging that questionnaire responses indicated that clinical staff were engaged with the 
concept of propolis as a wound therapy and would welcome more research in this area.  
 
Clinical staff did not have great concern regarding the financial cost of wound therapies.  It is 
likely that this is because their clinic is established and relatively well-resourced as its 
primary concern is to effect appropriate clinical outcomes.  It is widely known that health 
complications such as foot ulcers in diabetes are more prevalent in lower socio-economic 
groups (Dalstra, Kunst et al. 2005) and therefore the low cost of propolis as a wound therapy 
may increase its appeal to clinics that are less well-resourced; individuals who finance their 
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 wound therapies themselves; and in developing countries where many modern wound 
therapies are unavailable or prohibitively expensive.  This research does not in any way 
detract from the established therapies and multi-disciplinary approach undertaken by the 
diabetes High Risk Foot Service, which were described in detail in Section 2.4 of this thesis.  
However it suggests that topical propolis therapy applied in the clinic in addition to 
established therapies may be effective especially in helping some ulcers to heal more rapidly 
and that it is well-tolerated. 
 
In summary, the results indicate that topical propolis is well-tolerated, highly acceptable to 
patients and staff, and may have efficacy in promoting healing rate in human diabetic foot 
ulcers above that seen by current optimised multi-disciplinary foot ulcer care.  
 
The following chapter extends the study of propolis by undertaking exploratory analysis of 
proteins and viable bacteria in diabetic foot ulcer wound fluid, in propolis-treated diabetic 
ulcers.  
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Chapter 6 
 
THE EFFECT OF PROPOLIS ON HUMAN WOUND CHEMOKINES 
 
6.1 Abstract 
 
Propolis is a naturally-occurring substance that contains more than 200 chemicals.  It is 
derived from bees, through plant buds that are collected on the hind legs of worker bees.  It is 
applied by bees to their hives as a protectant resin.  The most biologically-active fractions of 
propolis are reported to be flavanoids and esters of caffeic acid. In this chapter, post-
debridement human wound fluid extracted from propolis-treated wounds was examined and 
MMP, CTGF and viable bacterial number and type reported.  These results were compared to 
previous analyses of wound fluid from foot ulcers in historic controls that did not receive 
propolis treatment but had similar ulcers and demographic characteristics.   
 
6.2 Introduction 
 
Wound healing is impaired in diabetes, and this has been shown to contribute a significant 
burden to society.  One-third of US$116 billion directly apportioned to diabetes care in the 
US in 2007 was used to treat foot ulceration (Driver, Fabbi et al. 2010).  Growth factors such 
as intact CTGF are deficient in diabetic wounds (Thomson, McLennan et al. 2010) and the 
balance between proteases and their inhibitors is also disturbed (Muller, Trocme et al. 2008).  
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 Recent work has shown in animal models that both CTGF (chapter 4 of this thesis) and 
propolis (McLennan, Bonner et al. 2008) are able to improve wound healing and that 
increased MMP-9 predicts poor wound healing (Liu, Min et al. 2009). 
 
To explore the potential modes of action of propolis, wound fluid collected from propolis-
treated human wounds (as described in section 5.3.5) was tested for MMP-2 and -9 by 
zymography and CTGF by western immunoblot and the results were compared to control 
wounds.  Viable bacterial counts after propolis therapy were also determined.  Some of the 
wounds were small and/or dry and it was not possible to extract sufficient wound fluid to test 
for all biomarkers.  However, given that this was a preliminary study, the results are useful to 
test research methodologies and laboratory techniques and to target more specific outcome 
measures for future studies. 
 
6.3 Methods and Materials 
 
6.3.1  Wound fluid collection 
Wound fluid was collected from patients enrolled in the propolis trial.  On each occasion, 
following ulcer debridement, but prior to the application of propolis, 2 x 25µl samples of 
wound fluid were obtained from study subjects using a calibrated sterile paperpoint tip (Meta 
Biomed Co., Elmhurst, NY).  This was mixed with 100 µL sterile PBS and frozen at -80°C.  
The wound fluid solution was transferred to the University of Sydney Central Clinical School 
Endocrine Research Laboratory and analysed in the laboratory for wound fluid CTGF by 
Western immunoblot, MMPs by zymography and bacterial colony count by serial dilution 
and culture on agar plates, using established techniques in each case (Liu, Min et al. 2009; 
Thompson, McLennan et al. 2010; Xu, McLennan et al. 2007.  Some wounds were dry and it 
was not possible to collect enough fluid from these wounds for analyses.  For this reason, 
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 fluid was collected at visits 1, 2 and 3 because after this time the majority of wounds were 
unable to yield sufficient fluid as they were dry or had healed. 
 
On average, the time between visits was 10.5 days, with most individuals being seen weekly 
or fortnightly for standard care (as described section 5.3.5), as is usual practice in the High 
Risk Foot Clinic.  Therefore it was decided that changes in CTGF, MMP and bacterial load 
levels be calculated as a percentage change per 10 days.  Rate of change in wound area (%) 
was also calculated over the same period.  The data for the propolis-treated wounds were 
compared to a cohort of patients derived from the historical control cohort described in 
section 5.3.1 that had wound fluid analysed in the same manner in previous studies.  This 
included CTGF measured in 10 controls (from the cohort described in section 2.7.5) (Dr L. 
Lo, personal communication July 2008), MMP-2 and -9 in 39 controls (Liu, Min et al. 2009) 
and bacterial load in 32 controls (Xu, McLennan et al. 2007 ).  The demographic details of 
these three cohorts of patients are described below (Tables 6.1, 6.2 and 6.3). 
 
6.3.2 Study subjects 
Comparison of the control subjects with propolis-treated subjects whose wound fluid was 
analysed for CTGF indicated that in general, the two groups were of similar age and ulcer 
type.  The patients in the propolis groups had larger wounds (average of 139.7 mm² compared 
to 83.1 mm², not statististcally significant) and that these patients had on average a longer 
duration of diabetes (17.5 years vs. 11 years, p<0.05 by student’s t-test). 
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 Table 6.1: Demographic details of historic control patients used in the CTGF wound 
fluid analysis.   
 
Data are expressed as mean ± SD. 
 
The demographics of patients whose wound fluid was analysed for MMPs are displayed in 
Table 6.2.  The control and propolis cohorts showed similar HbA1c levels, although the 
propolis treated group had a generally higher proportion of subjects with type 1 diabetes 
(33.3% compared to 17.7% in the control group, p<0.05 by student’s t-test) and the control 
group had larger (average area of 168.3 mm² compared to 139.7 mm², not statistically 
significant) and more severe ulcers in terms of Texas grade and stage (p<0.001 by student’s t-
test) 
  Control Propolis 
Patient number (n)  10 15 
Males (%)  90 82 
Age (yrs)   58.0±9.7 57.4±11.5 
Diabetes duration (yrs)   11.0±5.9 17.5±5.1 
Ulcer area (mm2)  83.1±79.2 139.7±170.6 
Tex grade (%) 0 or I 80 100 
 
II or III 20 0 
Tex stage (%) A or B 100 93.4 
 
C or D 0 6.6 
Ulcer type (%) 
Neuropathic/neuro-
ischaemic 
90 87 
 
Post-surgical 10 6.6 
 Trauma 0 6.6 
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 Table 6.2: Demographic details of historic control patients used in the analysis of MMP 
- 2 and -9 
                  
*Data are expressed as mean ± SD. 
 
 
Comparison of patients whose wound fluid was analysed for bacterial count showed the two 
cohorts were similar in terms of age, ulcer type and ulcer Texas stage and grade.   The 
propolis-treated cohort had a generally longer duration of diabetes (mean 19.9 years 
compared to 14.6 years in the control group) and smaller wounds (90.8 mm² compared to 170 
mm²), although these parameters were not statistically significantly different across the 
groups. 
 
 
  Control Propolis 
Patient number (n)  39 15 
Males (%)  79 80 
*Age (yrs)   62.0±11 57.4±11.5 
*HbA1c   8.4±2.1 8.3±1.9 
*Ulcer area (mm2)  168.3±79.2 139.7±170.6 
Tex grade (%) 0 or I 70 100 
 
II or III 30 0 
Tex stage (%) A or B 71 93.4 
 
C or D 29 6.6 
Ulcer type (%) Neuropathic/neuro-ischaemic 77.5 86.8 
 
Post-surgical 17.7 6.6 
 Trauma 4.8 6.6 
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 Table 6.3: Demographic details of historic control and propolis groups used in the 
analysis of bacterial load..   
 
 
Data are expressed as mean ± SD. 
 
6.3.3 Measurement of biomarkers in wound fluid 
6.3.3.1  Western immunoblot to measure wound fluid CTGF 
For the analysis of diabetic wound fluid, CTGF was measured by Western immunoblot. For 
each lane of the Western blot, 6.6 µL of wound fluid solution (collected was mixed with 17 
µL of Laemmli sample loading buffer (5 ml 1M Tris pH 8.8, 2 g SDS, 10 ml glycerol, 100 
mg bromophenol blue in 20ml distilled water and 2% v/v β-mercaptoethanol/L) and the 
solution made up to 45 µL with 21 µL PBS.  Separation of the proteins was achieved on 
  Control Propolis 
Patient number (n)  32 11 
Males (%)  69 82 
Age (yrs)   60.0±9 58.5±9.9 
Diabetes duration (yrs)   14.6±10.1 19.9±10.6 
HbA1c level (%)   7.9±1.4 8.8±1.9 
Ulcer area (mm2)  170±312.6 90.8±81.5 
Tex. Grade (%) 0 or I 100 100 
 II or III 0 0 
Tex. Stage (%) A or B 100 100 
 C or D 0 0 
Ulcer type (%) Neuropathic/neuro-ischaemic 
 
100 100 
 Other 0 0 
Concurrent antibiotic 
therapy (%) 
 83 73 
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 SDS-PAGE using 4-15% graded mini TGX gels (BioRad) in running buffer (3 g Tris, 14.4 g 
glycine, 10 g SDS) at 150V for 45 min.  Proteins on the TGX gel were then transferred onto a 
nitrocellulose membrane (BioRad Transfer Mini) using a BioRad Turbo Transblot SD Semi-
Dry Transfer Cell.  The nitrocellulose membranes were blocked using 5% (w/v) skim milk 
powder in Tris-Buffered Saline and 0.05%Tween (TBST) for 30 minutes at RT and then 
subjected to 3 x 5 minute washes with TBST. 
 
Membranes were probed for CTGF using an in-house manufactured CTGF antibody (CTGF 
196 end terminal (Tikellis, Cooper et al. 2004) antibody diluted 1:1000 in TBST for two 
hours at RT with gentle agitation, as previously described (Thomson, McLennan et al. 2010).  
Following the incubation with primary antibody, the membrane was washed with 3 x 5 
minute washes in TBST and incubated with horseradish peroxidase-conjugated anti-rabbit 
IgG at a 1:20000 dilution (Sigma, Vector laboratories, CA, USA) at RT with gentle agitation 
for one hour.  Membranes were washed for 3 x 5 minutes in TBST and immunoreactive 
proteins were detected by chemiluminescence using the ECL plus Western Blot Detection 
System (ECL) (Amersham Biosciences, Piscataway, NJ, USA).  The light emitted by the 
labelled protein was detected by ChemiDoc fluorescence and chemiluminescence gel 
documentation system (Bio-Rad, Gladesville, NSW).  Protein was quantitated using semi-
quantitative methods by Phoretix 1D Advanced Version 3 (NonLinear Dynamics Ltd., USA) 
all as previously described (Thomson, McLennan et al. 2010).    
 
Some samples had been freeze-thawed more than once which could potentially lead to some 
CTGF degradation, affecting the validity of the results.  To test this, one wound fluid sample 
from a study subject was aliquoted into three eppendorf tubes in triplicate.  One of the three 
samples was frozen at -80°C; then the second was frozen and thawed twice in the same 
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 manner; the third was frozen and thawed four times.  All samples were thawed and assessed 
by CTGF Western immunoblot the average results are shown below in Table 6.4.  These 
were not significantly different. 
 
Table 6.4: Volume of CTGF detected on Western immunoblot after single or multiple 
freeze-thaws 
 1 Freeze 2 Freezes 4 Freezes 
65kDa 5.97 x 106 5.85 x 106 6.79 x 106 
26kDa  2.18 x 106 3.07 x 106 2.23 x 106 
Total 8.14 x 106 8.92 x 106 9.02 x 106 
 
6.3.3.2 Measurement of wound fluid MMP-2 and -9 by gelatine zymography 
MMP-9 and MMP-2 in human wound fluid were measured by zymography.  For this 
analysis, 1µl of wound fluid (in 4µl of PBS, as diluted on collection) was run on each gel.  
The fluid was mixed with 2µl sample loading buffer (5ml 1M Tris pH 6.8, 2g SDS, 10ml 
glycerol, 100mg bromophenol blue in 5ml distilled water).  The proteins were separated on 
SDS-PAGE using an 8% polyacrylamide gel with 3% stacking gel in running buffer (60.6g 
Tris, 288g glycine, 20g SDS/l) at 130V for 55 min.  The gels contained 1mg/ml gelatine, 
which had been fluorescently labelled with 2-methoxy-2, 4-diphenyl-3-dihydrofuranone.  For 
each assay, standards of known concentrations of MMP-9 and MMP-2, as well as a pre-
stained molecular weight marker (Invitrogen, CA, USA), were run on the gels along with the 
samples. 
 
The gel was incubated for 30 min with gentle agitation in 50ml Buffer #1 at RT (25 ml 2M 
Tris, 2ml 10% NaN3, 1µL1M ZnCl2,  25ml 100% Triton X-100, pH7.5, in distilled water). 
Buffer #1 was drained and the gel was incubated for 30 min with gentle agitation in 50ml 
Buffer #2 at RT (25ml 2M Tris, 2ml 10% NaN3, 1µl 1M ZnCl2, 25ml 100% Triton X-100, 
10ml 1M CaCl2, pH7.5, in distilled water).  Buffer #2 was drained, and the gel was covered 
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 with plastic and incubated at 37°C overnight with gentle agitation in Buffer #3 (25ml 2M Tris 
pH 7.5, 2ml 10% NaN3, 1µl 1M ZnCl2, 10ml 1M CaCl2, pH 7.5 in distilled water).  The gel 
was photographed under long-wave ultraviolet light illumination and MMP activity was 
quantitated using semi-quantitative methods by Phoretix 1D Advanced Version 3 (NonLinear 
Dynamics Ltd., USA).  
 
In this technique, gelatinases (including MMP-9 and MMP-2) hydrolyse the copolymerised 
protein substrate and are seen as dark bands on a grey background.  MMPs were identified by 
the position of the bands at their specific molecular weight (57 and 83 kDa for active MMP-2 
and -9 respectively).  Activity of the MMPs was calculated from the digital image, and 
percentage change in intensity was calculated by comparison with the loaded standard. 
 
6.3.3.3 Measurement of wound fluid bacterial load 
Wound fluid was mixed with PBS as described in section 6.3. Ten microlitres of the fluid-
PBS mixture was then serially diluted (10−2 to 10−7), streaked onto blood agar plates, and 
aerobically incubated for 24 h at 37°C.  Bacterial load was quantified by counting the CFUs 
on each plate.  The bacterial species were identified using standard microbiological 
techniques, including gram stain and microscopic examination.  Previous studies have 
verified the reproducibility of sampling in a post-debridement wound fluid sample by this 
method (Xu, McLennan et al. 2007 ). 
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 6.4  Results 
 
6.4.1  MMP-2 and -9 levels in wound fluid from propolis-treated and control wounds 
Wound fluid samples from the propolis-treated study participants were analysed by 
zymography to measure levels of active (as opposed to latent ‘pro’) MMP-2 and -9 at visits 1, 
2 and 3, as presented in the representative image (Fig.6.1).   
 
Figure 6.1: Representative zymograph showing MMP-2 and MMP-9  
The standard (STD) is a known quantity of MMP-2 and MMP-9. WF, wound fluid from 
propolis treated diabetic ulcers in duplicate at visit 1 in lanes one and two, and visit 2 in lanes 
three and four. 
 
The results for active MMP-2 and MMP-9 (n=15) (i.e. the small molecular weight form of 
each of the MMPs) were then compared with data from a previous study in which wound 
fluids were gathered from subjects (n=39, not treated with propolis) that had received 
standard wound care over a similar time period (described in section 5.3.5).  This control 
cohort had attended the same foot clinic and received similar care to the propolis group in this 
study (Liu, Min et al. 2009).  Wound fluid samples were analysed by zymography to measure 
levels of active (as opposed to latent ‘pro’) MMP-2 and -9, expressed as log10 values at visits 
1, 2 and 3.  Analysis of fluid obtained at visits 1 and 2 are presented in duplicate shown in the 
representative image (Fig. 6.1).  The rate of change in MMP levels was calculated as a 
percentage change over 10 days.  Rate of change in wound area was also calculated over the 
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 same period.  The changes in MMP levels and wound healing rate were transformed 
logarithmically in order to account for outliers, making graphical representation of these data 
more clear. 
 
Percentage change in active MMP-9 levels was lower between log-transformed data from 
propolis-treated subjects and the historical control group in the first time period (between 
visits 1 and 2)(*p< 0.05 by Mann-Whitney U-test; % change /10 days -0.68 (propolis) vs. 
2.64 (controls) mean ± SEM; Fig. 6.2 (A)).  During the second time period (between visits 2 
and 3), active MMP-9 was significantly lower in propolis-treated wounds (% change /10 
days, 0.05 (propolis) vs. 0.64 (controls), mean ± SEM).  This difference in active MMP-9 
between propolis and control treated wounds was statistically significant (**p<0.005 by 
Mann-Whitney U-test, as shown in Fig. 6.2 (B).  Wound healing rate over the same time 
points was increased in the propolis-treated groups compared to controls at visits 1-2 
(p<0.005) and visits 2-3 (p<0.001), as shown in Fig. 6.2 (C). 
 
Across visits 1 to 2, and 2 to 3, there were no differences in the change in MMP-2 levels 
between propolis-treated and the historic controls (Fig. 6.2 (A and B)). 
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Figure 6.2. MMP-2 and MMP-9 changes in post-debridement wound fluid. Active 
MMP-9 and active MMP-2 changes from (A) visit 1 to visit 2 and (B) visit 2 to 3, each per 10 
days, in control and propolis-treated wounds.   (C) Change in wound healing rate over these 
time points.  Data are mean ± SEM.   The y-axis data is log transformed in each case. At 
visits 1-2 and 2-3, the difference in the change in active MMP-9 between the propolis and 
control groups were significant; *p<0.05 and **P<0.005 by Mann Whitney U-test. No such 
differences were seen in MMP-2 levels.  Propolis-treated wounds healed at a significantly 
greater rate at both time points (*p<0.005 and **p<0.001 by Mann Whitney U-test). Results 
are expressed as mean ± SEM. 
     
 
 
 
 
 
 
** 
 
(B) 
* ** (C) 
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 6.4.2 CTGF levels in wound fluid from propolis-treated and control wounds  
CTGF was measured by Western immunoblot in the wound fluid collected from propolis-
treated diabetic foot ulcers, as described in section 6.3.1.1.  CTGF exists in differing 
molecular forms, as shown (Fig. 6.3) and  was found to be consistent with previously 
published data (Tan, McLennan et al. 2008), (Thomson, McLennan et al. 2010), (Tikellis, 
Cooper et al. 2004).  The main immunoreactive band was observed at 26 KDa in this wound 
fluid series. As CTGF is predicted to occur at 32-38 KDa on full length, this band likely 
represents a partially proteolysed, C-terminal form of CTGF whilst the less intense higher 
molecular mass material may be a homodimer of this protein (Thomson, McLennan et al. 
2010).  For these studies, CTGF immunorectivity detected in each entire lane of the gel was 
determined by densitometry as previously described (Tan, McLennan et al. 2008), with the 
background non-specific signal in the gel subtracted. 
 
 
 
 
 
 
 
  
 
 
Figure 6.3: Representative Western immunoblot showing bands of CTGF 
immunoreactivity. The right hand panel shows the molecular mass standard; the left hand 
panel shows five representative lanes of wound fluids samples derived from people with 
propolis-treated wounds. 
 
CTGF was measured in the propolis-treated subjects from whom adequate wound fluid was 
obtained (n=15).  These results were compared with a group of historic controls (n=10) 
whose wound fluid had been analysed for CTGF described from a cohort of patients 
described in the literature review (section 2.7.5) set out at Table 6.1.  This cohort of patients 
was also derived from those used as controls in the propolis wound closure study.  Wound 
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 healing rate as a percentage of original wound area was also calculated for both groups.   The 
changes in immunoreactive CTGF and wound healing rate were transformed logarithmically 
in order to account for outliers, making graphical representation of these data more clear. 
 
 The change in CTGF levels per 10 days was not different between the two groups (Fig 6.4 
(A) and (B)).  Furthermore, within the propolis group when CTGF changes across the visits 
indicated were related to ulcer healing rate, there was no significant correlation found (not 
shown). 
 
 
  
( 
 
 
 
 
 
 
 
 
 
Figure 6.4: Change in total immunoreactive CTGF in post-debridement wound fluids 
(A) and change in wound healing rate (B). (A) Change in the level of CTGF over a 10-day 
period in propolis-treated and control patients. (B) Change in wound healing rate over a 10-
day period. Data are mean ± SEM. 
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 6.4.3  Bacterial load in wound fluid from propolis-treated and control wounds. 
Wound fluid obtained at visits 1 and 2 from each study subject was analysed for bacterial 
load from propolis-treated wounds and control wound, as previously summarised in table 6.3.   
The results are reported as change in CFU per 10 day period.  The bacterial species identified 
in the wound fluid are presented in Fig. 6.5 as a pie chart with each slice reflecting specific 
bacterial CFUs expressed as a percentage of the total number of bacteria detected by species 
(per ml wound fluid).  The size of the pie chart is larger for visit 1 than visit 2, reflecting 
differences in total colony count (26% less at the second visit for the propolis-treated 
wounds). 
 
 
Figure 6.5: Pie charts showing relative amounts and types of bacteria at visit 1 and visit 
2.  The different bacteria cultured on blood agar after 24 hours are shown. The average time 
difference between visit 1 and visit 2 was 10 days and was within the range of 1-2 weeks. 
 
Following the first application of propolis, bacterial count was reduced in the whole cohort, 
from a total of 118.4 CFU to 87.6 mean per sample, ± SEM.  Whilst this was not statistically 
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 significant, possibly due to variation between study subjects, it indicates a 26% reduction in 
bacterial burden in the wound.  The most noticeable decrease in bacterial species between 
visits 1 and 2 was for P. aeruginosa.  This bacterial species was cultured from thewound 
fluids of three subjects and it was not possible to perform further statistical analysis for these 
samples. 
 
The data from the propolis treatment group was compared with a cohort of 48 patients in a 
comparable published cohort (Xu, McLennan et al. 2007) whose wound bacterial count had 
previously been determined and calculated as a percentage change per 10 days (Fig. 6.6).  
The bacterial count showed a decrease of less than 1% in the control group over 10-day 
period as opposed to 26% in the propolis-treated group. 
 
Figure 6.6: Graph of % change in bacterial colony forming unit counts in the first 10 
days.  The colony count had decreased by 26% in the Propolis treated group compared with 
no demonstrable decrease in controls * p<0.0001.  Results are expressed as mean ± SEM. 
 
The bacterial count decreased markedly in the propolis-treated group compared with historic 
controls, p<0.001 ± SEM (Fig.6.6). 
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 6.5  Discussion 
 
The previous chapter focused on the end-points of safety and tolerability in addition to the 
acceptance of propolis as weekly topical therapy delivered in a diabetes multi-disciplinary 
foot clinic.  The feasibility data was encouraging; pilot data examining the potential wound 
healing efficacy of propolis was also examined and found to hold some promise.  This 
chapter further explored the wound fluid microenvironment post-debridement in propolis-
treated ulcers. 
 
CTGF is known to be induced during normal wound healing (Frazier, Williams et al. 1996) 
but little is known regarding its levels in diabetic wounds.  Studies by Thomson et al. (2010) 
using a baboon diabetic model showed that this wound tissue contained less CTGF at 4 
weeks post-wounding compared with controls (Thomson, McLennan et al. 2010). 
Furthermore unpublished data Dr L. Lo, (personal communication, July 2008) has shown in 
wound fluids from diabetic patients the wound fluid CTGF correlates positively with wound 
healing. Propolis is known to possess anti-inflammatory properties so observing the levels of 
CTGF in propolis treated tissues assisted in determining whether CTGF is upregulated by 
propolis. However the extent to which wound fluid CTGF is affected remains unknown 
despite being investigated as part of this study, as endogenous CTGF could be examined over 
a relatively short time period only.    
 
The changes in CTGF levels in post-debridement wound fluid in propolis-treated wounds 
were not statistically different to untreated controls over a 10-day time period.  The similarity 
between the two groups may be attributable to the narrow (10 day) time period of 
measurement.  CTGF induction may not have been stimulated during this relatively early 
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 phase of wound healing following propolis topical application: as described in the literature 
review (section 2.7.5) changes in CTGF immunoreactivity may take series of weeks to be 
observed in wound fluid in human diabetes.  The data based on Western immunoblot analysis 
appear reliable and it is unlikely that technical issues affected the experimental outcomes as 
the techniques used have been trialled extensively in previous studies.  In cultured dermal 
fibroblasts propolis has no direct effect within hours or days on CTGF expression J. Jia, 
(personal communication, 8 October 2009) and it is possible that any link between propolis 
treatment and wound fluid CTGF is indirect, possibly secondary to general effects on wound 
healing per se. 
 
Previous studies over a more protracted period (3 months+) showed that increases in CTGF 
in the wound correlate positively with wound healing rate, section 2.7.5 (Fig. 2.4).  Given the 
data presented at section 2.7.5, it would be interesting to investigate these changes over a 
longer timeframe of 12 or 16 weeks in order to gain a more comprehensive, longitudinal 
understanding of the effect of propolis on CTGF. 
 
MMPs are involved in wound healing and continue to persist in inflamed wounds; causing 
excessive degradation of the ECM; and contributing to delayed healing that is observed in 
persistently inflamed wounds such as diabetic foot ulcers.  The protease MMP-9 in wound 
fluid is important as a marker and potential mediator of foot ulcer healing in diabetes. In 
contrast, high levels of persistent active MMP-9 correlate with poor wound healing and 
predict future non-healing (Ladwig, Robson et al. 2002).  Reductions in active MMP-9 
correlate with increased wound healing rates and collagen content in a diabetic rat model 
(Aparecida Da Silva, Leal-Junior et al. 2013 ).  For this reason, these were examined in the 
post-debridement wound fluid of propolis-treated wounds.  In the current study, propolis-
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 treated wounds showed significantly greater reductions in active MMP-9 than the untreated 
controls.  One potential mechanism to explain this activity is that caffeic acid a component of 
propolis, can inhibit expression of MMP-9 (Jin, Chung et al. 2005).  In addition to being a 
marker of wound healing, MMP-9 can potentiate inflammatory responses (Gill and Parks 
2008) and therefore, a propolis-mediated decrease in MMP-9 could attenuate and resolve 
persistent inflammation in diabetic wounds and leading to accelerated healing.  
 
Wound fluid could not be obtained in all cases for serial analysis due to dry, very small or 
healed wounds, which limited the analysis.  Owing to limited amounts of wound fluid being 
available, other pro-inflammatory proteins and markers were not measured.  Given larger 
fluid samples, factors such as TNF-α, IL-1, prostaglandin metabolites and neutrophil elastase 
could be examined since these are key mediators in the healing process.  
 
Bacterial load was decreased in propolis-treated wounds by 26% over 10 days whilst 
untreated control wounds showed no significant change in CFU count.  Therapy comprising 
topical propolis and where wounds were deemed to be clinically infected (73%), systemic 
antibiotics, resulted in this reduction of viable bacterial count.  By contrast control wounds 
which received systemic antibiotic therapy alone if deemed clinically infected (83%) did not 
show such a reduction.  This is in keeping with other studies that have recognised propolis’ 
antibacterial properties (Bonvehi, Coll et al. 1994; Lamprecht, 1994; Bankova, Christov et al. 
1995).   
 
As wounds heal, bacterial colony counts generally fall even where wounds that are not 
overtly clinically infected (Xu, McLennan et al. 2007).  Clinical data from our group has 
shown that there is a cross-sectional association between lower bacterial CFU count and 
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 human foot ulcer healing rate (Xu, McLennan et al. 2007).  Moreover, Edmonds et al. (2004) 
found in a study of diabetic foot ulcers, that even when an ulcer was not clinically infected, 
antibiotic therapy can reduce the incidences of  hospitalisation and amputation (Edmonds and 
Foster 2004).  Bacteria are destructive in the wound environments in a variety of ways.  For 
example, their ability to secrete proteolytic enzymes can lead to an increase in MMP 
secretion that may cause an alteration in the delicate balance of MMP/TIMP activity in 
wounds.  Further studies with a larger patient cohort will be needed to rigorously test the 
potential bactericidal activity of propolis and to explore more precisely which bacteria are 
sensitive to propolis.  
 
In summary, the exploratory laboratory examinations of post-debridement wound fluid in 
propolis-treated diabetic foot ulcers indicated a trend towards the effectiveness of propolis as 
a therapy.  Despite the small sample size and limited size of the comparator historic controls, 
the data were found to be consistent with the published ability of propolis to reduce wound 
inflammation and exert bactericidal activity (Kosalec, Peleljnjak et al. 2005; Ledon, Casaco 
et al. 1997; Lamberte, Cabrera et al. 2011).  Collectively, the wound fluid data parallel the 
improved ulcer healing rate seen by propolis therapy and help to form the basis for larger, 
multicentre randomised controlled trials of propolis as an intervention in addition to standard 
optimised care in foot ulcers in diabetes.  
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 Chapter 7 
 
DISCUSSION AND CONCLUDING REMARKS 
 
7.1 Introduction 
 
Foot ulceration commonly is seen in patients with diabetes causing significant mortality and 
morbidity (Boulton and Vileikyte 2005; Moulik, Mtonga et al. 2003).  The incidence of foot 
ulcers in people with diabetes ranges from 1.0% to 4.1%, and the incidence of lower-
extremity amputations ranges from 2.1 to 13.7 per 1000 in such patients (Bartus and Margolis 
2004).  Current treatment regimens include coordinated multi-disciplinary approaches to 
offloading, debridement, dressing, infection control and revascularisation (Kruse and 
Edelman 2006).  Evidence-based guidelines aims to standardise clinical decision making, 
therefore benefitting patient outcomes and streamlining health care systems (Wraight, 
Lawrence et al. 2005).  The benefits of this approach have been shown in the context of 
diabetes: in applying evidence-based multidisciplinary treatment a 50% reduction in major 
lower-limb amputation risk has been achieved in people with diabetes (Van Damme and 
Limet 2005). 
 
In addition to the traditional interventions mentioned above, other therapies have been 
developed to assist healing in wounds in diabetes.  These include negative wound pressure 
(NWPT), skin substitutes, hyperbaric oxygen and various growth factor therapies (Hopf, 
Humphrey et al. 2001).  Autologous platelet plasma gel (Driver, Hanft et al. 2006), 
ultrasound (Ennis, Foremann et al. 2005) and various autologous engineered scaffoldings 
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 (Uccioli, Giurato et al. 2011) have also been investigated as potential wound healing 
therapies.  Despite these interventions and the introduction of standardised guidelines, many 
ulcers still do not heal and others are recalcitrant.  It is essential that healing in wounds in 
diabetes is optimised in order to improve patient outcomes and to minimise use of limited 
health care resources. 
 
7.2  CTGF as a wound therapy 
 
 CTGF promotes the production of ECM and inhibits its degradation (Wang, McLennan et al. 
2010).  CTGF also functions by affecting cellular responsiveness to other cytokines such at 
TGF-β (Arnott, Nuglozeh et al. 2007).  Studies have shown that rhCTGF in human wounds 
correlates with wound healing rate (section 2.7.5).  To explore this finding, rhCTGF was 
added to diabetic and control rodent wounds using an established model in order to test 
whether CTGF could improve wound healing.  The main conclusion arising from this work 
was that rhCTGF improved epithelial closure and improved collagen-IV induction in rats 
with diabetes, in a statistically significant manner.   
 
As described in section 2.7.5, while some recent reports have implicated CTGF implicated 
CTGF in post-wound scar formation and keloid, macroscopic excessive scarring in the treated 
CTGF wounds was not observed in this study, although the planned limited study duration may 
have precluded the possibility of determining such a change.  It is possible that CTGF as 
topical therapy could induce scarring including in foot ulcer healing in diabetes.  
Furthermore, systemic adverse effects of CTGF topical therapy to induce ECM and scarring 
in non-cutaneous tissues is a realistic concern as described in the literature review in section 
2.7.4.  In particular, increased CTGF in an environment of diabetes could contribute to 
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 systemic effects such as scar formation in kidney, heart and liver and it could also potentially 
act as a cancer progression factor if cancer is present (Twigg and Cooper 2004).  However, as 
discussed in section 2.5.1, the growth factor PDGF has give rise to such concerns for foot 
ulcers in human diabetes yet it has been registered as a therapy for this indication.  It is 
envisaged that future preclinical studies will need to confirm that CTGF has bioactivity to 
induce healing in diabetes models in skin wounding. Toxicology studies will also be 
necessary to examine for degree of systemic absorption when CTGF is delivered to cutaneous 
ulcers.  Methods to minimise systemic CTGF levels from such administration should be 
investigated. 
 
7.3 Propolis as a wound therapy 
 
Based on the known anti-inflammatory and anti-microbial activity of propolis, we conducted 
a pilot study to determine its potential for treatment of human diabetic ulcers   It has not been 
possible to study CTGF in this manner as CTGF is not currently approved for use in human 
subjects.  However, propolis is TGA approved for human use and was chosen to be trialled in 
a small-scale human study.  Propolis is not a novel wound therapy per se, it has been used for 
thousands of years as a traditional wound therapy (Najafi, Vahedy et al. 2007) and has been 
shown to reduce MMP-9 and neutrophil counts in a rodent model of diabetic wound healing 
(McLennan, Sakar et al. 2009).  It has not previously been systematically studied in foot 
ulcers in human subjects with diabetes.  
 
Wounds in individuals with diabetes suffer from persistent inflammation and tend to be 
heavily and poly-microbially colonised (Dowd, Wolcott et al. 2008).  In such wounds, 
bacteria persist in adhesive biofilm communities, which further promotes chronic 
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 inflammation.  These bacteria are more resistant to anti-microbial therapy and healing is 
delayed as a result (Rhoads, Wolcott et al. 2008).  The known  anti-inflammatory and anti-
bacterial properties of propolis therefore, combined with positive preclinical data (McLennan, 
Bonner et al. 2008), make it a logical target for a human wound healing study.  Previous 
studies of propolis have indicated that it is well tolerated, minimally allergenic and low cost 
therapy. The human study results shown in Chapter 5 were consistent with the animal studies, 
showing improved wound healing with propolis treatment.  The rate of healing slowed when 
propolis therapy was ceased after 6 weeks, further supporting the therapeutic role of propolis 
in wound healing.  The trial design was positively rated by the clinical staff who were 
involved in the study and Likert scale responses indicated that the clinical staff viewed 
propolis to be a safe and well tolerated therapy warranting further investigation.   
 
In this pilot study, historical controls were used. Retrospective data has been used 
successfully in many studies elsewhere.  In work by Lawrence et al. (2004), a retrospective 
analysis of patient records concluded that variability in care ought to be addressed in order to 
optimise outcomes when using historical controls (Lawrence, Wraight et al. 2004). The 
controls had received standard care in the same multidisciplinary setting as the propolis-
treated subjects and were demographically similar, justifying their pre-specified plan as a 
valid comparator to the pilot study.   In the absence of any systematic study of propolis in 
people with foot ulcers in diabetes, the study team was keen to undertake an examination of 
tolerability and safety, as well as practicality of propolis as therapy added to routine clinical 
care. After considering this study’s outcomes it can be  concluded that the study was 
successful: tolerability and safety as well as practicality were addressed within the confines 
of the small sample size.  Furthermore efficacy data enabled calculations of best-estimate 
numbers required to treat in a multicentre, prospective randomised controlled trial format.  
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Mechanisms by which propolis may lead to improved wound healing were also examined.  
Propolis-treated wounds had less active MMP-9 than untreated controls.  High levels of 
MMP-9 have been shown to correlate with poor wound healing and predict future healing 
(Ladwig, Robson et al. 2002; Liu, Min et al. 2009). Sufficient wound fluid could not be 
collected from the propolis-treated wounds to permit effective measurement of other proteins 
or for cytokines involved in wound healing.  Many wounds were small or dry and did not 
yield adequate post-debridement fluid.  Ideally, fluid would have been collected from all 
wounds over a longer period allowing a more comprehensive analysis of wound proteases, 
their inhibitors and chemokines.  This would have enabled a connection between propolis 
treatment and CTGF induction to be established.  As discussed previously this may have 
occurred at a later time point than was considered in this study.  These may be significant 
considerations for future studies. 
 
Propolis treatment decreased bacterial load (CFU) significantly in diabetic wounds.  Studies 
by my colleagues in our laboratory found that increased bacterial count predicts poor wound 
healing in neuropathic ulceration, the predominant ulcer type in this study.  Therefore, the 
capacity of propolis to reduce bacteria is an important finding and it may go some way to 
explaining some of propolis’ efficacy in ulcer healing (Xu, McLennan et al. 2007). 
 
Multiple studies previously have found that propolis has a capacity to reduce bacterial load in 
wounds (Kosalec, Pepeljnjak et al. 2005; Marghitas, Mihai et al. 2010; Özkalp and Özcan 
2010).  This finding suggests the need for further investigation of the capacity of propolis to 
reduce bacterial burden and the maturation and differentiation of biofilms in clinical infection 
(Lamberte, Cabrera et al. 2011).   
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It has been established that the composition of propolis determines its efficacy at least against 
bacteria (Pepeljnjak and Kosalec 2004).  Yet studies have not yet been undertaken in skin 
ulceration in preclinical models in diabetes.  Differences in the antibacterial activities of 
propolis are observed, depending on region of origin and procedure used for the preparation 
of propolis.  
 
Propolis comprises over 200 individual constituents.  At this stage it is not productive to 
isolate each of these as it is more practicable to direct research into propolis as a composite 
instrument.  It may be for subsequent research to isolate the individual compounds for 
analysis.  Potency could also be studied in subsequent preclinical series in vivo, as published 
work indicates the efficacy of propolis may be dose dependent (Pepeljnjak and Kosalec 
2004).  
 
The mechanism of propolis delivery could be improved through its incorporation into a film 
or dressing through impregnation.  Gelatine-based films plasticised with sorbitol for ease of 
application, have the capacity to deliver antimicrobial activity and their polyphenol 
concentration remains stable for 177 days of storage (Bodini, Sobral et al. 2013).  Combining 
propolis which is known to have anti-inflammatory and anti-bacterial properties with such a 
scaffold could potentially deliver sustained anti-inflammatory and anti-bacterial elements to 
diabetic wounds and promote their healing over a prolonged time frame  in line with work 
published by Bodini et al. (2013) in which this method was used to deliver extracts of 
propolis to wounds,  (Bodini, Sobral et al. 2013).  In the human study in this thesis, propolis 
was easily applied as a thin film across the entire ulcer bed post-debridement.  However, it is 
anticipated that to further aid ease of use, full strength (that is, neat) propolis impregnated 
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 sorbitol dressings could be used in subsequent RCTs.  By this means propolis could be 
applied freshly with each change of dressing which in usual foot ulcers in diabetes occurs 
roughly every 3 days.  This approach would enable an ulcer to receive more constant 
exposure to propolis than the current study. 
 
7.4  Future studies and directions 
 
The positive outcome of the animal trial of rhCTGF suggests that CTGF could be examined 
in a pilot study in human foot ulceration for people with diabetes.  However growth factors in 
protein form are prone to proteolysis.  Moreover, it has been proposed that application of a 
growth factor in a liquid or gel form might not be the best approach to target the growth 
factor to the cells directly involved in wound healing (Margolis, Crombleholme et al. 2000) 
and alternative methods of delivery may be more effective.  For PDGF delivery, adeno-
associated viral vectors were found to deliver a more localised and prolonged effect (Chen 
and Giannobile 2002).  This type of vector to CTGF therapy is a promising approach.  In 
particular, localisation of the effects of CTGF to the wound, as able may be  crucial, because 
whilst its deficiency in diabetic wounds may be detrimental to wound healing, CTGF has 
been shown to be over-expressed in diabetic heart (Way, Isshiki et al. 2002), liver (Paradis, 
Perlemuter et al. 2001; Rachfal and Brigstock 2003) and kidney tissues (Twigg, Cao et al. 
2002), potentially leading to fibrotic damage. 
 
A larger scale, multicentre blinded randomised controlled trial (RCT) to determine if 
propolis, in combination with standard wound care, significantly improves the healing of 
diabetic foot ulcers compared with standard wound care alone should be performed, with 
assessment of wound size and closure.  Based on power calculations made from the data 
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 collected in this study, at least 68 subjects would need to be recruited into each arm of an 
RCT.  A multicentre study is indicated, including at least four diabetes multidisciplinary foot 
clinics.   
 
For a study such as this, the following protocol would need to be established;  The study 
patients should be treated with topical propolis to complete wound closure, as our preliminary 
studies observed wound healing rate decline in propolis-treated wounds when propolis 
treatment  ceased at 6 weeks.  Other acceptable and commonly used time points to predict 
longer term wound healing rate include 4 weeks and 12 weeks (Sheehan, Jones et al. 2003).  
These intervals could also be analysed as surrogate endpoints and, importantly, if the term of 
the trial precluded the parameter of complete wound healing from being achieved, these 
surrogate endpoints would allow an analysis of unhealed subjects in the trial. 
 
To date angiogenic properties have not been described for propolis.  At this stage propolis 
would not be expected to share the same efficacy in critically ischaemic that pro-angiogenic 
treatments such as activated protein C (Whitmont, Reid et al. 2008).  For this reason, patients 
with an ischaemic limb must be excluded from the proposed trial.  The threshold for 
ischaemia would be set at an ABPI of 0.7 or below, a commonly used cut-off point for 
ischemia. Patients with an abnormally high ABPI (>1.2) would also be excluded due to the 
likelihood of them having arterial calcification that precludes an accurate APBI reading from 
being obtained.  The proposed trial would be blinded, and an acceptable placebo for propolis 
would need to be developed.  The propolis would be applied post debridement as a thin 
topical layer by a healthcare professional in a clinical setting blinded to treatment group, at a 
standardised dose calculated per mm² wound area.  Standard wound care would also be 
administered to all participants.  
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Statistical analysis of results would examine incidence of closure endpoints, using categorical 
techniques (e.g., Chi-square,) and for time-to-closure endpoints, outcome survival analyses 
would be performed (e.g. Kaplan-Meier).    
 
Secondary endpoints that may provide some mechanistic insight include wound fluid analysis 
and wound tissue histology.  The calibrated paperpoint (described in section 6.3.1) enables a 
uniform amount of fluid to be drawn from a wound (providing the wound is large enough).  
Wounds of less than 5 mm diameter usually do not yield enough fluid for laboratory testing, 
so wounds would need to be excluded from the wound fluid analysis of the study when they 
reached this size.  A wound biopsy would enable histological changes to be monitored, such 
as macrophage, neutrophil, fibroblast and endothelial cell infiltration.  Wound biopsies are a 
safe procedure that do not delay overall healing of the chronic wound, so there should be no 
major ethical issues pertaining to the modification to include ulcer biopsy within this arm of 
the study (Panuncialman, Hammerman et al. 2010). 
 
7.4.1  CTGF and propolis as potential combination therapy. 
The concept of combined anti-inflammatory and a growth factor therapy is attractive as 
synergism could potentially occur in wound healing, including in diabetes where 
inflammation persists and growth factor proteolysis is recognised.  The data from our pilot 
study indicated that wounds heal more quickly and express higher levels of CTGF when 
treated with topical propolis.  Whether CTGF is directly induced by propolis is uncertain and 
such could not be detected in the short term examination in the current pilot. Studies of 
human and preclinical wounding for example by mechanical measures or burns, show that 
wound tissue CTGF is induced more than one week after wounding, and the studies described 
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 in the literature review in this thesis (2.7.5) found that some months were required in human 
ulcers in diabetes for CTGF to increase as human ulcers heal in diabetes. It may be that the 
link between propolis and CTGF is less direct and that if propolis is used as therapy, then 
CTGF should be analysed over subsequent months, as well as in the initial weeks after 
propolis application.   
 
If propolis is shown to induce CTGF across some days or weeks in wounds in people with 
diabetes, then this could occur through induction of CTGF gene expression and new protein 
synthesis and/or through inhibition of CTGF degradation. As described in the literature 
review in section 2.7.1 depending on the model used, it takes many days to some weeks for 
CTGF be induced during wound healing including normal healing.  Furthermore, in baboon 
studies CTGF levels were reduced at 2 and 4 weeks in sterile subcutaneous wound tissue of 
animals with diabetes compared with non-diabetic controls (Thompson and McLennan, 
2010). In that study, CTGF mRNA levels in the wound tissue were not different between 
diabetic and control animals.  Also in that study, wound fluid from diabetic animals was 
found to proteolyse CTGF through MMP activity including MMP-9 (Thompson and 
McLennan, 2010) suggesting that CTGF in diabetic wounds may experience proteolysis.  In 
wounds in animals with diabetes the theme of growth factor degradation through proteolysis 
is quite common (Roth, Piekarek et al. 2006), reflecting the increased inflammatory and 
protease active environments in wounds in diabetes (Wetzler, Kampfer et al. 2000). Hence 
any increased CTGF after propolis therapy in preclinical or clinical studies in ulcers in 
diabetes may be attributable to decreased CTGF proteolysis since MMP-9, a powerful 
proteinase, was significantly decreased in propolis-treated wounds in the current pilot.  This 
decrease in MMP-9 could prevent degradation of CTGF, leading to enhanced CTGF-
mediated wound healing through its chemotactic, proliferative and angiogenic functions. 
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 7.4.2  Therapeutic delivery systems 
The study in Chapter 4 shows that CTGF can augment the self-healing capacity of wounds by 
enhancing one or more processes important for healing.  However, the mechanisms to apply 
topical growth factors in clinical settings remains limited attributable to lack of robust 
delivery systems and biomaterial carriers (Koria 2012).  In general, it has been difficult to 
maintain full bioactivity of  proteins applied to wounds due to protein instability in the 
protease-rich environment of the wound  (Choate and Khavari 1997).  This suggests that 
protease inhibitors added with CTGF could potentially augment the enhanced wound healing 
due to topical CTGF application.  This notion is supported by Wlaschek et al (1997), who 
identified that the most prominent isoform of PDGF, PDGF-PDGF is degraded by wound 
fluid from chronic venous leg ulcers, and that the loss of PDGF stability could be prevented 
by addition of specific protease inhibitors. For example, the serine protease inhibitor 
phenylmethylsulphonyl fluoride could prevent the degradation of PDGF by chronic wound 
fluids (Wlaschek, Peus et al. 1997). 
 
Anionic collagen mimetic peptides (CMPs) were shown in studies by Wang et al (2008) to 
exhibit specific binding affinity to type I collagen substrates and to attract vascular 
endothelial growth factors (VEGFs).  Subsequent enhanced morphological features of 
endothelial cells showed that these newly developed CMPs could be used to direct 
proliferation and differentiation of cells in collagen scaffolds by promoting localisation and 
sustained delivery of growth factors (Wang, Leong et al. 2008).  Collagen gelatinase sponge 
scaffolds have been developed that release positively charged growth factors such as bFGF in 
a sustained manner.  Such scaffolds and also CMPs hold promise as vehicles for growth 
factors, including CTGF for skin regeneration (Kanda, Morimoto et al. 2012). In another 
analysis, Geer et al (2005) conjugated keratinocyte growth factor (KGF) into a fibrin matrix 
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 to achieve ongoing, localised KGF infiltration into wounds, in concert with wound cellular 
demand (Geer, Swartz et al. 2005).  Strategies such as this to optimise delivery of topical 
therapies ‘on demand’ would potentially accelerate wound healing. 
 
Upton et al. (2008) reported that complexes comprising IGF and IGF-binding proteins that 
are bound to the ECM protein vitronectin (VN) significantly enhanced cellular functions 
related to wound repair (Upton, Cuttle et al. 2008).  Moreover, the delivery of growth factors 
in this manner resulted in therapeutic benefit at doses 1/10th–1/2,000th of those previously 
trialled with growth factor alone.  Given the high costs associated with growth factor therapy, 
these results indicate that relatively low dose CTGF (eg less than 0.1 mg of CTGF, rather 
than the 0.4 mg or more used in PDGF studies) in combination with vitronectin may be both 
effective and cost saving.   Recent studies have shown that propolis treatment stimulated 
significant increases in vitronectin complexes (Olczyk, Komosinska-Vassev et al. 2012), 
providing a further dimension to this field. 
 
7.5  Study limitations 
In the first study the growth factor CTGF was assessed for its ability to heal wounds.  A more 
highly powered study would enable more robust conclusions to be derived from the studies.  
For example macrophage numbers appeared to be normalised by CTGF in diabetic wounds 
but this was not statistically significant, possibly due to type II error due to small numbers.  
Dosing of CTGF was also relatively limited, as only 2 doses were administered.  A more 
sustained delivery of CTGF to the wound might result in greater observable effects of this 
treatment. 
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 The propolis study was carefully described as a pilot study and therefore one must be mindful 
of this in drawing conclusions from the results.  Obviously a larger scale, randimised 
controlled study would allow more reliable results to be shown but this was not the purpose 
of this work.  As previously discussed it was difficult to obtain adequate amounts of wound 
fluid for analysis of propolis treated wounds.. Ideally larger wounds would be included as 
they usually yield more fluid and this would be taken into account in future study designs.  
Also in future studies a qualitative element could be added to ascertain the patients opinions 
regarding the propolis treatment.  This would add another dimension the the study. 
 
7.6  Concluding remarks 
 
In conclusion, it is important to recognise that with good care and standardised evidence-
based protocols, most wounds in people with diabetes will heal.  Not all people with diabetes 
have access to this optimal care and amputation rates amongst patients with diabetes remain 
unacceptably high.  It is important to improve healing rates in order to improve patient 
quality of life and to decrease demands on funding and resources.  This work has shown in 
preliminary studies that wound healing rates can be improved by using topical agents to 
manipulate the wound microenvironment. These agents are potentially easy to administer and 
cost-effective when compared to other wound healing therapies.  Laboratory studies also 
indicated that these agents have the capacity to improve the quality of the healing tissue 
within a wound in diabetes so that they are able to more closely approximate a normally 
healing, granulating non-diabetic wound. 
 
The novel studies of topical rhCTGF in ulcers in rats with diabetes indicate that like some 
other growth factors, such as PDGF and bFGF, CTGF improve ulcer healing including 
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 wound closure and quality of dermal tissue in subjects with diabetes.  Future studies will need 
to examine defining optimal doses and methods of CTGF administration to ulcers to enhance 
its local effect and minimise its potential systemic adverse effects. It is envisaged that CTGF 
delivery as protein or in a viral vector or protective scaffold, possibly even with propolis, 
may ultimately, after series of supportive studies, be demonstrated to aid ulcer healing in 
humans with diabetes.  
 
The study of propolis efficacy and tolerability in human foot ulcers in diabetes and the 
exploratory, laboratory-based examinations of post-debridement wound fluid in propolis-
treated diabetic foot ulcers demonstrate the potential of propolis as an effective therapy.  Its 
anti-inflammatory and anti-bacterial properties were demonstrated.  Although this was a pilot 
study, the data obtained were promising and consistent with these published positive 
activities of propolis.   Collectively, these promising data promoting propolis as therapy 
forms the rational basis to consider a larger, multi-centre randomised controlled trial with 
propolis as a topical therapy to optimise foot ulcer care in peole with diabetes.  
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